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Psoriasis – gene to clinic
Wayne P. Gulliver, MD, New Lab Clinical Research, Inc., Newfoundland, Canada
Since the mid-1960s, under the auspicious beginnings of Danish Dermatologist Gunnar Lomholt,
thousands of genetic studies and analyses have not only established a definite genetic component
of psoriasis – a chronic inflammatory dermatosis – but have both discovered and mapped several
psoriasis susceptibility loci: PSORS1 on 6p21.3, PSORS2 on 17q, PSORS3 on 4q, PSORS4 on
1cen-q21, PSORS5 on 3q21, PSORS6 on 19p, and PSORS7 on 1p, consequently narrowing the
search for the precise susceptibility allele which has managed, so far, to elude the conquests of
modern science. As these genetic investigations have grown in both scope and technological
sophistication, so too have they advanced on the therapeutic level. As current psoriasis research
focuses on T-cell mediation and hyperproliferation, and the function of the skin as an
immunological tissue, multiple breakthroughs in the treatment of psoriasis, involving tumor
necrosis factor (TNF-a) inhibitors –primarily alefacept, infliximab, and etanercept –have begun to
emerge for the effective treatment of psoriasis. As current psoriasis research focus on T-cell
mediation hyperproliferation and the function of the skin in its immunological tissue, multiple
breakthroughs in the treatment of psoriasis which target genes in psoriasis susceptibility loci are
being used (anti-TNFs and PSORS1, infliximab, etanercept, onercept, and adalimumab or in
development such as anti-IL8 and rh IL10 in PSORS3; ICAM-1 topical inhibitor located in
PSORS6 and anti-CD2 located in PSORS7). Further studies to identify new potential targets are
ongoing. We can expect new therapies to immerge to targets including HLACw6, which has been
identified as a psoriasis susceptibility gene in PSORS1 found in the Newfoundland and Labrador
population and confirmed in the Icelandic population.
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Association of Stat3 variants and psoriasis in the Newfoundland and Labrador
Founder population
Wayne P. Gulliver, MD, New Lab Clinical Research, Inc., Newfoundland, Canada, Proton
Rahman, MD, MSc, FRCPC, Katrin Zipperlen, Memorial University of Newfoundland,
Newfoundland, Canada, Lynette Peddle, BSc, Newfound Genomics, Newfoundland, Canada
Introduction: The Newfoundland and Labrador Founder population has been used to study
psoriasis and psoriatic arthritis. Significant associations have been noted to tumor necrosis factor-
a (TNF-a) and HLA-Cw6 in psoriasis as well as the IL-1 cluster, CARD15, TNF-a and HLA-Cw6 in
psoriatic arthritis. We undertake this study of Stat3 therein in this founder population. Stat3 likely
encodes a number of proteins that figure to be critically important in inflammation and immunity.
Recently, Sano et al. (2005) reported that epidermal keratinocytes in psoriatic lesions are
characterized by activated Stat3 (Nat Med). Furthermore, transgenic mice with keratinocytes
expressing a constitutively active Stat3 develop a skin phenotype resembling psoriasis. Thus, we
set out to examine the association between Stat3 variants and psoriasis in the Newfoundland and
Labrador founder population.
Methods: We assessed 246 psoriasis patients and 217 ethnically matched healthy controls from
Newfoundland (a recognized founder population). All psoriasis subjects and controls were
genotyped for Stat3 variants by time-of-flight mass spectrometry. Seven Stat3 single-nucleotide
polymorphisms (SNPs) were genotyped.
Results: As noted below the univariate analysis revealed no association between Stat3 variants
and psoriasis. Haplotype analysis using the PHASE software also noted no significant differences
in haplotype frequencies between cases and controls. (SNP ID NF cases NF controls P-value:
2293152 (C) 36% 41% 0.76; 3816769 (C) 37% 34% 0.79; 9912773 (G) 25% 25% 0.88; 744166
(C) 44% 41% 0.79; 957971 (G) 37% 34% 0.71; 7211777 (G) 37% 34% 0.76; 4796793 (G) 31%
26% 0.09.)
Conclusions: We failed to observe an association between Stat3 variants and psoriasis in the
Newfoundland and Labrador founder population. Thus, these variants are unlikely to be
associated with uncomplicated psoriasis in the Newfoundland and Labrador cohort. This founder
population will be useful to confirm other psoriasis genes linkages that are discovered.
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Comorbidities associated with psoriasis in the Newfoundland and Labrador
Founder population
Wayne P. Gulliver, MD, Zohair Tomi, New Lab Clinical Research, Inc., Newfoundland, Canada
Psoriasis is a common inherited inflammatory disorder of the skin that affects 1–2% of the
population. The relationship between psoriasis and psoriatic arthritis has been well established
clinically and genetically. Recently, researchers have suggested that there may be other
comorbidities such as lymphoma, obesity, type 2 diabetes, dyslipidemia, hypertension,
cardiovascular disease, and lymphoma and melanoma and nonmelanoma skin cancer linked
to psoriasis. Using the Newfoundland and Labrador founder population through the Newfound-
land & Labrador Centre for Health Information (NLCHI), we have undertaken the task of studying
3,400 psoriasis patients with respect to these comorbidities. Initial investigation involves 100
patients with severe psoriasis over the age of 50 compared to 100 patients with mild psoriasis over
the age of 50. The comorbidities will be compared to the founder population of Newfoundland
and Labrador that exists in the Newfoundland and Labrador Centre for Health Information
database. Once the pilot study is complete we will then analyze all 3,400 patients in our clinic
database. Other studies to be undertaken include the relationships of the comorbidities to the age
of onset of psoriasis, presence of psoriatic arthritis, and genetic markers such as HLA-Cw6 and
TNF-a 258.
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Confirmation of a susceptibility locus 2q33 9q34 for Chinese Hans family psoriasis
Xun-Jun Zhang, PhD, Liang-Dan Sun, Sen Yang, Xing Fan, Kai-Yin Lan, Min Gao, Yan-Hua Liang,
Anhui Medical University, Heifei, Anhui, China
Psoriasis is a heterogeneous disease with eight major psoriasis susceptibility loci PSORS1-7 and
PSORS9 and further 12 undesignated loci have been identified as potential psoriasis susceptibility
loci reported so far. To investigate the psoriasis susceptibility loci in Chinese Hans, a genome-
wide scan was performed by our group with two-point and multipoint parametric and
nonparametric linkage analyses in 61 multiplex families in 2002 and found two major
susceptibility locus 6p21 and 4q31 and other regions with weak evidence for linkage including
9q33. In this study to confirm whether 9q33 is a susceptibility locus for Chinese Hans family
psoriasis, the fine mapping on 9q33-34 was performed with 10 Marker flanking the initial peak
suggestive linkage marker D9S1682 and D9S290 with two-point and multipoint nonparametric
linkage analyses with 152 multiplex families. Fortunately, this time multipoint nonparametric
analysis demonstrated nonparametric linkage scores P¼ 0.000022 throughout a region between
134.15 and 145.3 cM (from pter) with a maximum peak of 4.04 (P¼ 0.00000439 at 141.1 cM,
which locates at D9S290 A maximum multipoint heterogeneity lod score of 4.5 (a¼ 46%) at the
same position. So this locus may be another novel susceptibility region for Chinese family
psoriasis patients except 6p21.3 and 4q31.
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A novel MGST2 nonsynonymous mutation in a Chinese pedigree with psoriasis
vulgaris
Xun-Jun Zhang, PhD, Kai-Yin Lan, Zhi-Min Wang, Sen Yang, Guo-Long Zhang, Jian Wang, Min
Gao, Anhui Medical University, Heifei, Anhui, China
A balanced translocation was recently identified in a German psoriasis patient. One of the
breakpoints was mapped immediately upstream of the microsomal glutathione S-transferase 2
(MGST2) gene, suggesting it as a candidate gene. Here, we report the identification of a novel
nonsynonymous mutation in MGST2 by a comprehensive sequence analysis of MGST2’s coding
region in Chinese psoriasis samples. We demonstrate that this mutation co-segregated with the
disease phenotype within a Chinese family affected with psoriasis vulgaris and is predicted to
have an impact on the normal function of MGST2 protein. However, the mutation was absent in
551 additional cases and 384 healthy Chinese controls. While requiring independent
confirmation, our results suggest that this rare mutation could play a causal role in a small
subset of psoriasis individuals.
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Follow-up analysis of PSORS9 in Chinese families: Refine the critical interval to
chromosome 4q31–32 and provide strong linkage evidence for early onset patients
by order subset analysis
Xun-Jun Zhang, PhD, Kai-Lin Yan, Wei Huang, Sen Yang, Yu-Ming Chen, Xing Fan, Min Gao,
Anhui Medical University, Heifei, Anhui, China
Psoriasis linkage to 4q28–32 was initially identified by our previous genome-wide scan in 61
Chinese multiplex families of psoriasis and was supported by a meta-analysis of the linkage results
of five genome-wide scans of western population. In this study, we performed a follow-up
analysis of PSORS9 using a greatly expanded sample size and considerably improved marker
coverage. By analyzing 13 markers surrounding PSORS9 in 151 families, we identified highly
significant LOD scores (HLOD¼ 4.53 (¼ 45%), NPL¼ 4.03 (P¼ 0.000003)) at the marker interval
D4S2997–D4S3033. Furthermore, our analysis of the independent sample of 90 new families
identified strong linkage evidence (HLOD¼4.33 (¼ 69%), NPL¼ 3.15 (P¼ 0.00004)) at the same
region. Both the linkage evidences from the whole set of 151 families and the independent set of
90 new families suppressed the suggested genome-wide criteria for significant linkage evidence
and therefore confirmed the original linkage finding at 4q28–32 from our genome-wide scan. We
also incorporated mean age at onset of each family as a covariate in linkage analysis using a
procedure of ordered subset analysis and clearly demonstrated that evidence for linkage to
PSORS9 is concentrated in the families of early-onset psoriasis, at least in Chinese population.
Using the GENEFINDER analysis and the 1-LOD-down supporting interval analysis, we refined
the location of PSORS9’s underline susceptibility gene to a much smaller region of about 6 cM at
4q31.2–32.1 than our previous genome-wide scan. Taken together, our expanded follow-up study
of PSORS9 provided confirmative evidence for linkage, refined the location of underline
susceptibility gene and thus greatly facilitates future susceptibility gene identification.
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Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with
psoriasis vulgaris in Chinese population
Xun-Jun Zhang, PhD, Kai-Lin Yan, Zhi-Min Wang, Guo-Long Zhang, Sen Yang, Xing Fan, Min
Gao, Anhui Medical University, Heifei, Anhui, China
Psoriasis is a chronic inflammatory, hyperproliferative skin disease affecting approximately
0.1–5% in the general population. Although numerous putative susceptibility loci of psoriasis
have been described, the pathogenesis of which remains poorly understood. We refined our
previously defined linkage region for psoriasis on chromosome 4q28–32 (PSORS9) in an extended
families cohort. Family-based association and transmission disequilibrium tests showed
significant evidence of linkage in the presence of disequilibrium for several individual markers
in this region around D4S424, is about 140 kb away from IL-15. IL-15 is a cytokine that triggers
inflammatory cell recruitment, angiogenesis, and production of other inflammatory cytokines,
which looks like a very attractive candidate gene for psoriasis. Then we focus on investigating the
association between IL-15 and psoriasis in a large-scale sample. Significant evidence was
observed for association for an single-nucleotide polymorphism (SNP) in the 30-untranslated
region of the IL-15 gene (P¼ 0.000005) and for SNP haplotypes (P¼ 0.00004). We also identified
a haplotype of IL-15 associated with susceptibility to psoriasis that could potentially affect activity
of transcript. More interestingly, we observed an upregulation of IL-15 mRNA and protein in
psoriatic skin than in health skin. In conclusion, our results imply that variants of IL-15 are
involved in the pathogenesis of psoriasis by increasing IL production and inflammation in the
lesions.
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Systematic evaluation of association between the microsomal glutathione S-
transferase 2 common variation and susceptibility to psoriasis vulgaris in Chinese
population
Xun-Jun Zhang, PhD, Sen Yang, Kai-Lin Yan, Feng-Li Xiao, Xing Fan, Min Gao, Yong Cui, Anhui
Medical University, Heifei, Anhui, China
Several recent studies have demonstrated the possible involvement of the microsomal glutathione
S-transferase 2 (MGST2) gene in the pathogenesis of psoriasis, which prompted us to perform a
systematic evaluation of the role of MGST2 genetic variation in the risk to psoriasis by using
genetic association analyses in a large Chinese sample of psoriasis. We first characterized the
linkage disequilibrium pattern within MGST2 using 12 densely distributed single-nucleotide
polymorphisms (SNPs) and identified six SNPs for tagging common genetic variants. We then
performed an association analysis by genotyping the six SNPs in 188 probands, 364 sporadic
cases, and 384 controls, but none of genotype- and haplotype-based analyses revealed significant
evidence for association. We also performed family-based association analysis by genotyping the
six SNPs in 95 trios, no evidence for association was identified. Therefore, our comprehensive
genetic analysis of MGST2 common variants in a large Chinese sample of psoriasis did not
provide any supporting evidence for MGST2 to be the susceptibility gene within the PSORS9
locus.
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HLA-Cw*0602 and HLA-ER genotypes interact in psoriasis
Fabio Sanchez, MD, PhD, Kazuko Sakuraba, MD, PhD, Lina Carlen, BSc, Mona Sta˚hle, MD, PhD,
Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Psoriasis is an inflammatory disease where a complex genetic background interacting with
environmental factors contributes to triggering and maintaining disease activity. Several psoriasis
susceptibility loci have been detected in the genome, of which PSORS1 displays the strongest
association to disease, especially to guttate psoriasis. Previous work has implicated HLA-C as a
likely PSORS1 candidate gene by showing that certain NK and NK-T-cell activating receptors,
which specifically recognize HLA-C, are more common among psoriasis patients. Furthermore,
certain genotype combinations of HLA-C and killer immunoglobulin-like receptors (KIR)
characterize the psoriasis guttate phenotype and might have a functional role in regulating NK
and T-cell activities in this disease. Although the role of NK cells in psoriasis has not yet been
clarified, NK receptors are likely to interact with HLA class I molecules to modulate not only NK
cell but also T-cell activation. HLA-E is a class Ib molecule whose function is to present peptides
derived from the leader sequence of other HLA class I molecules, including HLA-C. There are two
HLA-E alleles reported so far, one with high (EG) and another with low (ER) affinity towards class
I-derived peptides. It has been clearly established that HLA-C, HLA-E, and HLA-G modulate NK-
cell activation in the trophoblast thus influencing fetal survival. We propose that interactions
between HLA-Cw*0602 and HLA-E may have an impact on psoriasis pathophysiology. To test this
hypothesis the two HLA-E alleles were genotyped in a sample of 407 healthy controls and 460
cases from the Stockholm Psoriasis Cohort. The results were then analyzed conditional on HLA-
Cw*0602 status. Irrespective of HLA-Cw*0602 status, HLA-ER was more common among guttate
psoriasis patients (P¼ 0.03). Regardless of phenotype, HLA-Cw*0602-positive patients had a
significantly higher frequency of the ER allele and correspondingly a significantly lower frequency
of EG/EG genotypes (P¼ 0.025). Immunohystochemical analysis revealed that both, HLA-C and
HL-E have lower expression in lesional psoriasis skin. It is therefore likely that inadequate
signaling by these two HLA class I molecules contributes to immune dysregulation in psoriasis.
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Characterizing susceptibility to phenotypic variations of psoriasis by comparing
allelic association signals on PSORS loci chromosomes
Jacqueline Panko, MD, Bob Wong, PhD, Kristina Callis, MD, University of Utah, Salt Lake City,
UT, USA, Steven Schrodi, PhD, Michele Cargill, PhD, Celera Diagnostics, Alameda, CA, USA,
Gerald G. Krueger, MD, University of Utah
Although the existence of a genetic component of psoriasis has been repeatedly observed, the
genes predisposing patients to psoriasis and its varied morphologies remain largely unknown. In
this analysis, we compare the allelic association peaks in psoriasis cases stratified by phenotype.
We collected DNA and phenotypic data on 500 psoriasis patients. We then pooled DNA into
groups based on several phenotypes, for example, psoriatic arthritis and thickness of lesions in the
untreated state, thereby stratifying the data. In each pool, we measured the allele frequencies at
numerous genetic markers on chromosomes 1, 3, 4, 6, 17, and 19 (these chromosomes house the
recognized PSORS loci that associate with psoriasis). After selecting all markers with allelic
association, Po0.05, we separated cases into two groups based on presence or absence of seven
phenotypic characteristics. The moving averages of the transformed P-values were plotted against
the location of markers on the chromosomes. Charted plots were superimposed for each group.
Peaks were observed in different locations that stratified patients based on different phenotypic
characteristics. The most pronounced peaks were observed for markers located on chromosome
6. We conclude from this analysis that psoriasis patients can be stratified based on phenotype.
Allele frequencies of markers are different between those patients based on the presence or
absence of specific phenotype traits. This demonstrates that variants in genes in this and other
regions may dictate phenotypic differences in patients with psoriasis.
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Role of chromosome 6P haplotypes in the susceptibility to psoriatic arthritis
Dafna D. Gladman, MD, FRCPC, University of Toronto, Toronto Western Hospital, Toronto,
Ontario, Canada, Fawnda Pellett, BSc, Toronto Western Research Institute, Toronto, Ontario,
Canada, Fotios Siannis, PhD, Vernon T. Farewell, PhD, Institute of Public Health, Cambridge,
England, Proton Rahman, MD, MSc, FRCPC, Memorial University of Newfoundland, New-
foundland, Canada
Psoriatic arthritis (PsA), an inflammatory arthritis associated with psoriasis (Ps), is related to alleles
of the HLA-B and -C loci on 6p. Tumor necrosis factor-a (TNF-a) promotor gene is implicated PsA,
whereas corneodesmosin (CDSN) is a proposed candidate gene for Ps. Both genes are in the HLA
region. We questioned their association with PsA and if it was related to linkage with HLA alleles.
Genomic DNA from 204 PsA patients and 101 healthy controls from Toronto, an admixed
population, and 235 patients and 102 controls from Newoundland, a founder population, was
tested. Single-nucleotide polymorphisms (SNPs) at positions 238, 308, 857, 863, and 1,031 of the
TNF-a gene and 619, 1,215, 1,236, and 1,243 of the CDSN gene were genotyped by time-of-flight
mass spectrometry using the Sequenom platform. w2 analysis was used. No association was seen
with either patient group compared to their respective controls for any of the SNPs. However,
associations were seen with specific HLA-B and/or -Cw alleles. At TNF-238, the minor A allele
was strongly associated with HLA-B*57 (Po0.000001); at CDSN-1215, the minor G allele with
HLA-B*13 and -Cw*0602 (Po0.000001), and at TNFa-308, the minor A allele with HLA-B*08
(Po0.000001). There were distinct SNP haplotypes extending from the TNF locus to the CDSN
locus associated with specific HLA-B and -Cw alleles. These haplotypes were seen in both
controls and patients groups. The TNF/CDSN SNP haplotype associated with HLA-B*57 and HLA-
Cw*0602 was increased in both patient groups compared to their respective controls, whereas
that with B*38 and Cw*12 was increased in the Toronto patients compared to their controls. The
TNF-a/CDSN haplotype associated with HLA-B*07 and -Cw*07 was decreased in both patient
groups. Specific SNP haplotypes extending from TNF-a to CDSN are associated with PsA. The
effect of these SNP haplotypes on disease expression and progression in both PsA cohorts remains
to be elucidated.
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Killer immunoglobulin-like receptors KIR2DS1 and KIR2DS2 are increased in
siblings concordant for psoriatic arthritis
Dafna D Gladman, MD, FRCPC, University of Toronto, Toronto Western Hospital, Toronto,
Ontario, Canada, Fawnda Pellett, BSc, Iva Vukin, Toronto Western Research Institute, Toronto,
Ontario, Canada, Vernon T. Farewell, PhD, Institute of Public Health, Cambridge, England, Cathy
T. Schentag, MSc, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western
Hospital, Toronto, Ontario, Canada, Proton Rahman, MD, MSc, FRCPC, Memorial University of
Newfoundland, Newfoundland, Canada
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis (Ps). Genetic factors,
particularly the HLA-Cw*0602 allele within the MHC on chromosome 6p, play an important role
in susceptibility to PsA. HLA-Cw alleles are ligands for activating and inhibitory killer
immunoglobulin-like receptors (KIRs), which are encoded by genes on chromosome 19q. KIRs
are regulatory molecules found on natural killer (NK) cells as well as subsets of T cells. Activating
KIR2DS1 and/or KIR2DS2 together with homozygocity of the HLA-Cw ligands for the respective
inhibitory KIR2DL1 and KIR2DL2/3 are implicated in susceptibility to PsA. Our current study
focuses on familial PsA. We had demonstrated excessive HLA haplotype sharing in sibling-pairs
concordant for PsA. We questioned whether there was also an increase in activating KIRs in PsA-
affected siblings given the fact that KIR and HLA are inherited independently. A total of 152
siblings of 106 PsA patients were recruited from PsA clinics in Toronto, Ontario and St John’s,
Newfoundland. All subjects were clinically evaluated to determine disease status. KIR typing was
performed on genomic DNA using PCR-SSP. Stratified conditional logistic regression analysis was
performed. We found that there was an increased frequency of both activating KIR2DS1 and
KIR2DS2 in the PsA-affected siblings. In comparison, there was an increased frequency of only
one activating KIR in PsA-discordant siblings. The presence of the HLA-C ligand for the
corresponding inhibitory KIR was noncontributory. Thus, KIR genes appear to play a role in the
susceptibility to familial PsA.
www.jidonline.org 1801
ABSTRACTS
13
Epidemiology of psoriasis: A study of 156 California twin pairs
Stefani Triff Kappel, Medical Student, University of Southern California, Los Angeles, CA, USA,
Myles Cockburn, University of Southern California, Los Angeles, CA, USA, Theodore Alkousakis,
Ashley Khalap, Thomas Mack, David H. Peng, University of Southern California
Background: The epidemiology and genetics of psoriasis have been studied extensively for
decades. Despite several familial studies and more recent genetic polymorphism and allele
clustering analyses, all that has been consistently established is the complexity of psoriasis. In
complex diseases, twin studies have often been useful in separating genetic and environmental
contributions. However to date such studies have been limited due to a paucity of twins with
psoriasis in a given population. The California Twin Program (CTP) Database represented a
unique opportunity to revisit psoriasis in a twin study.
Objectives: Objectives of this study were: (1) to obtain epidemiologic data, (2) to look for
environmental associations with psoriasis, and (3) to ascertain if patient profiles would segregate
to distinct presentations based on age of onset.
Methods: the CTP database included information for 265,000 twins born in the state of California
between the years of 1908 and 1982. Questionnaires that included demographic, birth history,
twin comparison, and medical history information were completed by 52,000 twins. Subsequent
psoriasis-specific questionnaires were sent to obtain information related to disease epidemiology
and associated factors.
Results: A cohort of 156 twins included both monozygotic (28%) and dizygotic (72%) twin pairs,
as well as responses from unaffected twins. Concordance was defined by the presence of psoriasis
in both members of a twin pair, regardless of zygosity. Monozygotic twin concordance was 32%
(14/44) and dizygotic twin concordance was 18% (19/105). The mean age of affected and
unaffected twins was 52710 (48% male, 52% female) and 53710 (48% male, 52% female),
respectively. Offspring of psoriatic females (x¼1.6) showed 21% affected by psoriasis (M¼ F).
Offspring of psoriatic males (x¼ 2) showed 3% affected by psoriasis (M4F).
Conclusions: The age of onset pattern was similar in both concordant and discordant twins. Age
of onset by gender revealed an earlier peak in females and an additional late surge in males. There
was a striking difference between maternal and paternal inheritance with a higher occurrence of
affected offspring of psoriatic females. This study demonstrated gender, zygosity, and
concordance-specific characteristics, disease associations, and demogeographic information
which may contribute to the understanding of the genetic and environmental factors associated
with psoriasis.
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Expression of IL-18-binding protein in monocyte and monocyte-drived Langerhans
cell of psoriasis
Huang Qiong, Zheng Zhizhong, Xiang Leihong, Zhu Luchuan. Department of Dermatology,
Huashan Hospital of Fudan University
Type-1 cytokine-producing T cells are important in the pathogenesis of psoriasis vulgaris. IL-18
synergizes with IL-12 to induce IFN-g production and a strong T-helper-1-mediated immune
response. IL-18-binding protein (IL-18BP) belongs to a new family of secreted proteins which act
as inhibitors of IL-18 signaling. IL-18BP effectively blocks IL-18 by forming a high-affinity
complex that exhibits a very low dissociation rate.
Objective: To measure serum IL-18BPa levels in patients with psoriasis vulgaris and expression of
IL-18BPa in monocyte and monocyte-drived Langerhans cell.
Methods: Serum samples were obtained from patients with psoriasis. IL18BPa was measured by
Sandwich ELISA. Reverse transcription-PCR (RT-PCR) was used to explore the mRNA expression
of IL-18BPa and IFN-g in peripheral blood mononuclear cells (PBMC) and monocyte-drived
langerhans cell.
Results: Thirty-five patients with psoriasis and 35 normal controls were evaluated. The level of IL-
18BPa in patients with psoriasis were much higher than those in normal controls (Po0.01) and
had the negative correlation with the score of Psoriasis Area Severity Index. IL-12 induced
peripheral blood mononuclear cells to express IFN-g mRNA and IL-18BPa mRNA both in
psoriatic patients and normal controls, but there was no expression of IL-18BPb mRNA. TGF
could suppress the expression of IL-18BPa mRNA by downregulating IFN-g mRNA, and the
expression of IFN-g mRNA and IL-18BPa mRNA were significantly higher in psoriatic patients
than that in the normal controls.
Conclusions: IL-18BPa was among a matrix of inflammatory cytokines produced abundantly in
PBMCs from patients with vulgar psoriasis and there was no difference between that of patients
and the healthy subjects. But decrease in plasma level of IL-18BPa in psoriatic patients was
probably the result of interaction in the complicated immune network that led to the abnormal IL-
18/IL-18BP-negative feedback loop and intense Th1 cellular immune responses and played an
important role in the pathogenesis of psoriasis. The level of IL-18BPa in psoriatic patients was
variable in different phase that could contribute to judge the progress and prognosis of disease
and the effect of therapy in clinical practice.
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Differential effects of TNF blockade on TB-induced genes and cytokines
Robert S. Wallis, MD, PPD, Washington, DC, USA, O.Y. Saliu, C. Sofer, University of Medicine &
Dentistry New Jersey, New Jersey Medical School, Newark, NJ, USA, Q. Wang, A. Brooks,
University of Medicine and Dentistry New Jersey, Robert Wood Johnson Medical School,
Piscataway, NJ, USA, S.K. Schwander, University of Medicine & Dentistry New Jersey, New
Jersey Medical School
TNF has a pathogenic role in psoriasis and other inflammatory diseases, but is essential for
antimycobacterial host defenses. The TB risk of infliximab appears greater than etanercept. We
examined the effects of infliximab, adalimumab, and etanercept on TB immunity in vitro to
understand the biologic basis of this difference. Infliximab and adalimumab, but not etanercept,
inhibited TB-induced T activation and IFN-g production, without causing T-cell death, when
added in therapeutic concentrations to whole-blood cultures of healthy volunteers. The drugs had
divergent effects on immune control of intracellular TB growth consistent with effects on T-cell
activation. However, all three drugs suppressed IL-10 equally. To understand better this cytokine-
specific regulation, we examined drug effects on 239 TB-induced genes identified by microarray.
Inhibition of these genes appeared greatest with infliximab, intermediate with adalimumab, and
least with etanercept. The differential effects of the three drugs were most apparent in 32 IFN-
inducible genes, intermediate in 18 TNF-inducible genes, and absent in six chemokine genes.
IFN-g and two unknown genes were among the three TB-induced genes that appeared most
divergently affected by infliximab versus etanercept. Despite sharing TNF as a common
therapeutic target, infliximab, adalimumab, and etanercept have distinct effects on mycobacterial
immunity. The increased risk of reactivation of latent TB infection posed by infliximab may reflect
its combined effects on TNF and IFN-g.
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The anti-angiogenic effect of photochemotherapy in vitro
Hui Deng, Shanghai Jiaotong University, The Sixth People’s Hospital of Shanghai, Shanghai,
China, Chunlin Yan, Fudan University, Huashan Hospital, Shanghai, China, Dingfen Yuan,
Shanghai Jiaotong University, The Sixth People’s Hospital of Shanghai, Liao Kanghuang, Fudan
University, Huashan Hospital, Shanghai, China
Background: Photochemotherapy has been long been used in the treatment of psoriasis; however,
the mechanism has not been completely elucidated. Psoriasis is now regarded as an angiogenesis-
related disease. Recent studies indicated that that the inhibition of angiogenesis by
photochemotherapy could be an underlying mechanism in the treatment of psoriasis. It was
found that photochemotherapy can downregulate the expression of angiogenic factors in
keratinocytes. However, the direct effect of photochemotherapy on endothelial cells has not been
studied.
Objective: To detect the antiangiogenic effect of photochemotherapy.
Methods: In this study, we determined the effect of photochemotherapy on the proliferation,
migration, tube formation ability and apoptosis of endothelial cells through MTT assay, cell
migration assay, in vitro tube formation assay, and fluorescence-activated cell sorting analysis
(FACS), respectively. Furthermore, the bioactivity or expression of gelatinases, angiopoietin and
integrin were analyzed through gelatin zymography, Enzyme-linked immunosorbent assay and
FACS, respectively.
Results: Combination of UVA (1.2–5.0 J/cm2) and 8-MOP (300 ng/ml) resulted in a dose-
dependent reduction in the cell viabilities and migration ability of endothelial cells. FACS data
showed an accumulation of cells in G0/G1 phase of cell-cycle and apoptotic features of cell death
after UVA irradiation with psoralen. The tube formation ability and expression of angiogenic
factors were significantly inhibited by photochemotherapy.
Conclusions: Our results showed that photochemotherapy inhibited the angiogenesis and
induced the apoptosis of human microvascular endothelial cells through the downregulation of
angiogenic factors in vitro, which may be a possible mechanism of photochemotherapy in the
treatment of psoriasis.
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Patients with psoriatic arthritis have an increased number of lymphocytes in the
duodenal mucosa in comparison with patients with psoriasis vulgaris
Gerd Michae¨lsson, MD, PhD, Ulla Lindqvist, MD, PhD, Gudjon Kristja´nsson, MD, PhD, Inger
Pihl-Lundin, PhD, Eva Hagforsen, PhD, University of Uppsala, University Hospital, Uppsala,
Sweden
The lower gastrointestinal tract in patients with psoriatic arthritis (PsoA) has been reported to
display discrete inflammatory abnormalities. PsoA patients also have an increased prevalence of
coeliac disease and of IgA antibodies against gliadin but irrespective of gliadin antibodies they
have raised serum IgA. This study was conducted to find out if there is any evidence of
inflammation in the duodenal mucosa in patients with PsoA and to compare the results with those
in patients with psoriasis vulgaris (PsoV). Nineteen consecutive patients with PsoA underwent
gastroduodenoscopy and biopsy specimens were taken from the duodenal and gastric mucosa. In
addition to routine processing, the duodenal mucosal specimens were stained for CD3þ , CD8þ
and CD4þ T lymphocytes, tryptaseþ mast cells, and EG2þ eosinophil granulocytes. The results
were compared with those in duodenal mucosal specimens from patients with PsoV and patients
with irritable bowel syndrome. Compared with PsoV patients (without antibodies against gliadin),
patients with PsoA had a highly significant increase in intraepithelial CD3þ and CD8þ
lymphocytes and also in CD4þ lymphocytes in the lamina propria in the villi. The lymphocyte
increase was not related to presence of IgA antibodies against gliadin, as only two PsoA patients
had such antibodies and none had endomysium or transglutaminase antibodies, or to
concomitant gastritis. Both PsoA and PsoV patients showed a pronounced increase in mast cells
and eosinophil granulocytes in the lamina propria PsoA patients have increased numbers of
lymphocytes, mast cells, and eosinophil granulocytes in the duodenal mucosa further indicating
that the gastrointestinal tract may have a pathogenetic role in PsoA.
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Release of INF-c from stimulated cultured T lymphocytes of psoriatic patients
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Ilan Bank, MD, Sheba Medical Center,
Ramat Gan, Israel, Michael David, MD, Rabin Medical Center, Petah Tikva, Israel
Comparison between patients and a control group and between different groups of patients with
increasing severity.
Background: psoriasis in a chronic inflammatory and immunologic disease with a Th1 profile
affecting the skin and joints in 2–3% of the population. INF-g is a cytokine derived from Th1 cells
that takes part in the immunopathogenesis of psoriasis in several levels. We wanted to find out
whether there was a correlation between severity of the disease and release of INF-g from cultured
and stimulated T cells from psoriatic patients and to compare these results to a control group.
Methods: 40 patients with psoriasis vulgaris were examined, percent of skin involvement and
Psoriasis Area and Severity Index score calculated. Blood samples were taken. T cells were
extracted and cultured in 1,640 RPMI mediun with 10% fetal calf serum in a humidified CO2
incubator in 371C for 10 days. Anti CD3 was added as stimulation. Table 1: area of psoriasis: INF-
g (mg/ml)avg7SD (med): 80–90% psor n¼6 31.6724.8 (30), 60–70% psor n¼15 35770 (0),
10–30% psor n¼ 9 46.33761.88 (15), 1–6% psor n¼ 6 174.167243.03 (102.5), total psor n¼36
62.367117.4 (15), healthy n¼ 15 139.667218.19 (40). We conclude that the more severe the
psoriasis, the less INF-g was secreted from the cultured T lymphocytes. The results were
statistically significant. P¼ 0.02 – comparing patients with mildest psoriasis (1–6% body area) to
the most severe patients (80–90% body area) P¼ 0.03 comparing healthy control group to the
most severe patients. The explanation to our results may be the fact that we were dealing with T
cells in culture and did not measure INF-g in the serum. The INF-g secreting cells may be
trafficked to the skin and remaining T cell left in the blood stream may have a decreased potential
to secrete INF-g.
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The expression of VLA-1(a/b1) on T lymphocytes CD4þ and CD8þ in psoriatic
patients
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Ilan Bank, MD, Sheba Medical Center,
Ramat Gan, Israel, Michael David, MD, Rabin Medical Center, Petah Tikva, Israel
The expression of very late antigen 1 (VLA-1) on T lymphocytes CD4þ and CD8þ in psoriatic
patients before and after incubation –a comparison study between patients and control group and
between mild and severe patients.
Introduction: Psoriasis in a chronic inflammatory and immunologic disease with a Th1 profile
affecting the skin and joints in 2–3% of the population. VLA-1 is an a1/b1 integrin expressed on T
lymphocytes, especially with Th1 profile, 2–4 weeks after their activation. VLA-1 plays an
important role in inflammatory responses involving T cells. VLA-1 is expressed in excess in animal
models (rats) with arthritis and colitis and on T lymphocytes from synovial fluid of rheumatoid
arthritis patients. VLA-1 has affinity for collagen type IV with is abundant in the basement
membrane. The interaction of VLA1þ lymphocytes with collagen type IV is succeeded by release
of proinflammatory cytokines with Th1 profile (IFN-a, TNF-a, and IL-2). Considering the fact that
psoriasis is a Th1-mediated disease and the fact that there is abundance of collagen IV in the
basement membrane, that can take part in trafficking these T cell to the epidermis as well, we
suggest that these VLA1þ T lymphocytes play an important role in psoriasis. We checked the
expression of VLA1þ on T lymphocytes CD4þ and CD8þ taken from blood samples of
psoriatic patients before and after culturing. We compared the results with a control group and
compared patient with severe psoriasis (Psoriasis Area and Severity Index (PASI)X20) and mild
psoriasis (PASIo20). A same comparison was made with PASI 40 as a cutoff point.
Methods: Forty patients were examined and their PASI scores calculated. We checked the
expression of VLA1þ on T lymphocytes CD4þ and CD8þ taken from blood samples of
psoriatic patients. We compared the results with a control group (10 people) and compared
patient with severe psoriasis (PASI 20) and mild psoriasis (PASIo20). A same comparison was
made with PASI 40 as a cutoff point. The same analysis was done on T-cell cultures. We used
fluorescence-activated cell sorting analysis and adhesion to collagen 4 and BSA kits.
Results: We found an increased value of CD8þ VLA1þ /total CD8þ in the blood of psoriatic
patients compared to a healthy control group. (P¼ 0.07). There were no significant differences
between the other parameters, CD4þ cells before and after culturing or CD8þ cells after
culturing.
Conclusions: our findings may give rise to the significance of CD8þ cells and subclass of
CD8þVLA1þ T cell in the pathogenesis of psoriasis. This finding and the fact that VLA-1 plays
an important role in inflammatory responses involving T cells may open new opportunities to
understanding the pathogenesis of psoriasis and seeking for new treatment options – VLA1
blocking.
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Substance P and its receptor neurokinin-1 in psoriasis: A pathoetiological role?
Klas Nordlind, MD, PhD, Charlotta Remro¨d, Sol-Britt Lonne-Rahm, MD, Karolinska Institutet,
Karolinska University Hospital, Stockholm, Sweden
It has earlier been suggested that the neuropeptide substance P and its receptor neurokinin (NK)-1
have roles in the pathogenesis of psoriasis. Stress has also been reported to play a role in the onset
and exacerbation of psoriasis, and the substance P-NK-1 receptor pathway might be involved. A
feature of psoriasis, which has been previously correlated to the severity of stress and secretion of
substance P, is pruritus. The objective of this study was to investigate the expression of substance
P and its receptor NK-1 in involved and noninvolved psoriatic skin. In addition, we investigate a
possible correlation between the patient’s level of chronic stress, salivary cortisol levels, degree of
lesional pruritus and the expression of substance P, and the NK-1 receptor in the skin. Patients
measured their ongoing chronic stress by means of a visual analog scale, an Everyday Life Stress
scale, and by salivary cortisol samples. Pruritus was measured by means of a visual analog scale.
A biotinylated streptavidin technique was used to demonstrate substance P and the NK-1
receptor. A tendency was observed toward an increased number of substance P positive nerve
fibres in noninvolved compared to involved psoriatic skin. The number of substance P and NK-1
receptor-positive cells was increased in involved compared to noninvolved psoriatic skin. The
substance P-positive cells were mostly lymphocytes, whereas most of the NK-1 receptor-positive
cells were mast cells. NK-1 receptor immunoreactivity was also seen as a reticular pattern in the
epidermis of involved psoriatic skin in the majority of the patients. We found a tendency toward a
correlation between subjective stress, determined by a visual analogous scale, and the number of
substance P- and NK-1 receptor-positive cells in involved skin. Cortisol ratios, however, were
correlated to an increased number of substance P and NK-1 receptor immunoreactive cells in
noninvolved psoriatic skin. Pruritus could not be correlated to any of the stress or to the
immunohistological parameters. Substance P and its receptor NK-1 might have a role in psoriasis,
also during chronic stress.
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Serotonin receptors in psoriasis
Klas Nordlind, MD, PhD, Kristoffer Thorslund, Student, Sol-Britt Lonne-Rahm, MD, Karolinska
Institutet, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, Sheila
Mohabbati, PhD, Uppsala University, Uppsala, Sweden, Timea Berki, PhD, University of Pe´cs,
Pe´cs, Hungary, Marisela Morales, PhD, National Institute on Drug Abuse, Baltimore, MD, USA,
Efrain Azmitia, PhD, New York University, New York, NY, USA
Psoriasis appears to be influenced by stress, which causes release of adrenal hormones. Serotonin,
or hormonal actions on serotonin and serotonin receptors, may have a role in psoriasis.
Distribution of serotonin receptors was studied in involved and noninvolved skin in patients with
psoriasis and compared to normal skin, by using immunohistochemistry and antibodies to 5-
HTlA, 5-HT2A and 5-HT3 receptors (R). There was a decreased number of 5-HT1AR-positive
cells, the majority being tryptase-positive, in involved and noninvolved psoriatic papillary dermis,
compared to normal skin. 5-HTlAR expression was also found in the upper part of the epidermis,
on vessel walls, and on melanocytes. 5-HT2AR expressing papillary mononuclear cells, CD3-
positive, were increased in involved and noninvolved psoriatic skin, compared to normal skin, an
increase also being found in the involved compared to noninvolved skin. Expression of 5-HT3R
could be found in the basal epidermal layer of noninvolved but not in the involved skin of
psoriasis, where it was only found in the acrosy-ringium. The present findings are compatible with
the 5-HT1A and 5-HT2A receptors having antagonistic functions, and raise the possibility of using
receptor specific drugs in the treatment of psoriasis.
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Common TCR rearrangements in psoriatic skin lesions and streptococcal angina
Joerg C. Prinz, MD, University of Munich, Munich, Germany, Laura Diluvio, University of Rome
Tor Vergata, Rome, Italy, Sigrid Vollmer, Petra Besgen, University of Munich, Sergio Chimenti,
University of Rome Tor Vergata
Today, psoriasis vulgaris is considered as a T-cell-mediated autoimmune disease of the skin. In a
subtype of patients psoriasis may be triggered by streptococcal angina. Using T-cell receptor
(TCR) analysis we sought to identify a link between streptococcal tonsillitis and the T-cell-
mediated autoimmune response in psoriasis. The TCR b-chain variable region gene (TCRBV)
usage of psoriatic skin lesions, peripheral blood lymphocytes, and tonsillar T cells was
determined in three psoriasis patients. They had undergone tonsillectomy because recurrent
streptococcal sore throat had been associated with psoriasis onset and flares. RNA and cDNA
were prepared from the different tissues using standard procedures. TCRBV-gene-specific PCR
was used to amplify the whole TCRBV repertoire. Fragment length of the PCR products was
analyzed on an ABI prism gene sequencer using gene scan software. cDNA of TCRBV genes with
evidence of clonal selection was cloned and sequenced. Spectratyping identified several TCRBV-
gene families with evidence of clonal T-cell selection within the psoriatic skin lesions that was
confirmed by sequencing of the TCR rearrangements. In all three patients, several of the lesional
psoriatic TCR clonotypes were also identified within the corresponding tonsils. In one of the
patients, these TCR rearrangements could be assigned to the small fraction of skin-homing
tonsillar T cells expressing the cutaneous lymphocyte-associated antigen. Psoriasis cleared in all
three patients after tonsillectomy. Our observations therefore provide first evidence that T cells
may represent the functional link between streptococcal tonsillitis and psoriatic inflammation.
They suggest that the chronic streptococcal immune stimulus within the tonsils is a source for
pathogenic T cells in poststreptococcal disorders, and they explain why eliminating this source
with tonsillectomy may improve streptococcal-induced sequelae. Thus, T cells appear as a
functional link between streptococcal angina and psoriasis.
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Detection of SERUM B-endorphin and its significance in psoriatic patients
Xue-qin Yang, Li You, Li-Jun Zhang, Air Force General Hospital, Beijing China
Aim: To study the levels of serum b-endorphin and its significance in psoriatic patients.
Methods: We detected the levels of serum b-endorphin in 70 psoriatic patients and 32 normal
controls by radioimmunoassay.
Results: The differences of levels of b-endorphin between psoriatic patients and normal controls
were not significant. Levels of b-endorphin psoriatic patients 1 and normal controls 1 was
significantly higher than those psoriatic patients 2 and normal controls 2 according to whether
involving psychological factors or not Po0.01. Areas of psoriatic lesions were not significantly
correlated to levels of serum b-endorphin.
Conclusions: It is indicated that there is possibly a correlation between b-endorphin and
psychological factors. b-endorphin is likely to participate in adjusting the whole-body state. It
provides the foundation for psychology treatment.
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Ectopic lymphoid neogenesis in psoriatic arthritis.
Juan D. Can˜ete, MD, PhD, Hospital Clinic and IDIBAPS, Barcelona, Catalunya, Spain, Begon˜a
Santiago, PhD, Hospital 12 de Octubre, Madrid, Spain, Raimon Sanmartı´, MD, PhD, Hospital
Clinic and IDIBAPS, Beatriz Gil-Torregrosa, PhD, Hospital Clinic, Agustin Garcı´a-Peı´ro, PhD,
Hospital Clinic and IDIBAPS, Antonio Palacin, MD, Hospital Clinic, Jose´ L. Pablos, MD, PhD,
Hospital 12 de Octubre
Objective: Ectopic lymphoid neogenesis has been demonstrated in rheumatoid synovium where
it is associated with local antigen-driven B-cell development and autoantibody production. This
process involves the expression of specific homing chemokines and the development of high
endothelial venules (HEVs). We aimed to investigate whether these phenomena occur in psoriatic
arthritis (PsA) synovium where the organization and function of B cells is not clear.
Methods: Arthroscopic synovial biopsies from PsA patients were obtained and characterized by
histology and immunohistochemestry for T-cell/B-cell segregation and peripheral lymph node
addressin (PNAd)-positive HEV in relationship to the size of lymphoid aggregates and the
expression of CXCL13, CCL21, and CXCL12.
Results: Lymphoid aggregates of variable size were observed in 24 of 25 PsA synovial tissues. T-
cell/B-cell segregation was observed and correlated with the size of lymphoid aggregates. A close
relationship between the presence of large and highly oganized aggregates, the development of
PNAdþ HEV, and the expression of CXCL13 and CCL21 was found. CXCL12 expression by
stromal cells was observed in all tissues and did not correlate with lymphoid neogenesis, although
it was strongly expressed on HEV endothelium.
Conclusions: This is the first description of lymphoid neogenesis in PsA synovial tissues and its
close relationship with the development of PNAdþHEV and CXCL13, CCL21 expression. These
observations demonstrate that in PsA the microanatomical bases for germinal center formation are
present and, therefore, the function and pathogenic relevance of B cells in this context merits
further investigation.
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Functional role for intraepidermal T cells in the development of psoriasis
Curdin Conrad, MD, Giulia Tonel, Frank O. Nestle, MD, University Hospital of Zurich, Zurich,
Switzerland
Clinical appearance of psoriasis is mainly caused by epidermal changes, including hyperpro-
liferation and altered differentiation of keratinocytes. Thus, epidermal changes are believed to be
of prime importance for disease pathogenesis. Recent evidence suggests that T cells play an
important role during psoriasis development. To determine the functional role of T cells in
psoriasis, we took advantage of a recently described xenotransplantation model with spontaneous
development of psoriasis. Uninvolved skin from psoriasis patients was engrafted onto AGR mice,
mice deficient in type I and II interferon receptors and being RAG/. Five weeks after
transplantation, skin grafts develop psoriasis with typical histological features. Time-course
experiments revealed pronounced dermal T-cell proliferation early during psoriasis development
in the absence of any increase of keratinocyte proliferation or acanthosis. Starting 3 weeks after
transplantation, the percentage of Ki-67-positive keratinocytes and the onset of a psoriatic
phenotype paralleled the migration of T cells into the epidermis. In one experiment, T cells did
not markedly proliferate upon engraftment and no T-cell migration into the epidermis was
observed. As a consequence, psoriasis was not induced, and after 5 weeks, grafts were
indistinguishable from uninvolved skin before engraftment including percentage of Ki-67-positive
keratinocytes. These findings indicate that in developing psoriasis lesions dermal T-cell
proliferation precedes epidermal changes and that hyperproliferation of keratinocytes is linked
to an influx of epidermal T cells. To confirm the essential role of epidermal T cells in psoriasis we
investigated the functional role of VLA-1, a major collagen receptor that was exclusively
expressed by epidermal but not dermal T cells in psoriasis lesions. In our mouse model, blocking
VLA-1 almost entirely inhibited the expansion of the epidermal T-cell pool, thereby completely
blocking psoriasis formation as compared to isotype control. Our findings indicate that migration
of expanded dermal T cells into the epidermis is required for psoriasis development and that
epidermal T cells expressing VLA-1 represent potential key inducers of typical epidermal changes
in psoriasis.
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Activation of nuclear factor kappa B and mitogen-activated protein kinases in
psoriatic arthritis before and after etanercept treatment
Kurt de Vlam, MD, Inger Derese, Frank P. Luyten, Rik J.U. Lories, University Hospital Leuven,
Leuven, Belgium
Objectives: To study activation of intracellular pathways depending on nuclear factor kappa B
(NF-kB) and mitogen-activated kinases (MAPKs) in the synovium of patients with psoriatic arthritis
before and after treatment with etanercept.
Methods: Synovial biopsies were obtained by needle arthroscopy of the knee in nine patients with
active psoriatic arthritis before the initiation of etanercept. Follow-up biopsies were taken in the
same knee after 6 months. Synovitis was studied by histology. Pathway activation was studied by
immunofluorescense for phosphorylated extracellular signal-regulated kinase (ERK), phosphory-
lated p38, phosphorylated Jun N-terminal kinase (JNK) or phosphorylated inhibitor of kappa B
(IkB) using digital image analysis.
Results: Histological severity scores were significantly reduced after etanercept treatment.
Activation of NF-kB signaling was found in the lining layer, and of infiltrating and perivascular
cells in the sublining zone. Activated p38 was present in both lining and sublining layer. In the
sublining layer, positive cells were found in inflammatory infiltrates, in perivascular zones and in
endothelium. Activated ERK was mainly present in the sublining layer, both in mononuclear cell
infiltrates and perivascularly. Occasional positive cells were found in the lining layer. Activation
of JNK was recognized in cells of the lining layer, in some of the sublining cell infiltrates, and in
the perivascular compartment. Etanercept therapy resulted in a significant decrease in NFKB, JNK,
and ERK, but not in p38 activation. Despite a reduction in activity, all signaling pathways
remained active.
Conclusions: Persistent activation of these pathways, albeit reduced, may trigger the positive
feedback loops and flares of arthritis after cessation of etanercept.
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Decreased secretion of interferon a by activated peripheral blood T cells in severe
psoriasis
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Michael David, MD, Rabin Medical
Center, Petah Tikvah, Israel, Ilan Bank, Sheba Medical Center, Ramat Gan, Israel
Background: Psoriasis is a chronic inflammatory Th1 immune-mediated disease affecting the skin
and joints that afflicts 2–3% of humans. We evaluated the correlation between severity of disease
and release of INF-a by ex vivo-activated T cells in the peripheral blood (PB) of psoriatic patients.
Methods: Percentage area of skin involvement was measured in 36 patients with psoriasis
vulgaris. Mononuclear cells (MCs) were isolated from PB of the patients and 15 healthy controls
by Ficoll Hypaque density centrifugation. T cells in the MC were activated with monoclonal
antibody to CD3 followed by culture in RPMI medium with 10% fetal calf serum in a humidified
CO2 incubator at 371C for 10 days, at which time supernatants were removed for analysis of INF a
concentration by ELISA.
Results: Table 1 shows [IFN-a] (pg/ml) in patients, stratified according to area of diseased skin,
and in the healthy controls. The concentration of INF-a in the severely affected patients was found
to be significantly decreased relative to both normal individuals and mildly affected patients
(Po0.02 and 0.03, respectively, two-tailed Student’s t-test). Table 1: area of psoriasis: IFN-a (pg/
ml) avg7SD (med): 80–90% 31.6724.8 (30), n¼ 6; 60–70% 35770 (0), n¼ 15; 10–30%
46.33761.88 (15), n¼ 9; 1–6% 174.167243.03 (102.5), n¼ 6; total psor 62.367117.4 (15),
n¼ 36; healthy 139.667218.19 (40), n¼ 15.
Summary and Conclusions: Ex vivo-activated and -cultured PB T lymphocytes from patients with
severe psoriasis secrete significantly less IFN-a than healthy individuals and patients with mild
psoriasis. We speculate that preferential migration of large numbers of IFN-a secreting T cells to
the skin in patients with severe psoriasis may account for these findings.
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A trend toward an increase of the VLA-1þCD8þ subset in the peripheral blood of
psoriatic patients
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Michael David, MD, Rabin Medical
Center, Petah Tikva, Israel, Ilan Bank, Sheba Medical Center, Ramat Gan, Israel
Background: Psoriasis is a chronic inflammatory Th1 immune-mediated disease affecting the skin
and joints that afflicts 2–3% of humans. T cells infiltrating the epidermis in psoriasis express very
late antigen (VLA)-1, a1/b1-integrin receptor that preferentially marks a subset of tissue infiltrating
effector memory Th1 cells and enables their migration and adhesion on collagen. To evaluate
further the significance of this subset of T cells in psoriasis, we examined the expression of VLA-1
on peripheral blood (PB) T lymphocytes in psoriatic patients.
Methods: Forty patients were examined and their Psoriasis Area and Severity Index (PASI) score
calculated. PB mononuclear cells (PBMCs) were dually stained with monoclonal antibodies
(mAbs) to CD4 or CD8 conjugated with PE, and mAb to VLA-1 conjugated with fluorescein
isothiocyanate (FITC) and analyzed by flow cytometry. We compared % VLA-1þCD4þ and
%VLA-1þCD8þ in the PBMC of a control group of normal individuals (n¼ 10) to those of
patients with moderate-to-severe psoriasis (PASI 20) and mild psoriasis (PASIo20). In addition,
PBMCs were activated in vitro with anti-CD3 mAb and the expression of VLA-1 evaluated in each
subset after 10 days of culture.
Results: Table 1 shows that the % VLA-1þCD8þ subset was increased in the psoriatic patients
compared to the normal controls (P ¼ 0.07). In contrast, VLA-1þCD4þ T cells were not
significantly increased. Interestingly, by contrast, after nonspecific in vitro activation using mAb
to CD3, cultures of normal and psoriatic patients contained similar numbers of VLA-1þ T cells of
both subsets.
Conclusions: These results demonstrate a trend toward an increase, relative to normal controls, of
the VLA-1þCD8þ subset in the PB of patients with psoriasis. This increase is not observed after
nonspecific ex vivo expansion, suggesting that antigenic stimulation of CD8þ T cells in vivo
specifically drives the activation and expansion of these T cells to express VLA-1 in the patients.
This increased induction of VLA-1 on CD8þ T cells in vivo may enhance their ability to localize
in the psoriatic epidermis. Table will be sent as an attachment to the confirmation Table 1:
Percentage VLA1þ T cells in CD8þ and CD4þ subsets in vivo and after ex vivo stimulation
CD8þVLA1þ /TOAL CD8þ avg7SD (median): mod-severe psor, n¼ 11 7.877.7 (5.2); mild
psor n¼ 13 5.375 (4.9); total psor n¼ 24 5.975.6 (4.1); healthy n¼ 9 373.6 (1.4);
CD4þVLA1þ /TOTAL CD4þ avg7SD median); mod-severe psor n¼ 11 3.673.7 (1.6); mild
psor, n¼ 13 5.575.6 (3.8); total psor n¼24 4.774.6 (3.6); healthy n¼ 9 372.7 (2.2);
CD8þVLA1þ /TOAL CD8þ after stimulation avg7SD (median); severe psor n¼ 8 11.177.5
(9.97); mild psor n¼ 11 11.9710 (10.2); total psor n¼ 19 11.679.6 (9.4); healthy n¼ 3
20.7711.9 (1.92); CD4þVLA1þ /TOTAL CD4þ after stimulation avg7SD (median); one
severe psor n¼8 0.676.3 (10.1); mild psor n¼ 11 17.5710.3 (11.5); total psor n¼19 14.679.3
(11.5); healthy n¼3 1777.8 (176).
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Increased frequency of circulating osteoclast precursors in psoriasis patients
Christopher Ritchlin, MD, Robert Loss MD, Tienmeng Shao, MS, Robert Durham, Edward
Schwarz, PhD, University of Rochester, Rochester, NY, USA
Purpose: Plaque formation precedes joint inflammation in most patients with psoriatic arthritis
(PsA). Thus, factors that lead to arthritis can be analyzed in psoriasis (Ps) patients. We
demonstrated previously that in PsA, circulating osteoclast precursors (OCPs) are elevated and
that PsA peripheral blood mononuclear cells (PBMCs) differentiated less efficiently into dendritic
cells (DCs) compared to PBMC from healthy controls (HCs) and patients (pts) with Crohn’s
disease. We hypothesized that PBMC from a subset of Ps pts without arthritis will also have
increased OCP levels and diminished conversion of monocytes into DC.
Methods: Ps pts with mild skin disease and no known arthritis completed a validated arthritis
questionnaire and a joint count and Psoriasis Area and Severity Index (PASI) was performed.
PBMCs were drawn from pts with Ps, early rheumatoid arthritis (eRA) and HC. Freshly isolated
monocytes were analyzed by flow cytometry (FACS) to evaluate the circulating monocyte
population. These cells were cultured for 6 days in GM-CSF and IL-4, stained with antibodies to
CD1a, CD14, and CD209 and analyzed by FACS to quantify conversion of progenitors into DC.
In addition, OCP frequency was obtained by counting the number of TRAP-positive cells with43
nuclei present in unstimulated monocytes after 2 weeks in culture.
Results: We identified 21 Ps pts with a mean age of 50 years and disease duration of 14 years. The
mean Psoriasis Area and Severity Index was 2.54þ 0.42. None of the pts (PsA or eRA) were on
disease-modifying antirheumatic agents or biologic therapies. Seven of 21 Ps patients had signs
and symptoms of inflammatory arthritis based on the questionnaire results and joint exam. Freshly
isolated monocytes isolated from Ps pts were phenotypically similar to monocytes from seven
eRA and 15 HC pts with relatively equal expression of CD11b, CD11c, CD33, and CD64.
However, 64þ 4.6% of HC and 54þ11% of eRA monocytes converted into DC compared to
only 48.2þ4.2% of Ps monocytes (P¼ 0.02 for Ps vs HC). The absence of CD1aþ cells was not
due to generation of mature DC as determined by the absence of CD83 and CD207 expression.
Furthermore, the frequency of OCP in Ps pts was 79þ 28.5 cells per million monocytes compared
to 15þ4.3 in HC and 15þ5.0 in eRA (P¼ 0.02 Ps vs HC, P¼0.04 RA vs Ps). Ten of 21 Ps pts had
an elevated frequency of OCP compared to 0 of 6 eRA pts and none of the HC. Four of the 10 Ps
pts with increased OCP had arthritis symptoms and signs.
Conclusions: The finding of joint inflammation in one-third of Ps pts with no prior arthritis
diagnosis is consistent with recent reports that show a higher prevalence of musculoskeletal
disease in Ps than initially appreciated. Furthermore, the differentiation of cultured monocytes in
Ps is skewed towards the formation of OCPs and away from DC, a pattern that is also observed in
PsA but not RA and HC. Thus, circulating OCP frequency may be a susceptibility biomarker that
is elevated in Ps patients at risk for arthritis.
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Regulation of 12-LOX gene expression by insulin-like growth factor-II promote
cell proliferation through ERK and PI3K–PKC pathway in human keratinocytes
Tae-Yoon Kim, PhD, Su-Jin Kim, Hyun Yoo, Kangnam St Mary’s Hospital, Catholic University of
Korea, Seoul, Seocho-gu, South Korea
Insulin-like growth factor II (IGF-II) is known to induce the growth of keratinocytes and to be
significantly elevated in fluid of bullae developed from psoriasis patients. However, the role of
IGF-II in psoriasis is not well elucidated. In this study, we tried to investigate whether IGF-II is
involved in the regulating gene expression of 12-lipoxygenase (12-LOX), which is already known
to be overexpressed in keratinocytes of germinal layer in psoriatic lesions. We found that IGF-II
upregulated the expression levels of 12-LOX mRNA and protein. To examine further the cellular
mechanism of IGF-II actions, we have studied the effects of IGF-II on two major signal
transduction pathways: mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-
kinase (PI3 kinase). 12-LOX gene expression by IGF-II was reduced by pretreatment with
inhibitors of tyrosine kinase and PI3 kinase. The inhibition of extracellular signaling-regulated
kinase (ERK) and MAPK also reduced the gene expression of 12-LOX elevated by IGF-II. 12-LOX
expression was blocked by cotransfection with dominant-negative plasmids of p38 and MEK.
However, DN-JNK did not block the IGF-II-induced 12-LOX expression. In addition, when we
treated HaCaT cells with 12(S)-HETE directly stimulated DNA synthesis and mitogenesis. Taken
together, the increased expression of 12-LOX gene by IGF-II might be involved in cell
proliferation through the ERK–MAPK and PKC–PI3 kinase pathway.
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Novel innate response cytokines in psoriatic arthritis
Iain B. McInnes, MRCP, PhD, David Kane, BSc, PhD, J. Alastair Gracie, BSc, PhD, University of
Glasgow, Glasgow Royal Infirmary, Glasgow, Scotland, Martin Gogarty, Barry Bresnihan, Oliver
FitzGerald, PhD, University College Dublin, St Vincent’s University Hospital, Dublin, Ireland
Purpose: Innate immune response cytokines are of importance in the pathogenesis of
inflammatory arthritis and may offer therapeutic potential. This study localized and quantified
expression and production of a variety of innate response cytokines in the inflamed synovium
(SM) in psoriatic arthritis (PsA) before and after immunomodulatory treatment with methotrexate.
Methods: Ten PsA patients (median duration of PsA¼ 18 months) underwent arthroscopic SM
biopsy of an inflamed knee before and after methotrexate treatment. Immunohistological (IH)
analysis was performed by semiquantitative analysis on a 0–5 scale in a minimum of three
biopsies for each patient using antibodies to CD3, CD4, CD8, CD68, Factor VIII, VCAM, e-
selectin and ICAM, Ki67, IL-12p70, IL-15, and IL-18. In parallel studies, IFN-f , IL-10, IL-12p35
and IL-12p40, IL-15 and IL-18 mRNA expression was quantified by Taqman PCR (relative to
normal SM or HPRG).
Results: Patients received a median methotrexate dose of 13.75 mg/week (7.5–15) for a median
duration of 11.5 months (7–14) resulting in significant reductions in Ritchie Index (P¼0.01),
swollen joint count (P¼ 0.02), and Disease Activity Score (P¼ 0.01). Methotrexate treatment
produced a significant decrease in sublining layer (SLL) T-lymphocytic and macrophage
infiltration and in lining layer (LL) macrophage infiltration but with no reduction in
hypervascularity, a prominent differentiating feature of PsA synovitis. Specifically, before
treatment IL-12 mRNA was expressed in 6/10 patients before treatment and IL-12 protein was
present in occasional cells (o1%) located in SLL lymphocytic infiltrates in only 3/10 patients. By
contrast, IL-15 and IL-18 were detected in 10/10 patients by PCR and IH. IH demonstrated a
similar degree but a differential distribution of IL-15 expression (predominantly localized in SLL
endothelial cells) and IL-18 (present in LL and in cellular infiltrates in the SLL). Methotrexate
reduced IL-15 (SLL: 1.7 reduced to 0.8, P¼ 0.003) and IL-18 (SLL: 1.2 reduced to 0.5, P¼ 0.02)
expression by IH analysis. IL-15 expression correlated significantly with SLL T lymphocyte
infiltration (r¼ 0.55, P¼ 0.02) and IL-18 correlated with SLL vascularity (r¼0.67, P¼0.004).
Conclusions: IL-15 and IL-18 likely play an important role in PsA via enhanced T-cell recruitment/
activation, neutrophil activation, and angiogenesis. Methotrexate produced a clinical response in
PsA associated with a reduction but not abolition of IL-15 and IL-18 expression in SM. Subsequent
targeting of these cytokines could therefore provide additional clinical benefit. The role of IL-12 is
less clear.
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Are the pathogenic T cells in psoriasis generated in the tonsils and what are they
reacting to in the skin?
Helgi Valdimarsson, Landspitali University Hospital, Reykjavik, Iceland
Psoriasis is frequently referred to as a T-cell-mediated autoimmune disease, but recent reviews
have mostly focused on genetic aspects of the disease and new biological agents for treating it.
Yet elucidation of the mechanisms that initiate psoriasis and the entities that the T cells are
reacting to in the skin lesions is prerequisite for the development of measures that prevent or
permanently cure the disease. Numerous studies have consistently identified oligoclonal T cells in
chronic psoriatic lesions, indicating that the pathogenic process is driven by relatively simple
antigenic entities. We have recently observed a markedly increased frequency of skin homing
(CLAþ ) T cells in the tonsils of psoriasis patients compared to recurrently infected tonsils from
non-psoriatic controls. This, together with our observation of a strong correlation between the
frequency of circulating CLAþ T cells and disease severity, as well as the oligoclonality of
lesional T cells in the skin, indicates that the pathogenic T cells may be primed in the tonsils. We
have, furthermore, observed that T cells circulating in psoriasis patients respond to peptides that
share amino acids with streptococcal M proteins and the keratins that are overexpressed in
psoriasis, and the responding T cells are CLAþ . In contrast T cells from non-psoriatic controls
only show relatively low responses to the M-peptides but no or minimal responses to the keratin
peptides. We have also observed an abnormal expression in the tonsils of psoriasis patients of the
antibacterial peptide cathelicidin (LL-37). We conclude that psoriasis patients may have
immunoregulatory abnormalities in their tonsils and that their tonsillar T cells may be primed
by external agent(s) (b-haemolytic streptococci) to recognize keratin epitopes in the skin.
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Vascular endothelial growth factor in psoriatic arthritis
Hanna Przepiera-Bedzak, MD, PhD, Iwona Brzosko, MD, PhD, Katarzyna Fischer, Marek
Brzosko, MD, PhD, Pomeranian Medical University, Szczecin, Poland
Introduction: The potential role of vascular endothelial growth factor (VEGF) in the pathogenesis
of psoriatic arthritis (PA) has not been studied.
Objective: The objective of this study was to evaluate serum VEGF levels in PA patients and to
look for association with markers of disease activity.
Materials and Methods: we studied 30 patients (22 women, eight men) with confirmed diagnosis
of PA. The following information was recorded: age, sex, disease duration, the Health Assessment
Questionnaire (HAQ) score, SF-36 questionnaire score, ESR. The following indexes were
assessed: BASFI, BASDAI, BASG, BASMI. Serum VEGF levels were determined using sensitive
sandwich ELISA.
Results: Mean age of patients was 52.2 years (SD: 13.1), mean disease duration was 9.1 years (SD:
6.6). The mean serum level of VEGF was 507 pg/ml (SD: 485.1). There were no significant
differences of VEGF mean levels when we compared PA patients with mean scores of BASFI,
BASDAI, BASG 4¼ 5 with group which had this scores o5 (P40.1). We did not find any
significant correlation of serum VEGF levels with ESR (r¼ 0.05), HAQ (r¼0.16), SF-36
(r¼0.16), BASFI (r¼ 0.1), BASDAI (r¼0.01), BASG (0.07), and BASMI (0.21) scores,
P40.1. We found significant negative correlations of ESR with SF-36 score (r¼0.36; P¼ 0.05)
and of SF-36 score with BASFI score (r¼0.54; P¼0.01).
Conclusions: Serum levels of VEGF appear to be not associated with markers of disease activity in
PA patients.
QUALITY OF LIFE
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Psoriasis impacts daily life and carries a substantial burden: National Psoriasis
Foundation Survey Panels
Elizabeth J. Horn, PhD, National Psoriasis Foundation, Portland, OR, USA
Psoriasis is a chronic disease that significantly impacts daily life and carries a substantial burden.
To understand better the impact of this disease, the National Psoriasis Foundation has conducted
surveys twice each year beginning in 2003 of individuals with psoriasis and psoriatic arthritis.
These survey panels are composed of approximately two-thirds of respondents who report having
been diagnosed with psoriasis and approximately one-third of respondents who report having
been diagnosed with both psoriasis and psoriatic arthritis. In addition, more than one-fourth of
respondents without a psoriatic arthritis diagnosis report having joint pain or stiffness lasting more
than 3 months. Psoriasis significantly impacts quality of life with approximately one-half of
respondents reporting strong feelings of anger and frustration, helplessness, self-consciousness,
and embarrassment with their psoriasis (Koo Menter Psoriasis Instrument). Psoriasis negatively
impacts daily life with respondents reporting problems sleeping, using their hands, walking,
sitting for long periods, standing for long periods, and interference with sexual activities because
of their psoriasis. More than one-third of respondents consider their psoriasis to be a large
problem in everyday life. Psoriasis also negatively impacts ability to work, as respondents report
not working because of their psoriasis. Approximately one-third of respondents report psoriasis
negatively affects their job. Respondents report missing days from work because of their psoriasis,
and many of those days missed are to receive treatment. These surveys provide additional
evidence that psoriasis can negatively impact quality of life. The National Psoriasis Foundation
encourages clinicians to incorporate the impact of psoriasis on patients’ quality of life in their
treatment decisions.
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Quality of life and quality of care in psoriasis: An initial clinical study of an
international disease management program
John de Korte, Academic Medical Center, Amsterdam, The Netherlands
Introduction: Health-related quality of life has become an essential outcome measure in the
treatment of psoriasis. Outcome studies demonstrate positive effects of dermatological treatment
on physical, psychological, and social functioning and well-being. Dermatological treatment in
combination with interventions explicitly focusing on improvement of adherence, coping
behavior, and psychosocial functioning, may result in an even higher degree of improvement of
quality of life. For these reasons, a simple disease management program was developed. This
program consisted of disease education, disease management training, and psychological
support, together with topical treatment.
Objective: To test the feasibility of a disease management program in dermatological practice,
and to assess patients’ satisfaction with this programme, adherence to topical treatment, disease
severity and quality of life.
Methods: An initial clinical investigation was conducted in 10 European treatment centers. A total
of 330 patients were included. Patient satisfaction, adherence, disease severity, and quality of life
were measured with study-specific and standardized self-report questionnaires.
Results: Patients reported a high degree of satisfaction with the disease management program, and
a high degree of adherence to topical treatment. Disease severity and quality of life significantly
improved. The program was well received by the participating professionals.
Conclusions: The disease management program was found to be a useful tool in the management
of psoriasis, providing patients with a relief from the burden of psoriasis in everyday life.
Reference: de Korte J, Van Onselen J, Kownacki S, Sprangers MAG, Bos JD. Quality of care in
patients with psoriasis: an initial clinical study of an international disease-management
programme. J Eur Acad Dermatol Venereol 2005;19:35–41.
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Activities of the German Psoriasis Association (DPB)
Joachim Barth, MD, Rudolph-Virchow-Strasse 4, Borna, Saxony, Germany, Hans-Detlev Kunz,
German Psoriasis Association, Hamburg, Germany
The German Psoriasis Association (Deutscher Psoriasis Bund e. V., DPB) has about 8,000
members from all over the country. These represent o4 of the estimated number of psoriasis
patients in Germany. A preliminary study in 252 randomly selected families in Dresden/Saxony
found a prevalence rate of 2.71%. Until the end of 2005, the DPB run the information center for
people with skin problems in Germany. The DPB in involved in different advisory boards of the
German ministry of health. There exist very close relations to the German Society of Dermatology
(DDG) and the Association of German Dermatologists (BVDD). The DPB is also supported by
insurance companies and a sponsor group of pharmaceutical companies according to the ethical
rules of sponsorship for patients’ organizations. On the other hand it supports itself different
research projects on psoriasis in Germany.
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The World Health Organization (WHO) International Classification of Function-
ing, Disability and Health (ICF) as a framework for understanding the
manifestations and consequences of psoriasis and psoriatic arthritis
Philip Mease, MD, Swedish Medical Center, University of Washington School of Medicine,
Seattle, WA, USA, W.J. Taylor, Wellington School of Medicine & Health Sciences, University of
Otago, Wellington, New Zealand
Background: The ICF represents an important step in developing a universal language and
terminology for comprehensively describing how disease affects people. It consists of a model
that incorporates five elements: the disease, impairments (problems at an anatomical or
physiological level, for example. joint pain), activity limitations (problems with a task or action at
a whole person level, for example walking), participation restrictions (problems with life
situations at a societal level, for example. engaging in noncompetitive sports), environmental
factors (external factors that modify the impact of disease, for example attitudes of family), and
personal factors (internal factors that modify the impact of disease, for example age). The ICF also
consists of over 1,000 specific items grouped under these categories: body functions, body
structures, activities and participation, environmental factors.
Purpose: To develop a comprehensive but concise list of ICF items that captures the total
experience of having psoriasis and psoriatic arthritis for use in assessment and outcome
measurement in this population.
Methods: In collaboration with the core-set project of the ICF Research Center of the University of
Munich, the following studies were developed: (a) a consensus exercise (Delphi) with health
professionals to identify relevant ICF items for psoriasis and psoriatic arthritis; (b) a systematic
review of outcome measures in randomized controlled trials of psoriasis and psoriatic arthritis to
map outcome measures to ICF items; (c) direct application of an abbreviated form of the ICF to
people with psoriatic arthritis; (d) elicitation of issues mapped to ICF items of direct relevance to
people with psoriasis and psoriatic arthritis (focus groups).
Results: To date, the consensus exercise among health professionals has been completed. This
identified a large number of relevant ICF items for psoriatic arthritis and psoriasis; many more are
being measured in standard outcome measures. These will be presented. Analysis of a focus
group study in people with psoriasis is not yet complete, but preliminary results confirm that
social issues are a dominating concern. Other studies are in progress.
Conclusions: Comprehensive understanding of how psoriasis and psoriatic arthritis affect people
can be facilitated by the ICF framework. Gaps in current assessment and outcome measures can
be identified using the ICF approach. Further work to develop standardized tools to apply the ICF
in clinical practice or clinical trials of psoriasis or psoriatic arthritis will be required.
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Koo-Menter Psoriasis Instrument & PQOL-12
John Koo, MD, University of California San Francisco, San Francisco, CA, USA, Alan Menter,
MD, Baylor Medical Center, Dallas, TX, USA
The Koo-Menter Psoriasis Instrument (KMPI) is a one-page (front and back) tool that can be used
to easily and objectively identify patients who would benefit from systemic antipsoriasis therapy.
One side of the page is completed by the patient and includes: the validated 12 item Psoriasis
Quality-of-Life Questionnaire (PQOL-12); a diagram on which patients can identify the location
and extent of their psoriatic lesions; and questions relating to joint symptomatology. On the
reverse side of the page, the physician records the results of a physical assessment and answers
key ‘‘yes/no’’ questions regarding the severity of the patient’s psoriasis, previous treatment, and
the feasibility of phototherapy. The patient’s need for systemic therapy can then be easily
determined from the patient’s and physician’s response. The KMPI is a simple but powerful tool
that assesses health-related quality of life, joint symptomatology, and disease severity and can
serve as an important guide to dermatologists in their treatment decision for the use of systemic
therapy in patients with psoriasis. PQOL-12, which is an integral part of KMPI, is a newly
introduced quality of life instrument which was validated over 6 years time period through both
multi-centered clinical validation study involving 483 patients recruited across the continent of
the United States and through application in clinical trials. It is an easily administered, reliable
instrument with outstanding sensitivity for the entire range of severity of psoriasis. PQOL-12 has
been derived from a series of empirical testing followed by factor analysis starting from US wide
population sample and distilled down to 12 items that are most valid and most sensitive. The
incorporation of PQOL-12 in KMPI allows the clinician to make optimal decision regarding the
need for systemic therapy with the quality of life issues assessed using latest instrument derived
from refinement of one of the most extensive patient-based database ever employed in a
formulation of a QOL instrument.
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Revealing the extensive secondary impact of psoriasis on family members
Ahmed Eghlileb, Emily Davies, Andrew Finlay, MD, Cardiff University, Cardiff, Wales, UK
Psoriasis appears to affect all aspects of a patient’s life but can also affect the psychological health
of partners (Richard HL, Chong SLP, Mason DL, Griffiths CEM. The impact of psoriasis on healthy
partners of patients with psoriasis. Br J Dermatol 2002; 147 (Suppl 62): 40). Very little is
documented concerning this secondary impact of psoriasis on partners and family members. The
aim of this study was to identify the different aspects of the lives affected of family members and
partners of patients with psoriasis. Intensive qualitative interviews with 19 family members and 14
partners of 33 adult patients with psoriasis were conducted. Twenty-four (73%) of partners and
relatives described psychological pressures including anxiety, upset and worry about the patient’s
future. Seventeen (51%) described social disruption due to lack of social confidence either due to
embarrassment or due to time spent on care duties. Twelve (36%) described limitation on their
daily activities such as shopping, work, going out, and swimming. Ten (30%) mentioned the
adverse effects on their sexual relationships. Ten (30%) described the increased burden of care
related to extra time spent on cleaning and washing because of treatment and scales. Five (15%)
felt that their interpersonal relationships had deteriorated. Three (9%) described financial
difficulties relating to treatment cost and loss of work. Only two (6%) described no effect at all on
their quality of life. This study has demonstrated that the secondary impact of psoriasis on family
members is very extensive. Appropriate care strategies need to be developed to address this
additional unrecognized burden of psoriasis.
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Experiences from a hotline providing guidance for members of the Danish
Psoriasis Association and their families
Ingelise Randboell, N.S., Lis Larsen Olesen, Danish Psoriasis Association, Hvidovre, Denmark
Two hours once a week the members of The Danish Psoriasis Association and health-care
personal can get guidance and advices regarding treatment, choice of job, economical problems,
psychosocial aspects, coping with a chronic disease, etc. The hotline is established by phone or e-
mail. The guidance is given by a social worker and a nurse specialist. The possibility is used often
by people with the disease as well as their relatives. Typical questions asked: I am afraid to use
steroid cream, is it a danger to my health? My psoriasis has a flare up, it’s getting totally out of
control, what should I do? I can’t use my hands because of fissures, what’s to be done? Suffering
from psoriasis, can I get some sort of financial support? How can I get financial compensation for
the extra expenses that are associated with having a child with psoriasis? How can I manage my
present job having psoriatic arthritis? Have you any ideas for me so that I can remain at the labor
market? According to our experiences the most striking advantages of the hotline are that the
persons with psoriasis consider the psoriasis association as their own and therefore they regard the
advisors as being ‘‘on their side’’. They feel comfortable because they can keep the personal
distance that they prefer. Once the contact is established they often call again. On the other hand,
the lack of visual contact might also be a limitation in severe cases inasmuch as the advisers
cannot see the symptoms of the person. Five important messages: (1) a team comprising a social
worker and a nurse is a good combination. (2) The team should have broad-based experience
through many years of practice. (3) The advisors must have knowledge of problems connected
with children as well as adults. (4) Educational experience is warranted. (5) The hot line should be
available for contact by phone or e-mail.
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Stress and psoriasis: A reciprocal relationship?
Andrea W.M. Evers, PhD, P. Duller, MS, E.W.M. Verhoeven, MS, E. de Jong, F.W. Kraaimaat,
MD, J. Schalkwijk, MD, Peter C.M. van de Kerkhof, MD, Radboud University Medical Center,
Nijmegen, The Netherlands
Patients with psoriasis form a substantial part of the patients in dermatological and general
practice. Research findings in primary and secondary care regarding the impact of psoriasis on
daily life in 310 patients with psoriasis will be demonstrated, showing (1) a high impact on
psychosocial functioning of patients in primary and secondary care and significantly lower levels
of well-being in comparison to the general population, (2) a high level of physical suffering,
particularly for symptoms of itch and fatigue which are present in about three-quarter of patients,
(3) a considerable number of patients with psychiatric morbidity who score a risk for clinical
depression diagnosis, varying from 18% in primary care to 35% in secondary care. When looking
for individual differences between patients, results further demonstrate that particularly patients
who suffer from physical symptoms of itch and fatigue and who feel helpless in coping with the
disease, have more distress and should be a focus of attention. With regard to the effects of
psychological stress on psoriasis, a vast majority of patients with psoriasis believe that stress has
an effect on their skin status (about 88%). The effects of stress factors are currently studied on the
skin status of psoriasis patients, by following 100 patients with weekly and monthly assessments
of clinical and self-report data during a period of 6 months. Preliminary results of the prospective
relationships between stress measures and skin status and physical symptoms supported the
expected stress–disease relationships, showing that stress factors were predictive for future skin-
related changes. From the results of these studies, there is at least preliminary support for a
reciprocal relationship between stress and psoriasis, showing high levels of psychosocial
impairments in daily life for patients, which in turn can contribute to a further worsening of
psoriasis.
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Psoriasis and social stigma
Ray Jobling, St John’s College, University of Cambridge, Cambridge, UK
The social sciences offer concepts and theories that can illuminate the stigmatizing impact of
certain diseases and illnesses, including skin diseases in general and psoriasis in particular. There
is evidence confirming such stigmatization and the contributory processes at both macro amd
micro levels. The potential implications for social functioning and participation, and quality of life
have received attention. There have been some efforts to counter stigmatization and its effects at
both individual and social levels. Such interventions require more research and reflection, not
least to ensure that they are effective but also to minimize the risk of possible unintended amd
adverse consequences. The role of deliberate ‘‘disease awareness’’ campaigning in particular
deserves attention.
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Factors accounting for quality of life in psoriasis patients
Konrad Janowski, PhD, Catholic University of Lublin, Lublin, Poland
Psoriasis is a chronic skin condition with potential adverse effect on quality of life of the afflicted
individuals. However, the severity of the decrements in quality of life varies in particular
individuals, and little is known about which factors and to what extent determines these
differences. Several factors have been hypothesized to account for the differences in quality of life
among psoriasis patients including sociodemographic variables, severity of the disease,
personality or coping strategies. The objective of this study was to evaluate the extent to which
particular groups of factors contribute to the decrease in quality of life due to psoriasis. A sample
of 174 patients with psoriasis was studied by means of measures of (1) disease severity, (2)
personality, (3) coping strategies, (4) cognitive appraisal of the disease, and (5) quality of life.
Additionally, sociodemographic and relevant medical information was also collected. The
obtained data were analyzed by means of hierarchical regression analysis to yield the factors
significantly accounting for the level of quality of life and to estimate their relative contribution to
decrements in quality of life. The factors that were found to have the most profound influence on
quality of life involved some medical variables and cognitive appraisal. These results can be
translated into better evidence-based recommendations for psychosocial interventions to improve
quality of life in psoriasis patients.
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Variation of psoriasis impact on quality of life of Spanish patients between the
years 2003 and 2005
Miquel Ribera-Pibernat, PhD, Hospital Universitari Germans Trias i Pujol, Badalona, Spain,
Gloria Caballe´, MD, LEO Pharma, Barcelona, Spain, Maria Jose´ Fuente, PhD, Carlos Ferra´ndiz,
PhD, Hospital Universitari Germans Trias i Pujol
Introduction: Psoriasis is a chronic cutaneous disease that, despite its benign nature, has an
important impact on the patients’ quality of life (QoL). In 2003, we performed a cross-sectional
survey on the impact of psoriasis on QoL of psoriatic patients (Ribera M, Caballe´ G, Ferna´ndez-
Chico N, Fuente MJ, Ferra´ndiz C. Impacto de la psoriasis en la calidad de vida del paciente
espan˜ol. Piel 2004; 19:242–9). There is no doubt that the introduction of biologic treatments has
increased the awareness of the illness among psoriatic patients and as a consequence some
changes in QoL could have happened.
Objective: The main aim of this study was to determine the variations of the QoL of psoriatic
Spanish patients during that period. An additional aim was to evaluate the change in patients’
degree of satisfaction with the treatment.
Patients and Methods: A cross-sectional survey on the impact of psoriasis on QoL was performed
using a postal questionnaire (EUROPSO). The same questionnaire was sent again to the 1,600
members of ‘‘Accio´n Psoriasis’’, a Spanish association of psoriatic patients. Four hundred and ten
(25.6%) of these patients replied within a month of receiving the questionnaire.
Results: During that period the survey response rate increases from 22.2 to 25.6%. These results
confirm an increase of psoriasis awareness among patients. There were no significant variations
on social and professional lives of patients. We only observed a small improvement in patient’s
psychological and emotional status due to the stress and insecurity caused by the disease. Doctor
and patient perceptions regarding severity of psoriasis continues to be different.
Conclusions: Small improvements in patients’ psychological and emotional status have been seen
during the study period. It seems that the increase of awareness of psoriasis could have favorable
impact on QoL of Spanish psoriatic patients.
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Impact of patients’ psoriasis on the quality of life of their families: Initial results
from a validation study of a novel dermatology-specific measure
Mohammad Khurshid Azam Basra, Cardiff University, Wales College of Medicine, Cardiff, Wales,
UK, Robert Su-Ho, Cardiff Royal Infirmary, Cardiff University, Cardiff, Wales, UK, Andrew Finlay,
MD, Cardiff University
Psoriasis has a major adverse impact on the quality of life (QoL) of patients (Finlay AY, Coles EC.
Br J Dermatol 1995; 132: 236–44). Little work has been done to assess the secondary impact of
psoriasis on the families (Richards HL et al. Br J Dermatol 2002; 147(suppl 62): 40) of patients.
The aim was to assess the impact of psoriasis on different aspects of QoL of patients’ families using
a new dermatology-specific QoL instrument. Ethical approval was granted. This work is a part of a
larger study to validate a newly developed QoL instrument – the Family Dermatology Life Quality
Index (FDLQI), which specifically measures the secondary impact of a patient’s skin disease on
his/her family. Nineteen psoriasis patients attending the dermatology outpatient clinic of a
university hospital were asked to complete the Dermatology Life Quality Index (DLQI), whereas
their accompanying family members/partners completed the FDLQI. The FDLQI contains 10
items (score range 0–3) and total score ranges from 0 to 30; increasing score indicates decreasing
QoL. The mean age of patients (n¼ 19, M¼ 8, F¼ 11) was 44 years, whereas the mean age of
family members (n¼ 19) was 49 years; most were either one of the parents (n¼ 6) or spouses
(n¼ 10). Duration of patients’ psoriasis ranged from 3 months to 42 years (mean¼ 17 years).
Patients’ DLQI scores ranged from 0 to 17 (mean¼ 7.6, SD¼4.7). The FDLQI scores ranged from
3 to 16 (mean¼ 6.7, SD¼3.1). The percentage of family members/partners who experienced
individual FDLQI items impact was as follows: emotional impact 79%, physical well-being 53%,
relationships 42%, people’s reaction to patient’s appearance 58%, social life 37%, leisure
activities 53%, burden of care 68%, effect on house work 53%, job or study 16%, and household
expenditure 74%. Psoriasis impacts not only on the QoL of the sufferer but also on his/her family.
This study demonstrates further evidence of the burden of psoriasis within society. The FDLQI
seems to have the potential to compare the secondary impact of psoriasis with other skin diseases.
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Members of the National Psoriasis Foundation: More extensive disease and better
informed about treatment options
Tamar Nijsten, MD, Erasmus Medical College, Rotterdam, The Netherlands, Tara Rolstad, Lake
Oswego, OR, USA, Steven Feldman, MD, PhD, Wake Forest University School of Medicine,
Winston-Salem, NC, USA, Robert Stern, MD, Beth Israel Cosmetic Surgery Center, Chestnut Hill,
MA, USA
Objective: Patient advocacy groups such as the National Psoriasis Foundation (NPF) serve as
representatives of those affected by disease and provide information about the condition. Our
objective was to assess the extent to which NPF members differ from nonmember patients with
psoriasis in their knowledge and use of therapies.
Participants: Using random-digit dialing, we identified and interviewed patients with psoriasis in
the general US population. Randomly selected NPF members were also interviewed.
Main outcome measures: Multivariate logistic regression models were used to estimate
differences (odds ratios and 95% confidence intervals) in demographic and clinical characteristics
and in awareness and use of therapies between members and others diagnosed as having
psoriasis.
Results: Of 601 individuals with psoriasis identified from the general population survey, 185
provided a second interview and were defined as nonmembers. We interviewed 289 randomly
selected members of the NPF. Although members were significantly older and wealthier and had
more extensive disease, they reported the disease to be significantly less of a burden and were
more satisfied with therapy than others affected. Compared with nonmembers, members were
significantly more likely to have heard of and used most of the 10 therapies assessed. However,
the proportion of respondents who were aware of a therapy and who also used it did not differ
between groups.
Conclusions: Members of the NPF are better informed and more satisfied with available treatment
options than nonmember affected patients.
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Adolescents with psoriasis and their quality of life
Peter Keins, Fachklinik Sylt fuer Kinder und Jugendliche, Westerland, Germany
The major part of studies about quality of life is done on adult patients. Presented here are two
studies about the way adolescents view their illness and what effect a patient education program
especially constructed for children and adolescents with psoriasis has on the quality of life of the
patients. Study 1: 300 adolescents and their parents were asked about their knowledge of
psoriasis, subjective theory of their illness, and their coping with the illness. All patients had been
in a rehabilitation clinic for children and adolescents where they had taken part in a patient
education program (PSORA). Fifty patients and their parents returned the questionnaire. The
profile shows a difference between female and male adolescents in theory of illness and quality of
life. There are differences between patients and their parents concerning knowledge and coping.
Study 2: the effectiveness of patient education programs for children and adolescents with asthma
and atopic dermatitis has been shown in larger studies in Germany. Based on the theoretical
concept of these programs a special program for psoriasis (PSORA) has been developed and
evaluated with three patient groups. A reduction in stress level, an increased knowledge on
psoriasis and an improved coping could be found with the patients participating in the program in
contrast to patients not participating. To see if these effects found at the end of the training were
still present at home, a study was made in which patients were presented a questionnaire a month
after having participated in the program. Thirty patients returned the questionnaire. At the end of
the training most patients had reported an improvement in coping with the disease. These
improvements were reduced after returning home. The data give a first impression about the way
adolescents cope with their disease. A patient education program for children and adolescents
with psoriasis has a positive effect on the quality of life of these patients. To stabilize the effects of
the training, further studies are needed.
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Patient reported outcomes show improvement within 1 week in patients with
psoriasis following etanercept treatment
Anca Serban, Wyeth Research, Collegeville, PA, USA, Alice Gottlieb, MD, PhD, University of
Medicine & Dentistry New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ,
USA, J.M. Woolley, D. Lalla, A. Jahreis, Amgen, Inc., Thousand Oaks, CA, USA
Objective: Evaluate the effect of etanercept on patient-reported outcomes (PROs) in patients with
moderate–to-severe psoriasis.
Methods: A 12-week, double-blind, multicenter, phase 3 clinical trial of etanercept was
conducted in the United States and Canada to confirm the efficacy and safety of etanercept 50 mg
twice/week in psoriasis patients. Six hundred and twenty patients with stable moderate-to-severe
psoriasis were randomized to receive twice/week etanercept 50 mg or placebo subcutaneously.
PROs included the DLQI, a disease-targeted health-related QOL 10 questions questionnaire and
six subscales (symptoms and feelings, daily activities, leisure, work and school, personal
relationships, and treatment). Total score ranges from 0 to 30, lower scores show better health
status. Patients who received at least one dose of study drug and provided baseline PRO
assessments (n¼ 308 and 304 for etanercept 50 twice/week and placebo, respectively) were
included in the analyses.
Results: Patients on etanercept achieved statistically significantly greater percent improvements in
the DLQI total score (Po0.05) by the first week relative to patients on placebo. At week 12, the
mean percentage improvement in DLQI was 69.1% for etanercept 50 mg twice/week and 22% for
patients on placebo (Po0.0001). Additionally at week 12, patients receiving etanercept 50 mg
twice/week improved (Po0.001) in each of the six DLQI subscales compared with those patients
on placebo.
Conclusions: Etanercept treatment improves PRO as early as 1 week. Improvement in DLQI
scores is consistent with improved DLQI scores seen in two other large phase 3 trials. Combined
with clinical evidence, these results show the efficacy of etanercept in patients with moderate-to-
severe psoriasis.
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Quantitative assessment on adherence to medication: Implications for treatment
Steven Feldman, MD, PhD, Wake Forest University, Winston-Salem, NC, USA, Rajesh
Balkrishnan, PhD, Ohio State University College of Pharmacy, Columbus, OH, USA
Psoriasis is a frustrating problem for patients, and often for physicians as well. The effectiveness of
treatments often does not meet expectations, particularly with long-term use. Poor adherence to
medication may account for much of the observed medication failures. Electronic monitors have
been developed that facilitate objective assessment of patients’ adherence. Using this technology,
poor compliance with topical treatment has been identified. Adherence to topical treatment of
chronic skin disease declines rapidly over time. The reduction in adherence over time may
explain much of the observed ‘‘tachyphylaxis’’ problem. It may also explain in large part other
topical treatment failures. Measures to improve adherence may be among the most effective
means to improve patients’ outcomes.
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Study of sleep quality in patients with psoriasis
Xue-qin Yang, Li You, Air Force General Hospital, Beijing, China, Jin Zhang-Rui, Institute of
Aviation Medicine, Beijing, China
Objective: To explore quality of sleep in patients with psoriasis.
Methods: Twelve psoriatic patients and 19 normal controls were examined by means of
polysomnography (PSG).
Results: The light sleep increased obviously, but medium and deep one decreased in psoriatic
group. Hypopnea index, apnea-hypopnea index, lowest saturation in arterial blood, o90%
oxygen desaturation index and SIT90 of psoriatic group were significantly higher than those of
normal control group. The values of rMSASD of psoriatic group were significantly lower than
those of normal control group. Arrhythmia of nonrapid eye movement sleep of psoriatic group
was significantly higher than normal control group.
Conclusions: It is indicated that sleep quality is lowered and levels of respiratory disturbance
index are on the high side in psoriatic patients. There is a likely advantage to the recovery if we
will try to improve sleep quality of psoriatic patients.
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Quality of life assessment in patients with psoriasis at Hospital Kuala Lumpur
Norashikin Shamsudin, Chuah Soo Le, Low Pek Gan, University Putra Malaysia, Kuala Lumpur,
Malaysia, Suraiya H. Hussein, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Psoriasis is a common chronic inflammatory skin disorder. It can have a major impact on patients’
quality of life that is increasingly recognized as an important outcome measure in dermatology.
Very few studies have assessed the quality of life in patients with psoriasis in the Asian population.
This study aimed to assess the quality of life in patients with psoriasis at Hospital Kuala Lumpur
using a psoriasis-specific questionnaire, the Psoriasis Disability Index (PDI). Patient satisfaction
with their treatment was determined using a pre-test questionnaire. A prospective cross-sectional
questionnaire study of 250 patients with all types and severity of psoriasis, aged 18–80 years,
treated at the Dermatology Department of Hospital Kuala Lumpur between June 2001 and August
2001 was performed. In addition to the PDI and the pre-test, there were six questions on the
physical and psychological aspects used. The total score of the PDI (0–45) for each patient was
expressed as a percentage. Results showed that the mean PDI score was 10.36% (range
0–64.44%, SD 11.37%). Majority of the patients (92%) were satisfied with their treatment. Further
analysis showed no significant difference in mean total PDI scores between both sexes and among
the races. Over 50% of the patients reported feeling self-conscious among strangers and
depressed/frustrated with their psoriasis. In conclusion, the quality of life in patients with psoriasis
in this study was only mildly affected as indicated by the low mean PDI score. This was also
reflected in the high patient satisfaction towards treatment. The majority of the patients, however,
were psychologically affected by the disease.
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Psoriatic arthritis: Patient knowledge and its relationship to quality of life
Marie O’Rourke, Oliver FitzGerald, PhD, Barry Bresnihan, St Vincent’s University Hospital,
Dublin Ireland, Douglas Veale, MD, FRCPI, FPCP, University College Dublin and St Vincent’s
University Hospital
Objective: The purpose of this study was to investigate the level of knowledge patients with
psoriatic arthritis (PsA) have of their disease and to assess if there is a relationship to quality of life.
PsA is associated with considerable joint damage, symptomatology, and quality of life (QoL). The
presence of two different disease manifestations (skin and joint) may be misleading for some
patients and could interfere with their knowledge process.
Methods: Ninety-one consecutive patients with established PsA completed the Patient Knowl-
edge Questionnaire and the PsAQoL questionnaire.
Result: The mean score on the Patient Knowledge Questionnaire was 18.5 (SD 4.3; range 7–28)
and the mean score on PsAQoL was 5.4 (S.D. 4.7; range 0–19). A Freidman’s Test found a
significant variation between the scores of the four areas of the Patient Knowledge Questionnaire
(P¼o0.0001). A significant correlation was found between the Patient Knowledge Ques-
tionnaire and the PsAQoL (r¼ 0.18; P¼0.03).
Conclusions: Results suggest that patient knowledge correlates with QoL. Patients who have more
knowledge of their disease seem to have a better QoL than patients less informed. This study is the
first to suggest such a link between Patient Knowledge and QoL. Future research could administer
the questionnaires at different time points to evaluate over time if patient knowledge parallels
with improvements in QoL as well as physical and functional improvements.
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Psoriatic arthritis patients treated with etanercept had reductions in healthcare
resource utilization: Results from the experience diagnosing, understanding care,
and treatment with Enbrel (educate) trial
J. Mark Jackson, MD, Dermatology Specialists, Louisville, KY, USA, Erin Boh, MD, Tulane
University, New Orleans, LA, USA, Drore Eisen, MD, DDS, Dermatology Research Association of
Cincinnati, Cincinnati, OH, USA, H. Amy Xia, Seth R. Stevens, MD, Amgen, Inc., Thousand
Oaks, CA, USA, Elaine Yu, MS, Genentech, San Francisco, CA, USA
Objective: To determine the effect of etanercept treatment on health-care resource utilization
(HRU).
Methods: In a multicentre, open-label study, psoriatic arthritis patients received etanercept 50 mg
weekly and were evaluated at baseline and weeks 2, 6, 12, and 24. At each visit, patients reported
their HRU since the previous visit. At baseline, patients reported utilization since the screening
visit. Data on the following categories of HRU were collected on 1,122 patients: (1) emergency
room (ER) or urgent care clinic; (2) physician’s office other than a dermatologist; (3) nurse
practitioner (NP) or physician assistant (PA); (4) psychologist, naturopath, acupuncturist, or
chiropractor; and (5) care from a health professional in the patient’s home. Only completers were
included in the analyses. Mean number of visits over each approximately 6-week interval was
compared to baseline using the Wilcoxon signed rank test.
Results: Reductions were seen in all categories of healthcare resource utilization with four out of
five categories being statistically significant. By week 12, utilization of each resource decreased
by more than half of the baseline value (Table 1).
Conclusions: The disease burden of psoriatic arthritis is reflected in health resource utilization.
Psoriatic arthritis patients treated with etanercept experienced reductions in health resource
utilization. These reductions may lead to savings in direct costs over the long term for psoriatic
arthritis patients.
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Psoriatic arthritis patients treated with etanercept reported reductions in
caregiver burden and absenteeism: Results from the experience diagnosing,
understanding care, and treatment with Enbrel (educate) trial
Jeffrey Sobell, MD, Tufts University Medical Center, Boston, MA, USA, Steven Grekin, MD,
Warren, MI, USA, Elaine Yu, Genentech, San Francisco, CA, USA, J.R. Antoni, PhD, Seth R.
Stevens, MD, H. Amy Xia, J. Michael Woolley, PhD, Amgen, Inc., Thousand Oaks, CA, USA
Objective: Little is known about the caregiver or workplace burden of psoriatic arthritis (PsA).
Changes in caregiver burden and sick days were evaluated in PsA patients treated with etanercept
(ETN) in a multicentre, open-label study.
Methods: Patients received ETN 50 mg weekly and were evaluated at baseline and weeks 2, 6,
12, and 24. At each visit, patients reported on their absenteeism and caregiver burden via a
questionnaire: (1) the number of sick days taken in the last month; (2) changes in job
responsibilities due to PsA since last visit; (3) paid assistance with house chores since last visit;
and (4) assistance from friends or family members since last visit. At baseline, patients reported
this information since the screening visit. The mean number of sick days per month between
baseline and weeks 6 and 12 were compared using Wilcoxon signed rank test. The percentages of
patients reporting paid assistance and assistance from friends or family members were compared
between baseline and weeks 6 and 12 using McNemar test.
Results: Of the 699 patients who reported working ł20 hours at baseline, the mean number of sick
days per month decreased from 0.80 at baseline to 0.54 at week 6 (Po0.0001) and 0.58 at week
12 (P¼0.0008). At baseline, 130 out of 1,030 (13%) patients reported having changed job
responsibilities because of PsA; this was reduced to 8% (P4o0.0001) at week 6 and 4%
(P4o0.0001) at week 12. The percentage of patients who reported having paid someone to help
with household chores was 21% (230 out of 1084) at baseline, 21%(P¼ 0.87) at week 6, and 13%
(P4o0.0001) at week 12. The percentage of patients who reported having a friend or family
member take time off work to provide care or transportation decreased from 8% (86 out of 1,083)
at baseline to 6% (P4o0.05) at week 6 and 3% (P4o0.0001) at week 12.
Conclusions: These findings suggest that PsA patients treated with ETN have meaningful
reductions in caregiver burden and absenteeism after only 12 weeks of ETN treatment. These
results may lead to savings on indirect costs over the long term for PsA patients.
Table 1. Mean numbers of health-care visits by
category compared to baseline
Baseline Week 6 Week 12
ER or urgent care 0.28 0.14* 0.07*
Physician’s office, other than dermatologist 1.20 0.67* 0.47*
NP or PA 0.40 0.14* 0.09*
Other health-care provider 0.52 0.26* 0.19*
Home care by provider 0.07 0.05 0.03
ER, emergency room; NP, nurse practitioner; PA, psoriatic arthritis.
*Po0.0001
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Response criteria for assessing peripheral arthritis in patients with psoriatic
arthritis: Analysis of performance characteristics in two randomized, controlled
trials of TNF inhibitors
J. Fransen, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands,
Christian Antoni, MD, Friedrich-Alexander University, Department of Medicine III, Erlangen,
Germany, Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA, USA, W. Uter, PhD,
Friedrich-Alexander University, Arthur Kavanaugh, MD, University of California San Diego, La
Jolla CA, USA, J.R. Kalden, MD, Friedrich-Alexander University, P.L.C.M. Van Riel, PhD,
Radboud University Nijmegen Medical Centre
In recent clinical trials in patients with psoriatic arthritis (PsA), response criteria designed for
rheumatoid arthritis trials were used for assessment of peripheral arthritis. These have not yet been
validated in PsA.
Objective: To compare the discriminative capacity of ACR, EULAR, and PsARC response criteria
in PsA patients with peripheral arthritis, using the data from two randomized placebo-controlled
trials of TNF inhibitors.
Methods: In the infliximab trial, 104 patients with active PsA were randomized to placebo or
infliximab for 16 weeks (Antoni, 2005). In the etanercept trial, 60 patients with active PsA were
randomized to placebo or etanercept for 12 weeks (Mease, 2000). Data from baseline and the end
of the intervention phase were used. Discriminative capacity of the response criteria was assessed
using the Mantel–Haenszel w2.
Results: Differences between placebo and active drug were found with Po0.0001 in both trials
by EULAR, ACR20, and PsARC criteria, thus all performed adequately. However, the percentage
of responders found in active drug and placebo groups differed. In the infliximab trial, there were
(active vs placebo) 92% vs 26% EULAR responders, 67% vs 10% ACR20 responders, and 82% vs
30% PsARC responders. The EULAR criteria discriminated better between active drug and
placebo than the ACR20 and PsARC criteria, with respective X2 values of 48.6, 36.2, and 27.9.
The ranking was similar in the etanercept trial. EULAR-28 criteria with 28 joint counts performed
better than the EULAR criteria with full joint counts. In both trials, ACR criteria with 50 and 70%
cutoff points did not perform better than ACR20.
Conclusions: Response criteria and pooled indices developed for rheumatoid arthritis are useful
for the assessment of arthritis in PsA clinical trials. The EULAR criteria discriminated better than
ACR criteria and PsARC in these trials of very effective agents.
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Childhood psoriasis: A study of 277 patients from China
Xun-Jun Zhang, PhD, Xing Fan, Feng-Li Xiao, Sen Yang, Jiang-Bo Liu, Kai-Lin Yang, Yan-Hua
Liang, Anhui Medical University, Heifei, Anhui, China
Psoriasis is common in childhood. The aim of this study was to present the clinical and
epidemiological profile of childhood psoriasis in China. A total of 277 childhood psoriasis
patients less than 16 years old were enrolled. Statistical analysis and heritability were performed
using EPI INFO 6.0, SPSS10.0, and Falconer’s method. The results show: (1) the median age was
11 years. The male:female ratio was 1:1.13. The median age of onset was 10 years. A total of
48.7% patients had previous episodes of psoriasis; (2) of the 277 children with psoriasis, 68.6%
had plaque-type psoriasis, 28.9% had guttate psoriasis, 1.1% presented pustular forms of
psoriasis, and 1.4% had erythroderma. The extensor surface of the extremities was the most
frequently affected site in our patients, followed by the appearance of lesions on the scalp; (3)
3.6% patients were accompanied with an associated disease; (4) a positive family history of
psoriasis was found in 34.3% patients. The prevalence of psoriasis in first- and second-degree
relatives was 7.0 and 1.0%, respectively. The heritability of psoriasis in first- and second-degree
relatives was 72.67 and 55.18%, respectively. Our epidemiologic studies offer the information
about Chinese Hans distribution, which provide clues to describe psoriasis in children.
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Comparison of clinical features in familial versus sporadic psoriasis vulgaris of
Chinese Han
Xun-Jun Zhang, PhD, Wei Li, Wei-Dong Du, Sen Yang, Feng-Li Xiao, Su-Min He, Wen-Hui Du,
Anhui Medical University, Heifei, Anhui, China
Psoriasis is a common, chronic and recurrent, inflammatory skin disease. Both genetic and
environmental factors play important roles in the pathogenesis of psoriasis. Psoriasis vulgaris is
the most common clinical type. This study aimed to explore some differences in clinical features
between familial and sporadic psoriasis vulgaris. Data collected from 582 familial patients and
678 sporadic patients with psoriasis vulgaris were analyzed by EPI and SPSS software. The age of
onset of familial psoriasis was significantly younger than sporadic psoriasis (Po0.001); familial
patients had a less onset frequency in summer (Po0.001). Sporadic psoriasis had a severer
(Po0.001) and more extensive cutaneous involvement (Po0.05) and more environmental impact
factors such as alcohol drinking, psychological stress, and drug intake (Po0.01), whereas
compared with familial psoriasis vulgaris. From the analysis of our data, it seems that familial and
sporadic psoriasis has different clinical feature and may have different genetic basis.
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Hormonal effects of pregnancy on psoriasis
Jenny E. Murase, MD, University of California Irvine Medical Center, Cupertino, CA, USA, Stefani
Kappel, Medical Student, School of Medicine, University of California, Irvine, John Koo, MD,
University of California San Francisco Medical Center, San Francisco, CA, USA, Kenneth K. Chan,
MD, Long Beach Memorial Medical Center, Long Beach, CA, USA, Thomas J. Garite, MD,
University of California Irvine Medical Center, San Juan Capistrano, CA, USA, Dan M. Cooper,
MD, University of California Irvine Medical Center, Orange, CA, USA, Gerald Weinstein, MD,
University of California Irvine Medical Center, Irvine, CA, USA
Background: Anecdotal reports suggest that psoriasis tends to improve in pregnancy. Other Th1-
mediated autoimmune diseases such as psoriatic arthritis, rheumatoid arthritis, and multiple
sclerosis have been shown to improve in pregnancy. This was postulated to be a result of
hormone-induced immune tolerance during pregnancy.
Objectives: To investigate prospectively how psoriasis fluctuates in pregnancy and postpartum.
Secondly, to correlate hormone levels in pregnancy (progesterone and estrogens) with psoriatic
change.
Methods: 47 pregnant patients with psoriasis and 27 nonpregnant, menstruating patients with
psoriasis (controls) were assessed five times over a year.
Results: During pregnancy 55% reported improvement, 21% reported no change, and 23%
reported worsening. However, postpartum only 9% reported improvement, 26% reported no
change, and 65% reported worsening. Psoriatic body surface area (BSA) decreased significantly
from 10 to 20 weeks gestation (Po0.001) compared to controls, whereas BSA increased
significantly by 6 weeks postpartum (P¼ 0.001) compared to controls. In psoriasis patients with
410% BSA who reported improvement (n¼ 16, mean BSA 40%), lesions decreased by 83.8%
during pregnancy. There were significant or near-significant correlations between improvement
in BSA and estradiol (P¼ 0.009, r¼ 0.648), estriol (P¼ 0.063, r¼ 0.491), and the ratio of estrogen
to progesterone (P¼ 0.006, r¼ 0.671).
Discussion: High levels of estrogen correlated with improvement in psoriasis, whereas
progesterone levels did not correlate with psoriatic change. We will discuss the possible
mechanisms of improvement in psoriasis resulting from hormone-induced immune tolerance
during pregnancy. We will also discuss estrogen as a possible therapeutic option for autoimmune
diseases such as psoriasis and psoriatic arthritis.
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Efficacy and safety of low-dose acitretin for the treatment of moderate-to-severe
plaque-type psoriasis
Leon Kircik, MD, Physicians Skin Care, PLCC, Louisville, KY, USA, Alex Yaroshinksy, PhD,
Connetics Corp., Palo Alto, CA, USA
The objective of this study was to evaluate the efficacy and safety of two low-dose regimens of
acitretin administered over 24 weeks in adult subjects with moderate-to-severe plaque-type
psoriasis. This multicenter, open-label, randomized study in the United States and Russia enrolled
213 adults 418 years age with moderate-to-severe plaque-type psoriasis defined as 410% total
body surface area involvement with psoriasis and an overall lesion assessment (OLA) score of43.
Subjects were randomized to acitretin 25 mg once daily for 24 weeks, or acitretin 25 mg once
daily for 12 weeks followed by ‘step down’ dosing of acitretin 10 mg once daily for 12 weeks.
Subjects who did not improve42 grades (OLA scale) at week 12 could be increased to 35 mg/day
at the investigator’s discretion. Efficacy end points included the proportion of subjects who
achieved an OLA score of 0 or 1 (none or minimal) at weeks 12 and 24 and the proportion of
subjects who achieved a Psoriasis Area and Severity Index (PASI) score reduction of 50% (PASI 50
response) and 75% (PASI 75 response) at weeks 12 and 24 relative to baseline. Subject’s Global
Assessment scores were also evaluated. An interim analysis of 54 subjects at six study centers in
Russia was performed. The baseline OLA (range 0–5) was 3 in 86% and 44 in 14% of subjects.
After 12 weeks of treatment an improvement in OLA score of 2 grades or more from baseline was
reported in 24% of the intent-to-treat (ITT) population and in 38% of the per-protocol population
(PPP). Complete study results will be available at the conference.
Conclusions: a meaningful response to low-dose acitretin was achieved by 12 weeks. 24-week
efficacy and safety data will be reported. If confirmed, these data suggest that a low-dose regimen
of acitretin may have utility in the treatment of moderate-to-severe psoriasis.
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Efficacy and safety of Dead Sea climatotherapy in the treatment of psoriasis
Michael David, MD, Tel Aviv University, Rabin Medical Center, Petah Tiqva, Israel, Avraham
Kudish, Ben-Gurion University of the Negev and Dead Sea Research Center, Beer Sheva, Israel,
Emmilia Hodak, Tel Aviv University, Rabin Medical Center, Marco Harari, Hani Giryes, Dead Sea
Research Center, Ein Bokek, Israel, Shimon Moses, Ben-Gurion University of the Negev, Dead
Sea Research Center, Neve Zohar, Israel
Dead Sea Climatotherapy (DSC) is very popular among psoriatic patients in Israel. The aim of this
paper is to report on recent investigations at the Dead Sea regarding optimal sun exposure
schedules, efficacy, and safety. Measurements of the daily variation of the ratio of UVB radiation
intensities at 30 and 312.5 nm (the ratio of the wavelength range of the erythema radiation to that
for the therapeutic radiation) were performed to determine the optimal sun exposure time
intervals. The clinical response and immunopathological changes were determined using
Psoriasis Area and Severity Index (PASI) score and immunohistological staining, respectively.
Lastly, psoriatic patients who underwent repeated DSC were interviewed and examined for sun
damage and skin cancer. As the time of sun exposure was distanced from solar noon, the
305:312.5 nm decreased significantly. The results can be cross-referenced to tabulated monthly
average hourly UVB radiation intensities to prescribe optimal patient sun-exposure time
schedules. After 4 weeks of treatment, the overall PASI score decreased by 81%. The number
of T-lymphocytes (CD3þ ; CD25þ ) was markedly decreased in psoriatic skin (depletion of 490
and 70% in epidermis and dermis, respectively). The average duration of remission was 3.3
months. Solar elastosis, solar lentigines, poikiloderma, and facial wrinkles were significantly more
common among patients compared to a control group. The prevalence of nonmelanoma skin
cancer did not differ between the two groups. No cases of melanoma were detected. DSC is
highly effective in the treatment of psoriasis in Israel. It is a remittive therapy leading to a reversal
of immunological abnormalities in psoriatic lesions. Medical staff at the Dead Sea now has access
to tabulated data to prescribe the optimal time of UV exposure. Consequently, this procedure
assures a proper dose of UV B radiation, whereas minimizing exposure to erythema radiation.
DSC is not associated with an increased risk of skin cancer for patients with psoriasis in Israel.
However, repeated UV exposure at the Dead Sea may play a role in the development of solar
damage. Various combinations of DSC with other drugs may increase efficacy and minimize the
risk for long-term solar damage.
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Association between psoriasis, diabetes mellitus and artherosclerosis. A case–-
control study
Jonathan Shapiro, Maccabi Health Services, Tel Aviv, Israel, Arnon Kohen, Klalit Health Services,
Beer Sheva, Israel, Michael David, MD, Emilia Hodak, Rabin Medical Center, Petah Tiqva, Israel,
Viner Ana, Maccabi Health Services, Ramat Hasharon, Israel, Eyal Kremer, Anthony Heymann,
Maccabi Health Services, Tel Aviv, Israel
Background: Previous reports demonstrated an association between psoriasis and other disorders
including obesity, smoking, heart failure, and diabetes mellitus.
Objectives: To describe the association between psoriasis, diabetes mellitus, and atherosclerosis
in Israel.
Methods: A cross-sectional study was performed utilizing the database of ‘‘Maccabi Health
Services’’ (MHS), a large health provider organization in Israel. Case patients were defined as
subjects who were diagnosed with psoriasis. Diabetes and atherosclerosis patients were identified
using the MHS diabetes and cardiovascular registries. The control group included MHS enrollees
without psoriasis. The proportion of diabetes and atherosclerosis among case and control groups
was compared. A multivariate logistic regression model was used to assess the association
between psoriasis and diabetes such as between psoriasis and atherosclerosis.
Results: The study included 46,850 patients with psoriasis and 1,578,282 subjects without
psoriasis. In subjects between the ages 25 and 55, age-adjusted proportion of diabetes and
atherosclerosis was significantly higher in psoriasis patients as compared to the control group
(odds ratio ranging from 1.3 to 1.4, Po0.001). In psoriasis patients above the age of 55, the
proportion of diabetes and atherosclerosis was similar to that of the control group. Among
psoriasis patients, a multivariate logistic regression model demonstrated an association between
diabetes and age (Po0.001), gender (Po0.001), use of potent topical steroids (Po0.01), or
systemic medication for psoriasis (methotrexate, cyclosporine or acitretin) (Po0.001). A similar
model demonstrated an association between atherosclerosis and age (Po0.001), gender
(P4o0.001), use of potent topical steroids (Po0.05), or phototherapy (Po0.001).
Conclusions: Our study supports previous reports for an association between psoriasis and
diabetes and between psoriasis and atherosclerosis, expressed by presentation of diabetes and
atherosclerosis earlier in life rather then true higher proportions. A possible association exists
between severity of psoriasis, diabetes mellitus, and atherosclerosis.
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Echocardiographic findings according to disease activity in patients with psoriatic
arthritis
Hanna Przepiera-Bedzak, MD, PhD, Iwona Brzosko, MD, PhD, Malgorzata Peregud-Pogorzelska,
MD, PhD, Marek Brzosko, MD, PhD, Zdzislawa Kornacewicz-Jach, Pomeranian Medical
University, Szczecin, Poland
Introduction: Cardiac involvement in psoriatic arthritis (PA) has not been studied.
Objectives: To assess echocardiographic abnormalities in patients with PA according to activity
of the disease.
Materials and Methods: We studied 30 patients (22 women, eight men) with confirmed diagnosis
of PA. The following information was recorded: age, sex, disease duration, the Health Assessment
Questionnaire (HAQ) score, SF-36 questionnaire score, ESR. The following indexes were
assessed: BASFI, BASDAI, BASG, BASMI. Serum VEGF levels were determinated using sensitive
sandwich ELISA. Echocardiographic examinations (M-mode, D-dimensional, and enriched with
color-Doppler technology) were performed in a standard manner with Acuson 128 XP
echocardiographic apparatus. Echocardiographic evaluation (ECHO) included: left atrial
diameter (LA), aortic width (Ao), leaflets and cusps of valves, valvular insufficiency (scored
0–4þ ), contractility, ejection fraction (EF) of the left ventricle (LV), right ventricular dimensions,
mitral valve prolapse (MVP), interatrial septum mobility, pericardium, and LV diastolic function
(E/A ratio, IVRT, DEC Time).
Results: Mean age of patients was 52.2 years (SD: 13.1), mean disease duration was 9.1 years (SD:
6.6). We found the following echocardiographic abnormalities: diastolic dysfunction of restrictive
type in 26.7% PA patients, systolic dysfunction (EFo55%) in 16.7%, aortic insufficiency in
–36.7%, mitral insufficiency in 16.7%. We found positive correlation between EF and VEGF level
(r¼ 0.40; P¼0.05). Patients with mitral insufficiency had lower disease activity assessed by BASG
(Po0.01), BASDAI (P¼ 0.01), BASFI (Po0.05). Patients with diastolic dysfunction and mitral
insufficiency had lower disease activity assessed by VEGF (P¼ 0.1).
Conclusions: Cardiac involvement in PA is not rare. Diastolic dysfunction of restrictive type,
ejection fraction, and mitral insufficiency correlate with activity of the disease.
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Echocardiographic abnormalities in patients with SAPHO syndrome
Hanna Przepiera-Bedzak, MD, PhD, Malgorzata Peregud-Pogorzelska, MD, PhD, Iwona Brzosko,
MD, PhD, Marek Brzosko, MD, PhD, Zdzislawa Kornacewicz-Jach, Pomeranian Medical
University, Szczecin, Poland
There are no data concerning cardiac involvement in the course of SAPHO syndrome.
Objective: To present chocardiographic abnormalities in the course of SAPHO syndrome.
Materials and Methods: We studied 12 patients (11 women, one man) with SAPHO syndrome.
Echocardiographic examinations (M-mode, D-dimensional, and enriched with colour-Doppler
technology) were performed in a standard manner with Acuson 128 XP echocardiographic
apparatus. Echocariographic evaluation (ECHO) included: left atrial diameter (LA), aortic width
(Ao), leaflets and cusps of valves, valvular insufficiency (scored 0–4þ ), contractility, ejection
fraction (EF) of the left ventricle (LV), right ventricular dimensions, mitral valve prolapse (MVP),
interatrial septum mobility, pericardium, and LV diastolic function (E/A ratio, IVRT, DEC Time).
Results: Mean age of patients was 50.6 years (SD: 10.6), mean disease duration was 2.6 years (SD:
1.9). Aortic insufficiency was found in six patients – clinically significant (score 42þ ) in one
patient. Mitral valvae insufficiency was present in seven patients – clinically significant (score
42þ ) in one patient. We found diastolic dysfunction of restrictive type in five patients. All
patients had no abnormalities concerning contractibility.
Conclusions: These are the first data concerning cardiac abnormalities in the course of SAPHO
syndrome. Main interest in this syndrome was pressed on skeletal involvement. Our findings
confirm that in the course of SAPHO syndrome cardiac involvement could be present and that it
is necessary to continue the studies concerning this problem.
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Sustained long-term clinical efficacy and safety in patients with psoriasis for up to
2.5 years on etanercept
Anca Serban, Wyeth Research, Collegeville, PA, USA, Boni Elewski, University of Alabama,
Birmingham, AL, USA, Craig Leonardi, MD, St Louis University, St Louis, MO, USA, Alice
Gottlieb, MD, PhD, University of Medicine & Dentistry New Jersey, Robert Wood Johnson
Medical School, New Brunswick, NJ, USA, Bruce Strober, MD, PhD, Johns Hopkins University,
New York, NY, USA, Peter C.M. van der Kerkhof, MD, PhD, University Hospital Nijmegen,
Nijmegen, The Netherlands, Jean Paul Ortonne, MD, Hospital de’Archet, Nice, France
Objective: To evaluate the long-term efficacy and safety of etanercept (ETN) in psoriasis patients
from two randomized controlled phase 3 trials who enrolled in an open-label extension study.
Methods: 1,235 patients from two phase 3 trials were allowed to enroll in a 72-week, open-label,
extension study. At entry, some patients had received up to 60 weeks of ETN therapy. All patients
received ETN 50 mg QW for the first 12 weeks with the option of increasing to 50 mg BIW
thereafter, based on three preset criteria.
Results: Nine hundred and twelve (74%) enrolled in the extension. Of these, 591 increased to
ETN 50 mg BIW sometime after 12 weeks of ETN 50 mg QW (BIW group), whereas 321 patients
maintained the dose of 50 mg QW (QW group). Among all patients, Psoriasis Area and Severity
Index (PASI) scores improved from a raw score of 18.9 at baseline in the phase 3 studies to 8.0 at
extension study baseline. Mean PASI score in the BIW group improved 67% from baseline, and
the proportion of patients achieving a Physician’s Global Assessment (PGA) of ‘‘mild’’ or better
status increased from 63% at extension baseline to 76% at week 72. Mean PASI score in the QW
group improved 76% from baseline. The proportion of patients in the QW group who achieved a
PGA ‘‘mild’’ or better status increased from 75% at extension baseline to 86% at week 72.
Exposure-adjusted rates of serious adverse events and SIEs in the BIW and QW groups were
similar to those in the blinded studies. No cases of TB were reported.
Conclusions: Etanercept therapy is safe and effective for the treatment of psoriasis, with sustained
clinical improvements observed for up to 2.5 years in clinical trials.
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Clinical response in psoriasis patients with an interruption of etanercept treatment
Anca Serban, Wyeth Research, Collegeville, PA, USA, Boni Elewski, University of Alabama,
Birmingham, AL, USA, Craig Leonardi, MD, St Louis University, St Louis, MO, USA, Peter C.M.
van der Kerkhof, MD, PhD, University Hospital Nijmegen, Nijmegen, The Netherlands, Jean Paul
Ortonne, MD, Hospital de’Archet, Nice, France, Meleana Dunn, Paul Peloso, Amgen, Inc.,
Thousand Oaks, CA, USA
Objective: Compare the clinical efficacy of psoriasis patients who had o30 days versus those
who had 430 days of interruption of etanercept (ETN) therapy between clinical trials.
Methods: Patients with psoriasis from two phase 3 trials enrolled in an open-label, extension
study. Five hundred and sixty-four patients had o30 days (median 5 days) and 343 patients had
430 days (median 108 days) of interruption of ETN therapy between their last dose of ETN in the
phase 3 studies and their first dose in the extension study. Efficacy end points included the
Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) of PsO
(scale 0–5, 0¼ clear, 5¼ severe). LOCF was used to impute missing values.
Results: Patients with 430 days of treatment interruption had a lower mean percent PASI
improvement at extension baseline 42%, which improved to 62% at week 12 and was similarly
maintained at week 72 (71%). Among patients with o30 days of treatment interruption, 45%
achieved a 75% improvement in the PASI 75 at extension baseline, which was maintained at
weeks 12 (48%) and 72 (47%). Among those with 430 days of treatment interruption, 14% had a
PASI 75 response at extension baseline, which increased to 34% at week 12 and 52% at week 72.
The proportion of patients with o30 days of treatment interruption who had a PGA clear or
almost clear status was 39% at extension baseline that was maintained at weeks 12 and 72.
Among patients with 430 days of treatment interruption, 12% had a PGA clear or almost clear
status at extension baseline, which increased to 33% at week 12 and 40% at week 72.
Conclusions: This study demonstrates the sustained efficacy of etanercept therapy in psoriasis
patients. Reinitiation of etanercept therapy after a significant interruption period allowed patients
to gradually achieve a similarly high, sustained response compared with those with a shorter
interruption period.
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Long-term treatment of 4 years with infliximab: A case report of a patient with
severe psoriasis
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Michael David, MD, Emilia Hodak, Rina
Segal, Hanna Feurman, Rabin Medical Center, Petah Tikva, Israel
A 48-year-old woman with recalcitrant generalized psoriasis vulgaris (almost maximal Psoriasis
Area Severity Index) and severe psoriatic arthritis who has been treated with infliximab for 4.5
years is described. To the best of our knowledge, this case describes the longest infliximab-treated
psoriatic patient reported in the literature so far. After the initial three infusions she was almost
completely clear, but relapsed after 9 weeks. Readministration of infliximab combined with low-
dose methotrexate again led to complete remission, only after additional six infusions. The patient
remained in remission for 4.5 years with repeated injection of infusions every 5–7 weeks and low-
dose methotrexate once weekly. Follow-up revealed no clinical side effects or laboratory tests
abnormalities apart from elevated antinuclear antibody with fluctuations of double-stranded DNA
without developing clinical lupus. We conclude that infliximab is a safe and efficacious treatment
for psoriasis and psoriatic arthritis. We would like to emphasize that readministration after a
relapse needs patients from the dermatologist. The patient needed more infusions (six infusions) to
get remission than needed in the initial treatment (three infusions). Review of the literature about
infliximab will be given.
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Infliximab (Remicade): A new treatment alternative for severe hidradenitis
suppurativa?
Anne-Marie Thielen, MD, Caroline Barde, MD, Jean-Hilaire Saurat, MD, University Hospital
Geneva, Geneva, Switzerland
Background: Severe hidradenitis suppurativa is a chronic disease characterized by an important
physical and psychosocial morbidity. Current medical therapies are minimally effective and
advanced stage treatment is limited to an invasive surgical approach.
Objective: We evaluate the effectiveness of infliximab for the treatment of severe hidradenitis
suppurativa in a patient with no clinical evidence of Crohn’s disease.
Results: A two perfusions’ treatment (5 mg/kg at W0 and W2) resulted in an important physician-
controlled improvement based on clinical, biological, and radiological findings. This correlated
with the patients’ self-reported disease activity improvement.
Conclusions: On the basis of subjective and objective evidence, infliximab should be considered
as a promising agent for the treatment of severe hidradenitis suppurativa in patients without any
evidence of Crohn’s disease. Further controlled studies of the effectiveness and the safety of
infliximab for the long-term treatment of hidradenitis suppurativa are still required.
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Acute cutaneous manifestations of a Reiter’s syndrome in an adalimumab and
leflunomide treated patient
Anne-Marie Thielen, MD, Caroline Barde, MD, Jean-Hilaire Saurat, MD, University Hospital
Geneva, Geneva, Switzerland
Tumor necrosis factor-a (TNF-a) antagonists are actually considered to be very promising agents
for the treatment of psoriasis. Despite their efficacy in this indication, several patients developed a
paradoxical psoriasiform rash under treatment and the pathogenesis of this entity is only poorly
understood. Our patient, suffering from Crohn’s disease and ankylosing spondylitis, was treated
by adalimumab (Humiras), a humanized TNF-a antagonist, and leflunomide (Aravas). He
developed a psoriasiform rash, plantar keratoderma, and circinate balanitis after the third
injection of adalimumab. Clinical and anatomopathological findings suggested the differential
diagnosis of cutaneous manifestations of a Reiter’s syndrome or the development of a new
psoriasiform rash under treatment. Infectious urethritis (ureaplasma urealyticum) was confirmed
by urine culture. To our knowledge, this is the first case report of acute cutaneous manifestations
of a Reiter’s syndrome that developed in a patient treated by TNF-a antagonists.
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Infliximab and methotrexate-resistant rebound after efalizumab (Raptiva)
discontinuation
Anne-Marie Thielen, MD, Caroline Barde, MD, Jean-Hilaire Saurat, MD, University Hospital
Geneva, Geneva, Switzerland
Whereas most of patients discontinuing efalizumab treatment experience a gradual recurrence of
their psoriasis, some patients may experience a rapid and significant worsening of their disease. A
rebound phenomenon (RP) is defined as a recurrence of the disease at a Psoriasis Area and
Severity Index score greater that 125% of the baseline status or the development of new
widespread pustular, erythrodermic, or more inflammatory psoriasis lesions occurring within 8
weeks from treatment discontinuation in responding patients. Our case report illustrates a severe
rebound phenomenon in an initially responsive patient. This acute adverse event was refractory to
a potent combination therapy consistent in methotrexate and infliximab. Clinical evolution was
excellent after the initiation of a potent topical treatment. The object of this publication is to
review the incidence of this adverse event and to discuss the treatment recommendations in
concerned patients.
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Distribution of psoriasis lesions in patients with psoriatic arthritis
Anne Lene Krogstad, MD, PhD, Karen Øien Forseth, MD, PhD, Rikshospitalet, Oslo, Norway,
Stefan K. Piechnik, MScEE, PhD, Centre for Functional Magnetic Resonance Imaging, Oxford
University, Oxford, UK
The distribution of psoriasis in patients with psoriatic arthritis (PsA) is not well known. We
propose a method to illustrate the pattern of clustering of the psoriasis lesions in a group of
patients with PsA.
Materials and Methods: One hundred and ninety-five patients with PsA who had applied to
participate in a program for climate treatment administered by the Norwegian National Hospital,
Department of Rheumatology were included in the study. They were asked by mail to mark their
psoriasis lesions on a provided template with anterior and posterior views of the body outline. The
drawings were scanned, co-registered and the patient’s marking separated out. Resulting images
were summed up for each pixel and divided by number of subjects yielding the map of the
distribution of lesion probability (LP) occurring at any point of the drawing.
Results and Discussion: The distribution density of lesions in the whole group, presented as a
color-coded map showed good symmetry between left and right side. The lesions clustered most
often on the scalp and the elbows (LP430% chance of lesion being indicated at any selected
point). With LP410% the lesions were distributed on knees, groin, area between buttocks,
toenails, shins and the groin. The rest of the area of the head, the axillae, submammary region,
sternum, palms inclusive fingernails, buttocks, and lower legs had more than 1 in 20 chances for
presence of lesion, whereas the remaining regions stayed relatively uninvolved.
Conclusions: The method provides a visually compelling way to describe the distribution of skin
lesions across large populations of patients. It may have considerable advantages in studies of the
distribution differences between groups, and in longitudinal studies to examine the efficacy of
treatment at different skin localizations.
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Efficacy of topical agents under hydrophilic occlusion versus unoccluded in
psoriasis
John Koo, MD, University of California Psoriasis Treatment Center, San Francisco, CA, USA,
Shanthi M. Colaco, MSIV, BA, University of California San Francisco Medical School, San
Francisco, CA, USA, Priya Sivanesan, MD, Farah Malick, MD, Julie A. Letsinger, MD, University
of California Psoriasis Treatment Center
Background: It is well established that occlusion enhances the efficacy of topical medications in
psoriasis. Current methods of occlusion such as hydrocolloid dressings and plastic food wrap are
less than ideal due to cost and inconvenience, respectively. Occlusion of topical agents under a
hydrophilic dressing for psoriasis has never been studied.
Objective: The safety and efficacy of a hydrophilic dressing used alone and in conjunction with
topical agents was evaluated in the treatment of stable, chronic plaque psoriasis.
Methods: One hundred and twenty patients with two symmetrical psoriatic lesions were enrolled
in this open-label, bilaterally controlled, single-center study. Target lesions were treated with
hydrophilic occlusion alone or one of five topical regimens: hydrocortisone 1.0% cream,
tacrolimus 0.1% ointment, triamcinolone 0.1% cream, calcipotriol 0.005% cream, or halobetasol
propionate 0.05% cream plus calcipotriol 0.005% cream, applied twice daily with and without
hydrophilic occlusion. Erythema, induration, and scale (score: 0, absent to 4, severe) were
evaluated. The primary efficacy parameter was a modified Psoriasis Area and Severity Index
(PASI) score, defined as the sum of scores for erythema, induration, and scale (range 0–12).
Results: To follow.
Conclusions: Occlusion of topical medications using a hydrophilic dressing is a safe and effective
therapy for psoriasis. Hydrophilic dressings present an affordable, convenient alternative to
current methods of occlusion in psoriasis.
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Diagnosis of arthritis in psoriasis patients presenting with joint pain to a
dermatology/rheumatology clinic
Elinor Mody, MD, Brigham and Women’s Hospital, Boston, MA, USA, Elaine Husni, MD, MPH,
Cleveland Clinic, Cleveland, OH, USA, Abrar Qureshi, MD, MPH, Brigham and Women’s
Hospital
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. Currently,
there are no formally accepted diagnostic criteria for PsA in adults. When untreated, PsA can be
progressive in some patients leading to permanent joint destruction. Consecutive patients
presenting to a dermatology – rheumatology clinic at an academic medical center with psoriasis
and joint pain were included in this study. All 71 patients were simultaneously evaluated by a
board-certified dermatologist and rheumatologist. The average age was 55 years and 52% were
women. On the basis of history, examination and radiographs, 41% (29/71) patients were
diagnosed with PsA, 27% (19/71) with osteoarthritis, 14% (10/71) with PsA plus osteoarthritis and
3% with gout. A total of 14% patients reporting joint pain were not classified into a particular type
of arthritis. Overall, 55% (39/71) were diagnosed with PsA in this population. The mean age of
patients in the PsA group was 49 years and non-PsA group was 57 years (P¼ 0.01). Radiograph
data was available for 51 participants and 39% (20/51) had erosions present. Data on Schober’s
test was available for 52 participants and the test was abnormal in 24% (16/52) – 88% with an
abnormal Schober’s were diagnosed with PsA (P¼ 0.001). About 40% (28/70) of participants
reported morning stiffness of greater than 1 hour – 82% with morning stiffness were diagnosed
with PsA (P¼ 0.001). Psoriatic arthritis may be more common among psoriasis patients than
reported previously. Interestingly, a large proportion of patients had coexisting PsA and
osteoarthritis. Thus joint symptoms in psoriasis patients are complex to diagnose. Care for patients
with psoriasis and PsA can be optimized in a multidisciplinary environment.
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Clinical follow-up 2–4 years after onset of guttate psoriasis
Katarina Wolk, MD, Petra Kjellman, MD, PhD, Lotus Mallbris, MD, PhD, Per Larsson, MD, PhD,
Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Mona Sta˚hle, MD,
PhD, Karolinska University Hospital, Stockholm, Sweden
Background: We investigated the clinical course after onset of guttate psoriasis patients in
Sweden.
Methods: A follow-up study on 95 patients with guttate psoriasis was conducted 2–4 years after
onset. Cases had a first incidence of psoriasis within 12 months before study baseline and of these
68 had an infectious onset. At follow-up, patients completed a self-administered questionnaire
reporting on phenotype, disease severity, and history of treatment. Eighty patients answered the
questionnaire and 53 were examined by a dermatologist.
Results: Total remission of skin lesions based on clinical examination and self-assessment was
observed in 32%. In 17% of patients, the guttate phenotype changed into plaque, in single
patients inverse lesions were also reported. During follow-up, 42% reported symptoms of
tonsillitis and 30% were treated with antibiotics; 5% underwent tonsillectomy and remained with
guttate phenotype without remission. At follow-up, the prevalence of positive swap test was
7.5%. At onset, 26% reported joint/muscle symptoms and psoriasis arthropathy (PsA) was verified
by a rheumatologist in 10%. At follow-up 19% reported such symptoms, but rheumatologic
examination of these is still pending. At follow-up, 74% were without treatment, 87% had history
of local treatment, 68% of phototherapy, and 11% of systemic treatment. At time of report, 15%
of patients had regular treatment, 9% local treatment, 4% systemic and 4% phototherapy, and
11% current irregular local treatment.
Conclusions: Total remission of guttate psoriasis was observed in one-third of the patients and
only 16% of patients had changed phenotype. Longer observation time is needed to evaluate the
stability of these results.
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Magnetic resonance imaging in dactylitis: What is the site of the inflammation?
Paul Healy, University of Leeds, Leeds, UK, C. Groves, R. Chandramohan, Bradford Royal
Infirmary, Bradford, UK, Philip Helliwell, PhD, University of Leeds
Objective: To use magnetic resonance imaging in patients with psoriatic dactylitis to determine
the imaging features of the disease before treatment.
Methods: Fifteen patients with recent-onset psoriatic dactylitis (11 toes, four fingers) were
evaluated using a shoulder coil with the field of view covering the whole of the affected hand or
foot. T1W, fat suppressed T2W, and contrast-enhanced sequences were acquired. Images were
scored by two observers independently, who then reached consensus.
Results: In all 15 patients, there was multifocal joint involvement in addition to the clinically
apparent dactylitic digit. The metacarpal/tarsal-phalangeal and proximal interphalangeal joints
were most commonly affected. Intracapsular fluid, synovitis, and circumferential subcutaneous
edema were found in all involved digits. Periarticular bone edema was present in most cases,
being maximal at the entheseal insertions. Erosions were found in approximately half of cases.
Fluid within the flexor tendon sheaths was observed, but this was not present in all cases.
However, inflammation of the adipose tissue between the tendons and the phalanges was
common, predominantly on the flexor surface. In some cases, there was evidence for
inflammation of the collateral ligaments, and plantar/volar plates. Sesamoiditis was seen in only
one patient.
Conclusions: The magnetic resonance imaging features of psoriatic dactylitis exceed and
outweigh the clinical appearance, with abnormalities in affected and non-affected digits.
Synovitis, intra-articular fluid, enthesitis, adipose tissue edema, and to a lesser extent
tenosynovitis, were seen in all cases.
1814 Journal of Investigative Dermatology (2007), Volume 127
ABSTRACTS
75
Efficacy of the two-compound product calcipotriol/betamethasone dipropionate
in the treatment of psoriasis vulgaris: A Romanian multicenter study
I. Nedelcu, Central Clinical Emergency Military Hospital, Bucharest, Romania, D. Forsea, C.
Giurcaneanu, Carol Davila University of Medicine & Pharmacy, Bucharest, Romania, R.
Orasanu, University of Medicine & Pharmacy, Cluj Napoca, Romania
A group of 20 patients, eight males and 12 males, aged between 31 and 78, diagnosed with stable
psoriasis vulgaris, with various sites involved, extension levels, and severity degrees were treated
with the two-compound product calcipotriol/betamethasone dipropionate once daily for 28 days.
Assessment of Psoriasis Area and Severity Index score was performed at baseline and after 1, 2, 3,
and 4 weeks. The mean PASI reduction was 38.2% after 1 week, 62.1% after 2 weeks, 75.2%
after 3 weeks and 80.1% after 4 weeks’ treatment, supporting the high efficacy of the two-
compound product calcipotriol/betamethasone dipropionate reported previously. The onset of
action was found to vary depending on duration of the disease, previous therapeutic history, and
especially the location of lesions. Even though the lesions located on shin, knees, and elbows had
the slowest response to therapy, the overall 28 days treatment response was very good. No side
effects were reported during the study. The two-compound product administered once daily in a
short-term treatment.
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Treatment of scalp psoriasis with the two-compound product calcipotriol/
betamethasone dipropionate: A pilot open label
Nicoletta Cassano, MD, Gino A. Vena, MD, University of Bari Policlinico, Bari, Italy
Several trials have documented the efficacy and tolerability of a two-compound product
containing calcipotriol and betamethasone dipropionate in psoriasis vulgaris. This pilot open-
label study evaluates the efficacy and tolerability of the two-compound product for the treatment
of scalp psoriasis. Inclusion criteria included: scalp psoriasis alone or associated with stable
localized lesions of plaque psoriasis adequately controlled by topical therapies. The two-
compound product was applied to the affected scalp areas once daily for 2 weeks, followed by
treatment with the two-compound product once daily, and calcipotriol 0.005% solution twice
daily on alternate days during the next 4 weeks. Calcipotriol solution was finally applied up to
week 12. Clinical evaluation was based on signs and symptoms (erythema, scaliness, thickness,
pruritus), which were scored from 0¼ absent to 4¼ severe, and was performed at baseline, weeks
2, 6, and 12. 25 patients (baseline mean total score: 8.3) were enrolled and completed the study.
A significant improvement of signs and symptoms was observed at week 2 (total score: 3.5), at
week 6 (total score: 2.6), and week 12 (total score: 3.2). The treatment regimen was well tolerated
and considered efficacious by 75% of patients. However, the cosmetic acceptability was rated as
poor by 36% of patients.
Conclusions: the two-compound product appears efficacious and safe for the treatment of scalp
psoriasis. It provides fast release of symptoms and its effect can be maintained for up to 12 weeks
by sequential therapy with calcipotriol scalp solution. The study indicates the need for a
cosmetically more acceptable formulation for scalp psoriasis. A gel formulation of the two-
compound product is under development.
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A new enthesitis index for psoriatic arthritis
Paul Healy, Philip Helliwell, PhD, University of Leeds, Leeds, UK
Objectives: To validate existing enthesitis indices and to develop a new concise enthesitis index
for use in psoriatic arthritis.
Methods: Data from a study of treatment intervention in psoriatic arthritis were used. In this study,
29 patients were followed from baseline for 6 months after a change in disease-modifying drugs
due to uncontrolled disease activity. Disease activity measures were assessed together with four
instruments to measure enthesitis: the Mander Enthesitis Index (MEI), the Maastricht Enthesitis
Index, the Major enthesitis index, and a modified index based on the SPARCC initiative.
Results: Data from individual visits were combined resulting in 89 observation points. An iterative
process of data reduction based on the frequency of involvement of entheses resulted in reduced
number of entheses that were applicable in 89% of all observations. These include both lateral
epicondyles of the humerus, both medial femoral condyles, and both Achilles tendon insertions.
Scored with a gradation (from 0 to 3) of tenderness or as a binary response (tender or not) gave an
almost full score distribution which correlated strongly with all the other methods of assessing
enthesitis. Only in seven observations where the MEI score 40, did the new psoriatic arthritis
index¼ 0. Correlations between the enthesis scores and disease activity measures were, on the
whole, positive and significant, although less so for the newly developed index.
Conclusions: The new psoriatic index for enthesitis is simpler to use than the other enthesitis
indices. Initial analysis demonstrates acceptable but diminished performance. We are grateful to
Sanofi-Aventis for funding.
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Calcipotriol plus betamethasone dipropionate gel is effective and safe in the
treatment of scalp psoriasis (a Phase II study)
Colin Buckley, MD, Waterford Regional Hospital Ardkeen, Waterford, Ireland, Jerry Shapiro, Skin
Care Centre, Vancouver, British Columbia, Canada, Seppo Saari, Policlinic of Dermatology,
Turku, Finland, Fre´de´ric Cambazard, Hospital Nord, St Etienne, France, Vibeke Hoffman, LEO
Pharma, Ballerup, Denmark
A proof-of-concept study was performed comparing the efficacy and safety of LEO80185
(calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate), compounded in a new gel
vehicle formulation) to betamethasone 0.5 mg/g (as dipropionate), in the same gel vehicle in
patients with scalp psoriasis. In total, 218 patients were enrolled and randomized. Of these
patients, 108 were treated with LEO80185 whereas 110 were treated with betamethasone
dipropionate in the same gel vehicle. The patients were treated once daily on the scalp for up to 8
weeks. The results indicate that LEO80185 is superior to betamethasone dipropionate in the same
gel vehicle in the treatment of scalp psoriasis. Superiority of LEO80185 was also observed when
comparing absolute change in redness from baseline to end of treatment. In addition, it was
shown that the patients treated with LEO80185 achieved ‘‘absence of disease’’ faster than the
patients treated with betamethasone dipropionate gel. The patients overall assessment for
treatment success was statistically in favor of calcipotriol plus betamethasone dipropionate
compounded in a gel (LEO80185). The adverse event profiles for the two products were similar.
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Treatment of psoriasis vulgaris with the two-compound product calcipotriol/
betamethasone dipropionate followed by calcipotriol in different formulations
Nicoletta Cassano, MD, A. Miracapillo, C. Coviello, F. Loconsole, M. Bellino, Gino A. Vena, MD,
University of Bari, Bari, Italy
The aim of the study was to evaluate the efficacy and tolerability of a 4-week acute treatment with
the calcipotriol/betamethasone dipropionate two-compound product followed by an 8-week
treatment with calcipotriol in different formulations in psoriasis vulgaris. After 4 weeks using the
two-compound product once daily, adult patients with stable psoriasis vulgaris entered an 8-week
maintenance phase using either calcipotriol ointment twice daily, calcipotriol cream twice daily,
or calcipotriol cream once daily in the morning combined with calcipotriol ointment once daily
in the evening. Clinical assessment (severity of pruritus, Psoriasis Area And Severity Index (PASI
scores) was performed at baseline, week 4 and 12. One hundred and nine patients (mean baseline
PASI¼8.7) entered the study. After 4 weeks, a mean percentage reduction of PASI of 71.3, 70.9,
and 72.7 was observed, respectively (Po0.001, each group vs baseline), as well as a significant
improvement of pruritus in all groups. Efficacy was maintained after the 8-week treatment with
calcipotriol, regardless of the formulation used (mean % reduction of PASI: 73.6, 70.9, and 72.7,
respectively). Treatment was very well tolerated and accepted by patients. On a scale ranging
from poor to excellent, more patients (49%) rated the acceptability of calcipotriol cream as
excellent when compared to patients treated with calcipotriol ointment (33%) or both
formulations (36%). In conclusion, the two-compound product leads to a rapid and marked
improvement of both psoriasis lesions and pruritus. The three calcipotriol-based regimens are
equally effective in maintaining the therapeutic results, calcipotriol cream being the most
accepted maintenance treatment, favoring patients’ compliance.
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Efficacy and tolerability of the two-compound product calcipotriol/betametha-
sone dipropionate in the treatment of moderate-to-severe psoriasis
M. Cacciapuoti A. Farris, U.O. Dermatologia, Savona, Italy
Moderate and severe psoriasis is often treated with systemic therapy such as retinoids,
cyclosporine, methotrexate, and more recently, biological compounds. These agents significantly
affect the immune response, leading to a T-cell-mediated suppression of the inflammatory
process. Despite their efficacy and innovation, the large use of these compounds are limited by
concerns about their long-term tolerability and high cost of repeated treatment cycles. A topical
two-compound product characterized by a stable association of calcipotriol and betamethasone
dipropionate has been extensively studied in mild and moderate psoriasis, showing the same
good efficacy regardless the severity of pathology. A spontaneous open study with the aim to
evaluate efficacy and tolerability of a once a day application of the two-compound product
(calcipotriol/betamethasone dipropionate) during 4 weeks of treatment was performed. Five
patients with moderate-to-severe psoriasis vulgaris were enrolled. In basal conditions, body
surface area (BSA) was between 25 and 30%, and mean Psoriasis Area and Severity Index (PASI)
score was 20.3 (15.6–30). After 2 and 4 weeks of treatment, a significant improvement in
erythema, desquamation, infiltration and itching and a stabilization or improvement of BSA was
seen. PASI score decreased to 11.2 after 2 weeks and to 5.3 at the end of treatment. Tolerability
was judged very good, as no adverse events were reported. This clinical experience leads to
consider the topical treatment with the two-compound product a valid alternative to the systemic
treatments in patients with moderate-to-severe psoriasis.
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A pooled analysis of studies with a calcipotriol/betamethasone two-compound
product in severe psoriasis vulgaris
Knud Kragballe, MD, Aarhus University Hospital, Aarhus, Denmark, A.V. Anstey, Royal Gwent
Hospital, Newport, Wales, UK
A two-compound product combining calcipotriol and betamethasone dipropionate in an
ointment vehicle has been formulated. Studies have shown efficacy superior to that of each
component used as monotherapy in terms of reduction in Psoriasis Area and Severity Index (PASI)
investigator’s and patient’s global assessments. The Medical Advisory Board of the National
Psoriasis Foundation has defined treatment success in psoriasis as an improvement in PASI of at
least 50% from baseline (PASI 50) and has recommended using this response criterion and PASI
75 in clinical trials. To relate the data obtained for the two-compound product with published
data for new biological therapies (efalizumab, alefacept, and etanercept), analyses were
conducted based on pooled data from six large, randomized, double-blind studies with the two-
compound product. Patients graded to have severe disease (PASI, day 17) at baseline were
included in the analyses (n¼ 268) to match the patient population included in studies of
biological treatments. After 4 weeks treatment with the two-compound product, 88.8% of patients
with severe psoriasis achieved PASI 50, compared with 59% for efalizumab, 56% for alefacept
and 74% for etanercept after 12 weeks treatment. PASI 75 was achieved by 54.1% for the two-
compound product after 4 weeks treatment, 27% for efalizumab, 28% for alefacept, and 49% for
etanercept after 12 weeks treatment. Even though cross-study comparison of data may be
controversial, this analysis shows that the two-compound product in patients evaluated to suffer
from severe psoriasis is highly effective.
82
Long-term efficacy of a calcipotriol/betamethasone dipropionate two-compound
product in psoriasis vulgaris
Knud Kragballe, MD, Aarhus University Hospital, Aarhus, Denmark, A. Bibby, LEO Pharma,
Buckinghamshire, UK
The calcipotriol/betamethasone dipropionate two-compound product has been shown to be safe
and effective in the short-term treatment of psoriasis. A long-term study was conducted to
investigate the safety of three treatment regimens involving use of the two-compound product
over 52 weeks in the treatment of patients with psoriasis. Efficacy results are presented here. Six
hundred and thirty-four patients were randomized double blind to 52 weeks’ treatment with
either: the two-compound product (two-compound group); alternating 4-week periods of two-
compound product and calcipotriol (4/4 alt. group); or 4 weeks of two-compound product
followed by 48 weeks of calcipotriol (4/48 group). Treatments were used once daily as required.
At each 4-week visit, the investigators’ assessment of psoriasis was categorized as satisfactory
(‘‘absence of’’, ‘‘very mild’’, or ‘‘mild’’ disease according to investigators’ global assessment) or
not satisfactory (‘‘moderate’’, ‘‘severe’’, or ‘‘very severe’’ disease) and the patients’ assessments of
treatment were categorized as ‘‘satisfactory’’, ‘‘not satisfactory’’, or ‘‘not applicable, as not used’’.
Investigators’ assessment: 76 (35.8%) patients in the two-compound group achieved 100%
satisfactory assessments (satisfactory response at all visits) compared with 59 (27.7%) in the 4/4
alt. group and 51 (24.4%) in the 4/48 group (P¼ 0.071, analysis of distribution). Patients’
assessment: 80 (37.7%) patients in the two-compound group achieved 100% satisfactory
assessments (satisfactory response at all visits) compared with 61 (28.6%) in the 4/4 alt. group and
60 (28.7%) in the 4/48 group (P¼ 0.071, analysis of distribution). The two-compound product
used on its own for up to 52 weeks was effective in treating psoriasis, with a trend towards a
higher satisfactory response compared to the other treatment groups.
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Comparative assessment of the efficacy of therapy with low and medium dose
methotrexate
Yulia L. Korsakova, PhD, Vladimir V. Badokin, Russian Medical Academy of Post-Graduate
Study, Moscow, Russia
Objective: 46 rheumatoid arthritis patients (pts) were randomized in two groups (23 pts in each).
Pts of the first group took methotrexate (MTX) by 15 mg/week and of the second –30 mg/week i.m.
The efficacy of therapy was assessed in 2, 6, and 12 months of continuous therapy. Before the
beginning of therapy 95.7% of pts from each group demonstrated high activity of the disease
according to the index DAS4 (DAS443.7). In the course of 2 months therapy, the number of pts
with moderate (2.4o0.01). Good effect of therapy according to DDAS4 (DAS41.2) was found in
2 months in 87% of pts from groups I and II, and in 6 and 12 months C in 87 and 96%,
correspondingly. In 2 months ACR20 corresponded to 61% of pts of the group I and 69.6% of the
group II (P¼ 0.45), ACR50 – 9% pts of the group I and 13% pts of the group II (P¼ 0.39). In 6
months in the group II, the number of pts with good (ACR50) and very good effect (ACR70)
increased to 34.8 and 8.7%, correspondingly, and in the first group the efficacy practically did not
change. In 12 months in the second group, ACR70 was peculiar to 39.1% of pts, ACR 50–30.4%,
whereas in the first group ACR20 criteria were peculiar to 57% of pts, ACR50 –30% and ACR70 –
9%. That in to the end of the year the considerable increase (ACR50þACR70) was reliably higher
in pts of the second group as compared with the first (P¼ 0.0007). During the therapy the reliable
drop of Psoriasis Area and Severity Index (PASI) index was found in both groups. In 2 months of
therapy an improvement of this index by 75% and more was found in 13% of pts of the first group
and in 17.4% of the second group. In 6 months 75% PASI improvement was found in 39.1 and
73.9% (P¼ 0.001), correspondingly. In 12 months 75% PASI improvement was found in 43.5% of
pts in the first group and in 82.6% in the second (P¼ 0.0009).
Conclusions: MTX therapy by 30 mg/week rendered more deep positive effect on the articular and
dermal PsA syndromes as compared with 15 mg/week.
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A 52-week long-term management of severe plaque psoriasis with a new
calcipotriol/betamethasone two-compound product and calcipotriol cream
A. Kastanis, E. Vakirlis, K. Patsatsi, D. Sotiriadis, D. Devliotou-Panagiotidou, Aristotle University
of Thessaloniki, Thessaloniki, Greece
Objective: To evaluate effects of calcipotriol/betamethasone dipropionate two-compound
ointment and calcipotriol cream for the treatment of severe plaque psoriasis.
Materials and Methods: Eleven patients (seven men and four women aged 19–76) were enrolled
in a 52-week study. They all suffered from severe plaque psoriasis, defined as baseline Psoriasis
Area and Severity Index (PASI) of 18 or more. The two-compound product (ointment containing
calcipotriol 50 mcg/g and betamethasone 0.5 mg/g as dipropionate) was applied once daily for 4
weeks. From weeks 4 to 8, patients continued treatment with the two-compound product once
daily, three times/week, and with calcipotriol cream twice daily, four times/week. From weeks 8
to 12, the two-compound product was administered once daily two times/week, and calcipotriol
cream twice daily five times/week. After week 12, some of the patients could choose between
calcipotriol cream monotherapy and the two-compound product and calcipotriol cream. Clinical
signs and symptoms were evaluated using the PASI score before treatment and at weeks 1, 2, 4, 8,
12, 26, and 52. Laboratory analyses did not show any specific abnormalities in our patients at
baseline (e.g. Ca2þ level).
Results: After 1 week of treatment, significant improvement in erythema and decrease of
infiltration was seen. After 4 weeks, the mean PASI reduction was 78%. After 52 weeks, the mean
PASI reduction was 62%.
Conclusions: The long-term management of severe plaque psoriasis is possible with a regimen
combining the calcipotriol/betamethasone two-compound product used once daily and
calcipotriol cream used twice daily.
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Intensive therapy of psoriatic arthritis
Vladimir V. Badokin, Yulia L. Korsakova, PhD, Russian Medical Academy of Post-Graduate
Study, Moscow, Russia
Aim: To assess PA therapy by high methotrexate (MTX) doses.
Objective: Twenty patients (pts) with severe psoriatic arthritis (PsA) course and severe psoriasis
(four erythrodermal, four pustular, six exudative and six general vulgar), refractory to nonsteroidal
anti-inflammatory drug and basic drugs were treated by high (100 mg of methotrexate (54.8,
03 mg/m2) intravenous every 2 weeks for 2 months). To decrease undesirable effect MTX 250 mg
of metipred was administrated simultaneously and folic acid was given by 3 mg/day for 3 days.
The efficacy of intensive therapy was assessed in 1 and 2 months. Activity index of the disease
DAS4 in all pts before therapy was higher than 3.7 (high activity of inflammatory process). After
two courses of intensive therapy, that in to the end of the first month of therapy the activity in 30%
of pts decreased to moderate (2.41, 2) was found, in 10% – satisfactory (0.6oDAS1.2), and no
effect was found in one pt (5%) (DAS0.6). To the end of 2 months of therapy 100% of pts
demonstrated criteria of good effect of the therapy. In 1 month from the beginning of intensive
therapy ACR20 criteria were peculiar to 13 (65%) of pts, ACR50 – 2 (10%), ACR70 – 1 (5%). To
the end of the second month of the therapy the number of pts corresponding to ACR50 criteria
reached seven (35%). ACR20 – 11 (55%) and ACR70 – one (5%) pts. Intensive therapy resulted in
quick improvement of dermal syndrome. To the end of the first month Psoriasis Area and Severity
Index value dropped from 35.4 and 4.4 to 24.3 and 3.5 (by 33%), in 2 months to 14,5 and 6 (by
59%). Achieved effect held further on while taking 15 mg/week in 6 and 12 months.
Conclusions: Pulse therapy in pts with severe PsA course and with its malignant form promoted
considerable and quick regression of articular and dermal syndrome.
86
The advantages of topical treatment with the two-compound product calcipotriol/
betamethasone dipropionate and calcipotriol cream in psoriasis patients
C. Giurcaneanu, MD, PhD, D. Giurcaneanu, C. Enachescu, I. Nedelcu, V. Chitu, 1st
Dermatology Clinic, Clinical Hospital Colentina, Bucharest, Romania
Aim: To evaluate the advantages of the two-compound product calcipotriol/betamethasone
dipropionate as acute treatment and calcipotriol cream as sequential treatment of different types
of psoriasis vulgaris.
Methods: During a period of 11 months, 64 patients, aged between 18 and 77 years, suffering of
different forms of psoriasis (plaque-type psoriasis vulgaris, palmo-plantar psoriasis) were selected.
Patients were treated with the two-compound product once daily for 4 weeks, followed by 4
weeks of calcipotriol cream twice daily 5 days/week and the two-compound product calcipotriol/
betamethasone dipropionate once daily in weekends, and continued with calcipotriol cream
twice daily for another 4 weeks.
Results: Treatment regimen resulted in marked reduction of PASI score compared to baseline:
77.9% after 4 weeks’ treatment with the two-compound product calcipotriol/betamethasone
dipropionate, 76.3% after 8 weeks, and 80.3% after 12 weeks.
Conclusions: The use of the two-compound product has the advantage of rapid relief of symptoms
in the acute phase of the disease. The sequential therapy with the two-compound product and
calcipotriol cream followed by monotherapy with calcipotriol cream provides a safe and effective
maintenance of the achieved improvements.
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Correlation of lipid parameters to the severity of psoriasis
Andreas Colsman, Mathias Bru¨gel, Joachim Thiery, Michael Sticherling, University of Leipzig,
Leipzig, Germany
In the past many studies have addressed perturbations of lipid metabolism in patients with chronic
inflammatory disorders. This was related to an increased atherogenic risk with cardiovascular
complications in such patients. Increased inflammatory parameters as mirrored by C-reactive
protein (CRP) are seemingly involved. In this respect, psoriasis vulgaris has not been examined in
depth recently. Therefore we studied highly sensitive CRP, triglycerides, low-density lipoprotein,
high-density lipoprotein, VDL, and lipoprotein A in 104 psoriatic patients and related the data to
the clinical activity as detected by Psoriasis Area and Severity Index (PASI) as well as biographic
data. A significant correlation was shown between PASI and CRP, whereas none of the lipid
parameters was related to the severity of the psoriasis. Accordingly the well-described increased
cardiovascular risk among psoriatics may be mediated by inflammatory factors rather than lipid
parameters. Still, based on the experience in rheumatoid diseases, an early and effective anti-
inflammatory treatment may help decrease the atherogenic risk.
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Methods for assessing efficacy of psoriasis therapies
Charles N. Ellis, MD, University of Michigan Dermatology, University of Michigan Hospital, Ann
Arbor, MI, USA, John Berth-Jones, MRCP, Walsgrave Hospital, Coventry, UK
Background: Reliable assessment of disease severity in psoriasis is essential in clinical research to
document response to treatment.
Methods: Two separate validation studies examined the relative variation in two measures for
rating psoriasis severity: the commonly used Psoriasis Area and Severity Index (PASI); and a newer
measure, the Lattice System Physician’s Global Assessment (LS-PGA). Each study was a separate
single-center, randomized evaluation of psoriasis patients using similar but not identical designs.
In the two studies, 14 and 17 physicians evaluated 16 and 35 patients in England and United
States, respectively. Each physician evaluated each patient with each rating system twice. We
assessed the variation in the results of scoring psoriasis between (inter-rater) and within (intra-
rater) physicians.
Results: The rating systems were well correlated with each other and had good intra-rater and
inter-rater reliability. In the study from the United States, inter-rater reliability for LS-PGA was
better than inter-rater reliability for PASI, whereas in the study from England, inter-rater reliability
for PASI was slightly better than LS-PGA.
Conclusions: PASI and LS-PGA are reliable measures for assessing psoriasis. Unlike the PASI, the
LS-PGA is standardized with specific descriptions of the input ratings of severity. Differences in
the results of the two studies may in part be the result of whether the physicians had training
immediately prior to performing the study or whether they had prior experience in the use of
PASI. (Studies supported by Biogen-Idec & GlaxoSmithKline; first author holds rights to LS-PGA.)
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Juvenile psoriatic arthritis
Robert Stawowski, MD Lidia Rutkowska-Sak, Institute of Rheumatology, Warszawa, Poland
Aim of the study: To evaluate the clinical pattern of juvenile psoriatic arthritis in patients who had
attended in our Rheumatology Institute in years 1995–2005.
Methods: In a study of 19 patients (seven males, 21 females) at the age from 6 to 16 with a mean
age of 11.2 years. An average time of disease’s period – 5.5 years. We also examined patient’s
movement instrument changes, skin changes, and inner and eye changes. Also laboratory activity
of disease and immunological indicators were examined.
Results: Ocular inflammation was noted in 15.7% (3/19), Uveitis occurred in 5.2% (1/19) and
conjunctivitis in 10.5% (2/19). The most common course of juvenile psoriatic arthritis was to start
as oligoarthritis and progress, usually to polyarthritis. Arthritis followed the skin lesion in 94.7%
(18/19) of patients and occurred simultaneously in 5.3% (1/19). A family history of psoriasis was
present in 31.5% (6/19). Antinuclear antibody (ANA) was present in 15.7% (3/19) of patients. ESR
and C-reactive protein (CRP) ware elevated in 68.5 and 42.1% of patients. Heart involved
observed in two children.
Conclusions: Juvenile psoriatic arthritis is more common in females. ESR and CRP can be normal
in juvenile psoriatic arthritis.
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Pooled, comparative analysis of one, 2- and 4-week efficacy rates of the two-
compound product calcipotriol/betamethasone dipropionate in severe psoriasis
Mark Lebwohl, MD, Mount Sinai School of Medicine, New York, NY, USA, C. Ganslandt, PhD,
LEO Pharma, Ballerup, Denmark
Introduction: Rapid onset of action is a primary concern to patients with severe psoriasis. We
report the pooled Psoriasis Area and Severity index (PASI) results for patients with severe psoriasis
included in five randomized, double-blind, vehicle- and/or active-controlled studies using the
two-compound product calcipotriol/betamethasone diproprionate. We sought to determine the
comparative decrease in PASI at 1, 2, and 4weeks.
Methods: Patients with severe psoriasis applied treatments once daily (OD) to lesions on the trunk
and limbs over 4 weeks. PASI assessments at 1, 2, and 4 weeks, were evaluated and included 671
patients (59% received the two-compound product).
Results: At the end of 1, 2, and 4 weeks, the mean percentage PASI reductions from baseline in
patients with severe (PASI412) psoriasis were, respectively: 41.2, 59.7%, and 71.5% using the
two-compound product 24.6, 37.5, 48.0% using calcipotriol in the same vehicle 33.3, 48.0, and
58.6% using betamethasone dipropionate in the same vehicle.
Conclusions: This analysis shows that, after 4 weeks of therapy, the two-compound product
calcipotriol/betamethasone diproprionate applied OD provides a quicker onset of action and
achieves PASI reductions that are superior to the comparators evaluated in patients with severe
psoriasis.
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Early changes in markers of bone metabolism in patients with psoriatic arthritis
treated with anti-TNFa therapy: A comparison with rheumatoid arthritis
Adrian Gibbs, MRCPI, Barbara Murray, Bea Radovits, Barry Bresnihan, Douglas Veale, MD, FRCPI,
FPCP, Malachi McKenna, Oliver FitzGerald, PhD, St Vincent’s University Hospital, Dublin, Ireland
Background: Rheumatoid arthritis (RA) is characterized by localized destruction of synovium,
cartilage, and bone. Loss of bone in RA is not only localized to joints, and generalized osteoporosis is
a recognized extraarticular manifestation of the disease. Psoriatic arthritis shows a notable propensity
for aggressive bone erosions with concomitant new bone formation in the form of periostitis and frank
ankylosis suggesting a disordered pattern of bone remodeling. Anti-TNFa therapy causes marked
reduction in disease activity in both RA and PsA. Therefore, we tested the hypothesis that anti-TNFa
therapy would modulate systemic and local bone metabolism leading to improved bone remodeling.
Objective: (1) To compare basal levels of markers of bone resorption and formation in patients
with RA and PsA. (2) To assess changes in bone metabolism in the same cohort after 1 month of
treatment with anti-TNFa therapy.
Methods: Twenty-one patients were recruited between May 2005 and November 2005, 11 with
RA and 10 with PsA. Mean age was 51712.9 years and mean disease duration was 1178.6 years.
Twelve patients were treated with etanercept and nine with adalimumab. No patient received
bisposphonates. No one was taking 45 mg prednisolone. All patients failed at least one DMARD.
In serum, we measured markers of calcium metabolism (ionized calcium, parathyroid hormone
(PTH), 25(OH) vitamin D). Bone formation was assessed by measuring serum levels of bone
alkaline phosphatase (BAP), osteocalcin, and N-propeptide of type I procollagen (PINP). Bone
resorption was determined by levels of C-terminal telopeptide of type I collagen (CTX-1) in serum,
and crosslinked N-telopeptide of type I oollagen (NTX-1) and deoxypyridinoline (DPD) in urine.
Data are expressed as means (SD). Data were compared using Wilcoxon’s signed rank sum test.
Results: There was no statistically significant difference in basal levels of any of the biomarkers
between patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). With treatment there
was an increase seen in all markers of bone formation in the two groups that reached significance
for BAP in the RA group. Similarly, all makers of bone resorption decreased, with significant
reduction seen in NTX-1 in the RA group, and in DPD and CTX-1 in the PsA group. There was no
difference seen between the two treatment groups for any marker. RA (n¼11) PsA (n¼ 10)
Baseline 1 month Baseline 1 month ionized calcium 1.23 (0.03) 1.24 (0.03) 1.23 (0.05) 1.24
(0.05); PTH 30.2 (9.8) 37.8 (18.8) 40.8 (16.1) 41.6 (15) 25 (OH); vitamin D 60.5 (27.5) 66.4 (25.9)
62.1 (33.5) 69.7 (22.8); BAP 12.2 (4.5) 13.2 (3.9)* 14.9 (3.6) 15.6 (5.5); osteocalcin 12.8 (6.7)
15.1 (5.8) 12.3 (4.9) 13.1 (4.4); PINP 54.9 (22.4) 63.3 (32.7) 52.8 (23.7) 55.9 (25.6); DPD 11.5
(6.5) 10.3 (3.2) 8.3 (4.1) 6.4 (3.1)*; NTX-1 79.7 (53.6) 50.8 (20.2)* 46 (28.3) 38.4 (17.8); CTX-1
0.52 (0.24) 0.47 (0.19) 0.45 (0.25) 0.39 (0.21)* *Po0.05.
Conclusions: This study shows that anti-TNFa therapy has a rapid and favorable impact bone
remodeling in both RA and PsA. Although the RA patients had higher baseline levels of bone
resorption markers these differences were not significant suggesting that the disordered bone
remodeling seen in PsA has a similar resorption/formation ratio to RA.
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Magnetic resonance imaging study assessing the efficacy of anakinra (Kineret) in
psoriatic arthritis: Evaluating compartment-specific synovitis using a novel scoring
method
Adrian Gibbs, MRCPI, Barry Bresnihan, Douglas Veale, MD, FRCPI, FPCP, Robin Gibney, Oliver
FitzGerald, PhD, St Vincent’s University Hospital, Dublin, Ireland
Background: Psoriatic arthritis (PsA) has historically been considered a milder rheumatic disease
not leading to significant clinical damage. However, recent studies have shown that PsA can be
deforming and debilitating and that joint damage can be severe. Traditionally, joint damage has
been assessed using plain radiographs. New imaging modalities such as magnetic resonance
imaging (MRI) can help detect early changes in the joints and periarticular tissues, thus helping in
the diagnosis and response to treatment in patients with PsA. There is currently no validated MRI
scoring system to assess synovitis in PsA.
Objective: To incorporate a novel compartment-specific synovitis scoring system (Rhodes LA,
Keenan AM, Grainger AJ, Emery P, McGonagle D, Conaghan PG. The relationship between
limited MRI section analyses and volumetric assessment of synovitis in knee osteoarthritis. Clin
Radiol 2005; 60(12):1295–9) in the assessment of MRI scans of the knee in a study evaluating the
efficacy of anakinra (kineret) in PsA.
Methods: Ten patients with active PsA were enrolled in a 12-week single-center open-label study to
assess the efficacy of the IL-1 receptor antagonist anakinra. All patients had an MRI scan of an index
knee joint at baseline and 12 weeks. Sagittal and coronal fat-suppressed T2-weighted and sagittal fat-
suppressed T1-weighted images were obtained precontrast. Sagittal and coronal T1-weighted images
using gadolinium DPTA as a contrast agent were also obtained. Four anatomical sites were
evaluated: the medial and lateral parapatellar recesses, suprapatellar pouch and intercondylar notch.
Synovitis was graded on a scale of 0–3, with 0 meaning absence of synovitis and three representing
severe synovitis. A single observer (R.G.) performed all the analyses in a blinded fashion. Scans were
also assessed for enthesitis, peri-enthesitis, bone erosions and bone marrow edema.
Results: Eight of the 10 patients had baseline and week 12 MRI scans. There was no significant
change seen in synovitis score in any of the knee compartments. No patient has enthesitis or peri-
enthesitis at baseline, but 1/8 (P¼ 0.32) and 2/8 (P¼0.16) patients, respectively, had these features at
week 12. No patient had evidence of bone erosion at baseline or week 12. One patient has bone
marrow edema at baseline, which failed to improve by week 12. These findings were reflected in the
fact that only modest, unsustained clinical benefit was seen. Baseline week 12 Global Synovitis Score
(0–3)*: compartment A 1.25 (1.03) 1.37 (0.74) (P¼ 0.7); B 1.25 (1.03) 1.25 (0.46) (P¼ 1); C 1.25
(1.16) 1.37 (0.74) (P¼0.78); D 1.25 (1.16) 1.5 (0.93) (P¼ 0.6) * values expressed as mean (SD).
Conclusions: The lack of MRI response in this study was mirrored by an unsustained clinical
response. This novel scoring system, although developed for assessing synovitis in osteoarthritis,
can also be applied to other inflammatory arthritides such as PsA. It is quick and easy to use, and
would enable feasible evaluation of synovium in larger cohorts. In this study, the low level of
entheseal involvement was also an interesting finding.
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Efficacy of anakinra (Kineret) in psoriatic arthritis: A clinical and immunohisto-
logical study
Adrian Gibbs, MRCPI, Martina Gogarty, Barry Bresnihan, Douglas Veale, MD, FRCPI, FPCP,
Oliver FitzGerald, PhD, St Vincent’s University Hospital, Dublin, Ireland
Background: Psoriatic arthritis (PsA), which accounts for 15% of new cases of inflammatory
arthritis, can result in joint damage, deformity, and disability. Both gene and protein expression of
IL-1 are highly upregulated in the synovium of patients with PsA. IL-1 is known to play a key role
in MMP upregulation, differentiation of osteoblast precursors into mature osteoblasts, angiogen-
esis and in the development of erosive disease.
Objective: The purpose of this study is to assess the effects of IL-1 inhibition on the clinical features
of PsA disease activity, and on synovial immunohistological features of an affected knee joint.
Methods: Twelve PsA patients (seven male; five female, average age 46 years (22–61)) with active
joint disease were enrolled in a 12-week open-label study of anakinra 100 mg daily by
subcutaneous injection. Physical examination, patient and physician global assessment of disease
activity (on a scale of 0–3), tender and swollen joint scores, ESR, C-reactive protein (CRP), and
Psoriasis Area and Severity Index (PASI) scores were performed at all visits. Plain x-rays of hands,
wrists, knees and feet were performed at baseline. Magnetic resonance imaging (MRI) scan of an
inflamed knee joint Health Assessment Questionnaire (HAQ) scores, patient assessment of disease
activity and pain using visual analog scales and PsA-quality of life (QoL) measurements were done
at baseline and week 12. Arthroscopy of the index knee joint was performed at baseline and week
12. Synovial biopsies were taken from six regions within the joint, and stained for CD3, CD68, and
factor VIII. Digital image analysis was used to quantify the percentage of tissue staining positive for
these markers. The primary clinical end point was the proportion of patients who met the Psoriatic
Arthritis Response Criteria (PsARC) at 12 weeks. The clinical effect after treatment was also assessed
using the Disease Activity Score (DAS28). MRI results will be reported elsewhere.
Results: Clinical data were collected on 10 patients. Two male patients withdrew due to
noncompliance with the study protocol and lack of efficacy, respectively. Baseline physical
examination revealed psoriasis and active synovitis in all patients. Six of the 10 patients (60%)
met the PsARC at week 12. Mean DAS28 score changed from 5.3 (3.8–7.2) to 4.2 (2.3–6)
(P¼ 0.027). Mean HAQ scores improved from 1.34 (0.63–2.38) to 1.09 (0.25–1.86) (P¼0.07),
whereas mean PsA-QoL scores changed from 26/46 (9–41) to 21/46 (5–40) (P¼ 0.078). Other
relevant clinical data are listed. Immunohistological data were collected on nine patients. Mean
FVIII, CD3, and CD68 scores changed from 6.1 (1.6–10.3), 2.77 (0.3–13.0), and 20.9 (8.2–53.1),
respectively, to 8.2 (4.5–15.4) (P¼0.66), 4.7 (4.9) (P¼ 0.11) and 25.9 (11.6–49.3) (P¼0.21),
respectively. Patient assessment of disease activity (0–3). Physician assessment of disease activity
(0–3). Tender joint score (0–78). Swollen joint score (0–76). Patient assessment of disease activity
on VAS Patient assessment of pain on VAS PASI score ESR CRP Baseline 2.2 (1–3) 2.4 (1–3) 28
(11–51) 21 (7–29) 61 (27–85) 63 (21–91) 6.3% (1–16) 22 (3–79) 26 (4–70); Week 12 1.7 (1–3)
P¼ 0.25 1.6 (1–3) P¼ 0.016 16 (2–36) P¼0.01 10 (0–25) P¼ 0.018 43 (12–70) P¼ 0.07 47
(20–75) P¼0.18 6.8%(0–26) P¼ 0.81 14 (2–46) P¼ 0.04 10 (4–29) P¼ 0.08.
Conclusions: This open-label, proof-of-concept study has shown anakinra to be of modest benefit
for articular but not skin disease in PsA. Significant improvements were seen in physician’s
assessment of disease activity, ESR, tender and swollen joint counts, and DAS28. Trends to
improvement were seen in all other clinical parameters. These clinical improvements however,
did not correlate with immunohistological findings, which showed a trend to overall worsening of
disease activity in the index knee joint.
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Chronic hepatitis B reactivation following etanercept therapy in a psoriatic
patient
Nicole Selenko-Gebauer, MD, Karolilne Stur, MD, Groeg Stingl, Franz Karlhofer, MD,
Department of Dermatology, Div. of Immunology, Allergy and Infectious Diseases, Vienna,
Austria
Treatment of moderate-to-severe plaque psoriasis with tumor necrosis factor (TNF) blocking
agents (i.e., etanercept, infliximab, adalimumab) has become a very effective and widely
accepted therapeutic option within the last years. Generally, the application of these substances is
safe and well tolerated. An increased risk, however, with respect to reactivation of certain latent
infections seems inherent to this group. Although severe reactivation of chronic hepatitis B has
been described in single cases in the context of infliximab treatment no such occurrence has been
reported with etanercept, a recombinant TNF receptor antagonist. Here, we describe a psoriasis
patient with chronic hepatitis B infection who developed a severe reactivation within the first 3
weeks upon initiation of etanercept therapy. The patient experienced malaise, nausea, jaundice,
and coluria. Serum aminotransferases were increased up to 50-fold and total bilirubin peaked at
14.04 mg/dl. Hepatitis B virus titers assessed prior and during this episode confirmed HBV
reactivation. Upon withdrawal of etanercept all serum parameters returned to normal within 2
months. This case illustrates that chronic hepatitis B reactivation is a potential risk inherent to the
whole group of TNF inhibitors. We conclude that screening for latent hepatitis B should be
routinely performed in all patients before initiation of TNF inhibitors.
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Linear nevoid psoriasis: A case report
Yong-Kwang Tay, MD, MRCP, Changi General Hospital, Singapore, Singapore
Linear distribution of psoriasis along the lines of Blaschko is rare. A 3-year-old boy presented with
non-itchy erythematous, scaly plaques on the right thigh of 6 months duration. This spread to
involve the right leg, extending to the dorsum of the right foot. There was no family of psoriasis
and no lesions elsewhere. The main differential diagnosis considered was inflammatory linear
verrucous epidermal nevus. Histopathology from any erythematous plaque on the right thigh
revealed typical features of psoriasis, including hyperkeratosis, acanthosis with regular elongation
of the rete ridges, parakeratosis, Munro microabscesses, suprapapillary thinning and an absent
granular layer. Blood vessels in the dermis were dilated with a lymphocytic inflammatory
infiltrate. A diagnosis of linear nevoid psoriasis was made and the child was treated with
calcipotriol ointment twice daily with significant improvement after about 3 months. Although
rare, true linear psoriasis exists. It could be explained by the migration of a clone of cells
harboring a somatic mutation following the lines of Blaschko during early embryogenesis.
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Development and evaluation of PASE: A self-administered psoriatic arthritis
screening and evaluation tool
Elinor Mody, MD, Abrar Qureshi, MD, MPH, Brigham and Women’s Hospital, Boston, MA, USA,
Elaine Husni, MD, MPH, Cleveland Clinic, Cleveland, OH, USA
The incidence and prevalence of psoriatic arthritis (PsA) is unknown at the population level. PsA
can lead to severe destructive joint disease if left untreated or undiagnosed. We have developed a
self-administered questionnaire that dermatologists can use to screen psoriasis patients for
evidence of PsA and refer to rheumatology. The Psoriatic Arthritis Screening and Evaluation
(PASE) questionnaire contains 15 five-choice items separated into two subscales: symptoms and
function. PASE minimum score was 15 and maximum score 75. Of the 45 consecutive
participants responding to the questionnaire before systemic therapy, 18 were diagnosed with PsA
plus psoriasis and 27 with psoriasis alone by a dermatologist and rheumatologist working in
collaboration. Mean age was 53 years and 21 were female. The PsA group was younger (mean
age difference 8.5 years, P¼0.06). In the PsA group, total median PASE score was 53 (25th, 75th
percentiles¼ 49, 63). In the psoriasis alone group, total median PASE score was 40 (25th, 75th
percentiles¼ 30, 47), Po0.01. Sensitivity was 0.83 and specificity was 0.70 for the total score.
Similarly, median function score for PsA was 27 (25th, 75th percentiles¼ 25, 31) and median
function score for psoriasis alone was 19 (25th, 75th percentiles¼ 15, 22), Po0.01. Median
symptom score for PsA was 24 (25th, 75th percentiles¼ 23, 30) and median symptom score for
psoriasis alone was 19 (25th, 75th percentiles¼ 14, 24), Po0.01. There is a need to identify
patients with PsA so that timely therapy can be initiated and long-term disability avoided. The
PASE questionnaire will be a useful adjunct to clinical care for potential PsA seen in dermatology
clinics. Further work is needed to test PASE in a larger sample of psoriasis patients.
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Classification criteria for psoriatic arthritis: Results from the CASPAR study
Philip Helliwell, PhD, University of Leeds, Leeds, UK, William Taylor, University of Otago,
Wellington, New Zealand
Objective: To compare the accuracy of existing classification criteria for the diagnosis of psoriatic
arthritis and to construct new criteria from observed data.
Methods: Data were collected prospectively from consecutive clinic attendees with psoriatic
arthritis and other inflammatory arthritis. Subjects were classified by each of seven criteria.
Sensitivity and specificity were compared using conditional logistic regression analysis. Latent
class analysis was used to calculate criteria accuracy to confirm the validity of clinical diagnosis
as the gold-standard definition of case-ness. CART methodology and logistic regression was used
to identify items for new criteria, which were then constructed using a receiver operating
characteristic curve.
Results: Data were collected on 588 cases and 536 controls with rheumatoid arthritis (n¼ 383),
ankylosing spondylitis (n¼ 72), undifferentiated arthritis (n¼ 38), connective tissue disorders
(n¼ 14), and other disease (n¼28). The specificity of each criterion was high. The sensitivity of
Vasey (0.97) was similar to McGonagle (0.98) and more sensitive than Bennett (0.34), Moll (0.86),
ESSG (0.54), and Gladman (0.87). The CASPAR criteria were: established inflammatory articular
disease with at least three points from the following features: current psoriasis (scores 2 – all other
features score 1), history of psoriasis (unless current psoriasis present), family history of psoriasis
(unless current or history of psoriasis present), dactylitis, juxta-articular new bone formation,
negative rheumatoid factor and nail dystrophy. These criteria were more specific (0.99 vs 0.96)
than Vasey but less sensitive (0.91 vs 0.97).
Conclusions: The CASPAR criteria are simple, highly specific but less sensitive than the Vasey
criteria.
98
Etanercept 50 mg once/week sustains clinical improvement in patients with
psoriasis transferring from 25 mg etanercept twice/week
Anca Serban Wyeth Research, Collegeville, PA, USA, Jean Paul Ortonne, MD, Hospital de
l’Archet, Nice, France, Boni Elewski, University of Alabama, Birmingham, AL, USA, Craig
Leonardi, MD, St Louis University, St Louis, MO, USA, Angelika Jahreis, Amgen, Inc., Thousand
Oaks, CA, USA
Etanercept is a highly effective and well-tolerated soluble tumor necrosis factor antagonist
approved for the treatment of plaque psoriasis in the United States and Europe. Patients who
received etanercept 25 mg twice/week (BIW) for up to 48 weeks in a previous study enrolled in an
open-label extension study and received etanercept 50 mg once/week (QW). A total of 265
patients who enrolled within 15 days of receiving the last dose of etanercept 25 mg BIW were
assessed for clinical efficacy after 12 weeks of open-label therapy. Primary end point was a mean
change in the Psoriasis Area and Severity Index (PASI) at 12 weeks of the extension study. Other
end points included a mean change in the DLQI and the percentages of patients who achieved a
DSGAP status of Clear or Almost Clear (0¼ clear, 5¼ severe disease) and a PSGAP score of 0 or 1
(0¼ clear, 5¼ severe disease) at week 12 of the extension study. Mean PASI score improved from
18.43 at baseline of the first study to 5.77 at baseline of the extension study after treatment with
etanercept 25 mg BIW. After 12 weeks of etanercept 50 mg QW, mean PASI score was sustained
at 5.82, a mean difference of 0.06 (95%CI (0.40, 0.29); P¼ 0.76) between the two dosing
regimens. Similar sustained improvements were observed in the DLQI with mean scores
improving from 10.77 at baseline of initial study to 3.13 at baseline of extension to 3.03 at week
12. Patients receiving 50 mg QW etanercept sustained significant improvements in disease status
that had been achieved with previous 25 mg BIW etanercept treatment.
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Adalimumab is efficacious in treating skin disease of psoriatic arthritis patients
with mild-to-severe baseline skin involvement: Subanalysis of ADEPT
Philip J. Mease, MD, Swedish Medical Center, Seattle, WA, USA, Dafna D. Gladman, MD,
FRCPC, University of Toronto, Toronto, Ontario, Canada, Ernest Choy, King’s College, London,
UK, Serge Steinfeld, Erasme University Hospital, Brussels, Belgium, Renee Perdok, Martin M.
Okun, Abbott Laboratories, Abbott Park, IL, USA
Purpose: Adalimumab is a fully human, monoclonal IgG1 antibody against tumor necrosis factor
(TNF) approved for treatment of psoriatic arthritis (PsA) in the United States and EU, based in part
on ADalimumab Effectiveness in Psoriatic arthritis Trial (ADEPT). Herein is a post hoc analysis of
skin outcomes in patients (pts) with mild-to-moderate (MM) and moderate-to-severe (MS)
psoriasis (Ps) at baseline (BL).
Methods: ADEPT was a double-blind, placebo (pbo)-controlled, Phase III study of adalimumab in
pts with PsA (4¼3 swollen and4¼3 tender joints). Pts were randomized to adalimumab 40 mg
every other week (eow) or pbo for 24 weeks. Psoriais Area and Severity Index (PASI) and
Physician’s Global Assessment (PGA) were measured for pts with 4¼ 3% BSA. Pts were
subgrouped by BL PGA as MM or MS, then. PASI and PGA were analyzed post hoc.
Results: Three hundred and thirteen pts (151 adalimumab, 162 pbo) enrolled in ADEPT. PASI was
evaluated for 138 pts (69 adalimumab, 69 pbo). Overall, ACR20/50/70 and PASI 50/75/90 at
week 24 were 57/39/23 and 75/59/42 for adalimumab vs 15/6/1 and 12/1/0 for pbo (Po0.001). At
week 24, PASI 50/75/90 in MM Ps pts were 77/60/40 (adalimumab) and 7/0/0 (pbo) (P4o0.001);
in MS Ps pts, PASI 50/75/90 were 74/59/44 (adalimumab) and 15/3/0 (pbo) (P4o0.001).
Conclusions: Significant benefits were seen for pts in ADEPT with mild-to-severe Ps involvement.
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Concurrent efficacy of adalimumab against skin and joint disease in psoriatic
arthritis
Christopher Ritchlin, MD, University of Rochester School of Medicine and Dentistry, Rochester,
NY, USA, Philip J. Mease, MD, Swedish Medical Center, Seattle, WA, USA, Eric Sasso, Abbott
Laboratories, Abbott Park, IL, USA
Purpose: This post hoc subanalysis evaluated the frequency of concurrent joint and skin responses
in ADalimumab Effectiveness in Psoriatic arthritis Trial (ADEPT) psoriasis arthritis (PsA) patients
(pts) treated with adalimumab for 48 weeks.
Methods: ADEPT was a double-blind, placebo-controlled study of adalimumab in pts with active
PsA. Pts were stratified according to methotrexate use (yes/no) and degree of psoriasis (Ps) (o3%
and 4¼ 3% body surface area (BSA)), and randomized to receive adalimumab 40 mg
subcutaneously or placebo (pbo) every other week (eow) for 24 weeks. Pts completing 24 weeks
were eligible to enroll in an open-label extension and receive adalimumab 40 mg eow. For this
analysis, pts with 4¼ 3% BSA affected at BL were categorized by Psoriais Area and Severity
Index (PASI) and ACR responses at weeks 24 and 48, vs BL. ACR and PASI scores were analyzed
in intent-to-treat (ITT) population, using NRI for missing data.
Results: BL data were similar between pbo (162) and adalimumab (151) pts. Mean BL PASI scores
were 8.3 and 7.4 for the 69 pbo and 69 adalimumab pts with BL 4¼ 3% BSA. At week 24, the
response rates for ACR20/50/70 and PASI 50/75/90 were 14/6/0 and 12/1/0 for pbo, and 54/36/23
and 75/59/42 for adalimumab pts. Among the 69 adalimumab pts, an ACR20 and/or PASI 75
response was achieved by 75% at week 24 and 68% at week 48. Simultaneous ACR20 and PASI
75 responses were achieved by 38 and 45% at weeks 24 and 48. Simultaneous ACR70 and
PASI75 responses were achieved by 22 and 26% at weeks 24 and 48. Among adalimumab pts
who achieved an ACR50 or an ACR70 response, a PASI 75 response was achieved at week 24 by
84 and 94%, respectively, and at week 48 by 83 and 95%. Among ACR nonresponders
(oACR20), PASI 75 and PASI 90 were achieved at week 24 by 47 and 28%, respectively, and at
week 48 by 29 and 29%.
Conclusions: Adalimumab is efficacious against both the skin disease and joint inflammation. As
the level of one type of response (skin or joint) increased, so did the frequency of the other, with
95% of ACR70 responders also achieving a PASI 75 response.
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Efficacy in moderate-to-severe psoriatic arthritis patients who have escalated
dosing due to subtherapeutic response to adalimumab eow
Christopher Ritchlin, MD, University of Rochester School of Medicine and Dentistry, Rochester,
NY, USA, Ernest Choy, King’s College, London, UK, Serge Steinfeld, Erasme University Hospital,
Brussels, Belgium, Martin M. Okun, Abbott Laboratories, Abbott Park, IL, USA
Purpose: ADalimumab Effectiveness in Psoriatic arthritis Trial (ADEPT) has shown that anti-TNF
therapy with adalimumab is efficacious against the arthritis and skin disease of psoriatic arthritis
(PsA) for up to 24 weeks (wks) (ACR20 of 57%, Psoriais Area and Severity Index (PASI) 75 of 59%
in adalimumab pts vs ACR20 of 15%, PASI 75 of 1% in placebo patients (pts)). Pts completing
ADEPT and a smaller 12-wk, Phase III PsA study could enroll in an open-label extension study
(OLES). This report describes the efficacy and safety in pts who started adalimumab 40 mg weekly
in the OLES.
Methods: Placebo (Pbo) pts started adalimumab 40 mg every other week (eow) when they
enrolled in the OLES, and adalimumab pts continued on their previous regimen. After 12 wks in
the OLES, pts with less than 20% improvement in both swollen and tender joint counts compared
to baseline could increase to adalimumab 40 mg weekly. Skin and joint outcomes and safety were
assessed after dose escalation.
Results: At week 12 of OLES observed ACR20 response was 58%. Of 395 OLES pts, 53 (13%)
started adalimumab 40 mg weekly. ACR 20/50/70 and PASI 50/75/90 response rates before dose
escalation were 11/2/0 (n¼ 45) and 55/18/14 (n¼ 22) and 12 weeks after dose escalation were
41/22/11 (n¼ 46) and 60/35/25 (n¼20), respectively. These improvements were sustained up to
36 weeks. Four pts experienced a serious adverse event (AE), including one serious infectious AE,
after dose escalation.
Conclusions: Almost 90% of PsA patients treated with adalimuab eow had a sufficiently
satisfactory clinical response and did not require dose escalation. Of the 13% who dose escalated
to 40 mg weekly, approx. 30% achieved joint and/or skin improvement, with an acceptable safety
profile.
102
Recent history of systemic or biologic therapy does not appear to adversely affect
adalimumab efficacy and safety in psoriasis
Richard G. Langley, MD, Dalhousie University, Halifax, Nova Scotia, Canada, Craig Leonardi,
MD, Central Dermatology Inc., St Louis, MO, USA, Darryl Toth, Probity Medical Research,
Windsor, Ontario, Canada, Martin M. Okun, Abbott Laboratories, Abbott Park, IL, USA
Purpose: A Phase II study demonstrated adalimumab is efficacious in moderate-to-severe plaque
psoriasis (Ps), with an acceptable safety profile. Some patients (pts) in this study had a recent
(within past 12 months) history of systemic or biologic therapy (but not with a tumor necrosis
factor antagonist), but could enroll if systemic therapy was stopped 4¼ 4 weeks before entry
(4¼ 12 weeks for biologics). The impact of prior treatment with these agents on the safety and
efficacy of pts receiving adalimumab is a practical concern to physicians and patients and is
investigated in this subanalysis.
Methods: Of 148 pts enrolled in a double-blind, placebo-controlled study, 147 pts received at least
one dose of study medication in one of three treatment arms: (1) pbo (n¼ 52); 2) adalimumab 80mg
subcutaneous (s.c.) at week 0, then 40 mg s.c. every other week (eow) starting at week 1 (n¼45); and
3) adalimumab 80 mg s.c. at weeks 0 and 1, then 40mg s.c. weekly (qw) starting at week 2 (n¼ 50).
Pbo pts were eligible at week 12 to receive adalimumab 40mg eow (pbo/adalimumab eow).
Results: Baseline data were similar between groups. Overall, % PASI 75 responders in the (pbo/
adalimumab eow)/adalimumab eow/qw arms were 55/64/72 at week 24 and 45/58/64 at week
60, respectively. For pts with prior systemic therapy (n¼ 58), these rates were 47/68/73 at week
24 and 41/68/64 at week 60. For pts with prior biologic therapy (n¼25), the rates were 63/50/67
at week 24 and 63/63/78 at week 60. For pts in neither of these groups (n¼ 73), the rates were 56/
65/76 at week 24 and 40/48/64 at week 60. Serious adverse events (SAEs) were detected in eight
prior-systemic pts, four prior-biologic pts, and five pts without recent prior systemic or biologic
therapy during the 60-week trial. Most SAEs did not appear to be related to adalimumab use.
Conclusions: This post hoc analysis suggests that recent treatment with systemic or biologic
therapy does not adversely affect adalimumab efficacy or safety in moderate-to-severe Ps pts.
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Adalimumab efficacy in treatment of moderate-to-severe chronic plaque psoriasis
is sustained through 60 weeks, with an acceptable safety profile
Richard G. Langley, MD, Eastern Canada Cutaneous Research Ltd., Halifax, Nova Scotia,
Canada, Craig Leonardi, MD, Central Dermatology Inc., St Louis, MO, USA, Darryl Toth, Probity
Medical Research, Windsor, Ontario, Canada, Martin M. Okun, Abbott Laboratories, Abbott Park,
IL, USA
Purpose: The objective of this study was to evaluate the long-term safety and efficacy of
adalimumab, a fully human, monoclonal IgG1 antibody against tumor necrosis factor, in the
treatment of moderate-to-severe chronic plaque psoriasis.
Methods: Patients (pts) enrolled in a 12-week, double-blind, placebo (pbo)-controlled study and
were randomized to one of three treatment arms: (1) adalimumab 80 mg at week 0 followed by
40 mg every other week (eow) beginning at week 1; (2) adalimumab 80 mg at week 0 and 1
followed by 40 mg wkly starting at week 2; and (3) pbo. Pts who completed the first 12 weeks
were eligible to continue in a 48-week extension trial where pts who initially received
adalimumab continued their assigned dosages. Pts on pbo received 80 mg of adalimumab at week
1 and 40 mg eow thereafter.
Results: A total of 147 pts at 18 sites in the United States and Canada enrolled and received at
least one dose of study medication. At baseline, mean duration of psoriasis was 19.3 years, mean
Psoriasis Area and Severity Index (PASI) score was 15.7, and mean % body surface area was
27.1%. At week 24, 64% of pts in the eow arm and 72% of pts in the weekly arm achieved a PASI
75 response. PASI 75 response was observed at week 60 in 58 and 64% of pts in the eow and
weekly treatment arms, respectively. At week 60, a PGA Clear or Almost Clear/PASI 90/PASI 100
response was achieved by 44/33/16 and 52/48/26% of pts in the eow and wkly treatment arms,
respectively. No new safety signals were reported compared to previous RA or psoriatic arthritis
clinical trials.
Conclusions: Adalimumab treated pts with moderate-to-severe psoriasis achieved sustained
efficacy through 60 weeks of treatment, with an acceptable safety profile.
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Long-term efficacy, safety, and inhibition of joint destruction by adalimumab in
psoriatic arthritis: Results from ADEPT
Philip J. Mease, MD, Swedish Medical Center, Seattle, WA, USA, Dafna Gladman, MD, FRCPC,
University of Toronto, Toronto, Ontario, Canada, Christopher Ritchlin, MD, University of
Rochester School of Medicine and Dentistry, Rochester, NY, USA, Eric Sasso, Abbott
Laboratories, Abbott Park, IL, USA
Purpose: To evaluate the efficacy/safety of adalimumab (Ada) over 48 weeks in patients (pts) with
moderate-to-severe psoriatic arthritis (PsA).
Methods: Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) was a controlled study of
Ada in pts with active PsA. Pts stratified for methotrexate (MTX) use (yes/no) and degree of
psoriasis (Ps) (o3% and 4¼ 3% body surface area (BSA)) received Ada 40 mg subcutaneous (sc)
or placebo (pbo) every other week (eow) for 24 weeks. Pts completing 24 weeks could enroll in
an open-label extension (OLE) and receive Ada 40 mg eow. For this analysis, pts with 4¼3%
BSA affected at BL were categorized by Psoriatic Area and Severity Index (PASI) and ACR
responses at weeks 24 and 48, vs BL. ACR and PASI scores were analyzed by intent-to-treat (ITT)
using NRI for missing data, and Health Assessment Questionnaire (HAQ) by LOCF. Radiographs
of hands/feet were taken at BL and weeks 24 and 48. Films were assessed by total Sharp score
(mTSS), modified to include additional joints involved in PsA, with data reported as observed.
Results: Of 313 pts randomized, 285 continued into the OLE. BL data were similar between arms. For
Ada pts (n¼ 151), the 24-week ACR20/50/70 responses were 57/39/23, and mean change in HAQ
was 0.4 (Po0.001 vs pbo). For the 69 (of 151) pts who had BL Ps of BSA4¼ 3%, PASI 50/75/90
response rates were 75/59/42, and mean % change in PASI was 66% (Po0.001 vs pbo). These results
were maintained through week 48. Pbo pts achieved similar responses in the OLE after 24 weeks of
Ada. ACR responses were similar between pts on Ada alone and those on MTX. PASI responses were
slightly higher in MTX pts, but not significantly so. The mean change in mTSS at week 24 was 0.2
for Ada (n¼ 144) and 1.0 for pbo (n¼ 152, Po0.001). Week-48 analysis of 128 Ada pts showed a
mean change in mTSS of 0.2 vs BL. Pbo pts who started Ada at week 24 had a mean change in mTSS
of 0.1 (week 48 vs week 24, n¼134). Ada was generally well tolerated. The OLE safety profile was
consistent with that reported for the initial 24 weeks and that observed for Ada in RA.
Conclusions: Ada was efficacious in treating PsA, with significant reductions in the burden of joint
and skin disease, and disability for 1 year.
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Epidemiology of psoriasis in Kuwait
Khairia Al-Mazeedi, Hejab Saud Al-Ajmi, Ameri Hospital, Bayan, Kuwait
Objective: This study aimed at identification of the minimal incidence and prevalence rates of
psoriasis and determining factors affecting occurrence and severity of the disease.
Methods: The study design can be differentiated into two components. The first was a descriptive
study to determine incidence and prevalence through record study of all psoriasis patients who
attended the selected outpatient clinic. The second was a case–control study to define factors
affecting occurrence of psoriasis and was conducted among 200 psoriasis cases and 200 control
subjects. Psoriasis cases were used to identify factors that might affect the severity of the disease
through a nested case–control study.
Results: The overall psoriasis incidence and prevalence in Kuwait were 0.11 and 0.45%,
respectively. Male gender, smoking, sunbathing, having arthritis or pharyngitis, liver impairment,
and positive family history of psoriasis were significant risk factors for developing psoriasis.
Alcohol consumption and numbers of patches 4¼ 5 at initial presentation were risk factors for
progression of psoriasis. Meanwhile, family history of psoriasis and treatment with Psoralen Ultra
Violet A (PUVA) were protective variables against progression of the disease.
Conclusions: The prevalence of psoriasis is low compared to other countries in the area. Psoriasis
is more liable to occur in male smokers with a family history of psoriasis. Treatment with PUVA
may protect against exacerbation of psoriasis.
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Liver injury in long-term methotrexate treatment in psoriasis is relatively
infrequent
Maartje Berends, MD, J. Snoek, Peter C.M. van der Kerkhof, MD, PhD, M.G.H. van Oijen,
E.M.G.J. de Jong, MD, PhD, J.P.H. Drenth, MD, PhD, H. Van Krieken, Radboud University
Medical Center Nijmegen, Gelderland, The Netherlands
Background: Methotrexate (MTX)-induced liver damage in psoriasis has led to dermatologic
guidelines that stipulate monitoring of liver injury by means of serial liver biopsies. Recent
literature data suggest that MTX may be considerably less hepatotoxic than previously assumed.
Aim: To evaluate prevalence and development of liver injury in MTX-treated psoriasis.
Methods: Retrospective chart review (1976–2005).
Results: One hundred and twenty-five patients (F58/M67; mean age 45.0, SD 12.7 years) received
a median cumulative MTX dose of 2,113 mg (range 180–20,235) over a median period of 228
weeks (range 16–1,763). Two hundred and seventy-eight liver biopsies were analyzed and 71%
were classified as Roenigk grade I, 14% as Roenigk II, 13% grade IIIa, 1% grade IIIB, and 1%
grade IV. Liver injury was not associated with cumulative dose, weekly prescribed dose, age, and
duration of treatment. Obesity and diabetes were significant risk factors for liver injury. A total of
68 patients had multiple biopsies, 3% improved, 72% did not change and in 25% liver histology
deteriorated. The majority of cases (84%) that progressed to Roenigk 2 had a cumulative dose of
1,500–6,000 mg.
Conclusions: MTX-related liver injury is less frequent than previously thought and mostly
occurred at cumulative dose of less than 6,000 mg. Diabetes and overweight are significantly
correlated with liver injury.
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Antiproliferative, antiangiogenic and apoptotic mechanism of photochemother-
apy (PUVA) in psoriatic patients
Romana Ceovic, MD, PhD, Aida Pasic, MD, Jasna Lipozencic, MD, PhD, Jasminka Jakic-
Razumovic, MD, PhD, Zagreb University Hospital Center, Zagreb, Croatia
Introduction: Psoriasis is characterized by keratinocyte hyperproliferation, abnormal differentia-
tion, neutrophil accumulation in the epidermis, and inflammatory infiltration, especially of T
lymphocytes. The exact cause of psoriasis remains unknown; therefore, the treatment is
symptomatic. PUVA photochemotherapy has for years been very successfully used in the
treatment of psoriasis vulgaris but the mechanism of its action has not yet been fully elucidated.
Objective: The aim of the study was to investigate the antiproliferative, antiangiogenic and apoptotic
action of photochemotherapy (PUVA), and to compare it with the clinical picture of the disease.
Methods: Proliferating keratinocyte count was immunohistochemically determined by use of anti
Ki-67 antibodies, the number of blood vessels in the dermis by use of F-8 antibodies, and cell
count expressing apoptotic oncogenes by use of anti-bcl-2 antibodies, all these before and after
photochemotherapy (PUVA). Psoriasis Area and Severity Index (PASI) score was determined
before and after treatment. The study included 20 patients with psoriasis vulgaris with indications
for photochemotherapy (PUVA).
Results: Study results demonstrated the antiproliferative, antiangiogenic and apoptotic effect of
photochemotherapy, and significant improvement of clinical picture according to PASI score.
Conclusions: Photochemotherapy (PUVA) was found to efficiently act on the main pathogenetic
mechanisms of psoriasis. In the era of biologicals, photochemotherapy (PUVA) remains one of the
most important therapies in management of chronic plaque psoriasis vulgaris.
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A randomized, double-blind, vehicle-controlled study of the efficacy of acitretin
with and without the co-administration of 0.1% tacrolimus topical ointment for
moderate-to-severe psoriasis
Alan B. Fleischer, Jr, MD, Steven R. Feldman, MD, PhD, Wake Forest University School of
Medicine, Winston-Salem, NC, USA, Andrew A. Nelson, Baltimore, MD, USA, Jennifer Krejci-
Manwaring, University of Kansas Medical Center, Kansas City, KS, USA, Joy Willard, M. Ann
McCarty, Wake Forest University School of Medicine
Background: Topical tacrolimus is effective as monotherapy for inverse psoriasis. Its use in
combination with other systemic agents may be an effective treatment for psoriasis in less
sensitive areas.
Objective: To determine if topical tacrolimus and oral acitretin is more effective than oral
acitretin and vehicle ointment.
Methods: All patients received oral acitretin; subjects were randomized to apply topical
tacrolimus to one side of their body and vehicle to the other. Treatment was for 8 weeks with a 4-
week follow-up period.
Results: Topical tacrolimus was more effective than vehicle ointment as early as week 4. There
were no severe adverse events or dose changes during the study. Limitations: Owing to the short
time horizon of the study, it may not be appropriate to generalize the results to longer treatment
periods.
Conclusions: Topical tacrolimus is an effective psoriasis treatment and was well tolerated when
combined with systemic acitretin in the treatment of psoriasis.
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Disease activity, radiographic features and bone density in psoriatic and
rheumatoid arthritis
Soumya M. Reddy, MD, New York University, Hospital for Joint Diseases, New York, NY, USA,
George Reed, PhD, University of Massachusetts, Worcester, MA, USA, Allen Anandarajah, MD,
University of Rochester, Rochester, NY, USA, Jeffrey D. Greenberg, MD, MPH, Steven B.
Abramson, MD, New York University, Hospital for Joint Diseases, Joel Kremer, MD, Albany, NY,
USA, Christopher T. Ritchlin, MD, University of Rochester
Purpose: Compare measures of disease activity, radiographic features, and bone density in
psoriatic arthritis (PsA) patients (pts) with matched rheumatoid arthritis (RA) cohort.
Methods: Five hundred and fifty-five PsA and 5,748 RA pts identified from CORRONA database
3/02–3/05. Presence of erosion, joint space narrowing (JSN), and deformity on radiographs and
lumbar spine (LS), hip, and femoral neck DXA T scores (TS) was analyzed.
Results: Disease activity – 509 PsA and RA pts matched for age, gender, and duration, PsA had
lower tender joint counts (TJC) compared to RA (3.3 vs 4.4, P¼ 0.001), lower swollen joint counts
(SJC) (3.3 vs 5.5, Po0.001), and lower mHAQ score (0.5 vs 0.6, P¼ 0.025). Pt general health
assessment was comparable in PsA and RA (29.2 vs 29.4 mm, P¼ 0.918), as were pt pain scores
(32.8 vs 31.2 mm, P¼ 0.341) and use of biologics (43.8 vs 42%, P¼ 0.612). Radiographs
percentage of pts with radiographic erosion was high but more prevalent in RA than PsA cohort
(52.3 vs 44.7%, P¼0.020). Radiographic joint deformities were similar in RA and PsA (28.4 vs
25.7%, P¼ 0.372), as was presence of JSN (58.6 vs 59.7%, P¼0.747). Bone density unadjusted
mean LS TS in 191 PsA and 4,171 RA pts was 0.4 and 0.8 U, Po0.001. In 164 PsA and RA pts
matched for age, gender, duration, weight (wt), and smoking, difference in LS TS was not
significant (0.4 vs 0.7, P¼0.143). In multivariate analysis wt contributed significantly to
differences in LS TS. Mean wt of PsA pts was heavier (males 5.25 kg; females 9.22 kg) than RA
(Po0.001). Differences in hip and femoral neck TS were similar to those in LS.
Conclusions: PsA and RA had comparable measures of disease activity, bone erosion, JSN, and
deformity despite lower TJC and SJC when matched for age, gender, and duration. Bone density
changes, adjusted for wt, were also similar in both groups. These data indicate that outcomes in
PsA and RA may be more similar than previously reported.
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A differential effect of calcitriol and calcipotriol ointment on epidermal
subpopulations, a quantitative study
J.E.M. Korver, MD, Desiree W.A. van Rens, MD, PhD, Marcel C. Pasch, Piet E.J. van Erp, Jan B.M.
Boezeman, Peter C.M. van de Kerkhof, Radboud University, Nijmegen, The Netherlands
Background: Calcitriol and calcipotriol are widely used in the topical treatment of psoriasis.
However, studies comparing both treatment modalities are scarce. Especially, there are almost no
studies comparing the effects on epidermal cell populations in a quantitative manner.
Objectives: The aim of this study was to quantitatively compare the effects of topical calcitriol
and topical calcipotriol on clinical scores and epidermal subpopulations.
Patients and methods: From five patients with stable plaque psoriasis, skin biopsies were taken
from two symmetrical regions on trunk or extremities before and after treatment with either
calcitriol or calcipotriol. Frozen sections were labeled immunofluorescently using direct
immunofluorescence for b-1 integrin and the Zenon labeling technique for keratin 6, 10, and
15. The digital photographs of the stained sections were quantitatively analyzed and the results of
both treatments were compared.
Results: The clinical SUM score improved significantly for both the calcitriol and the calcipotriol-
treated lesions. In the calcipotriol-treated group the expression of keratin 10 and keratin 15
increased and the expression of keratin 6 decreased significantly. No changes were seen for the
marker b-1 integrin. In the calcitriol-treated group none of the markers changed significantly. A
tendency towards significance was seen for the changes in the expression of keratin 6 and keratin
15 in favor of calcipotriol.
Conclusions: Both calcitriol and calcipotriol gave a significant improvement in clinical scores.
Treatment with calcipotriol, however, resulted in a normalization of keratin 6, 10, and 15,
whereas treatment with calcitriol did not. Comparison of both treatments showed a tendency
toward significance for the above-mentioned markers for calcipotriol only.
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Significantly higher plasma level of oxidized low-density lipoprotein at disease
onset in patients with psoriasis
Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD, Mona Sta˚hle, MD,
PhD, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
A combination of traditional and nontraditional risk factors related to cardiovascular disease has
been demonstrated in patients with psoriasis. However, previous studies include heterogeneous
patient groups with highly varying disease duration. Recently, we demonstrated that psoriasis
patients manifest significant lipoprotein abnormalities at the onset of disease that may predispose
them to atherosclerosis. Over the past century, there have been numerous efforts to explain the
pathogenic mechanisms of atherosclerosis, and several hypotheses have emerged. The oxidative
modification hypothesis is based on the notion that low-density lipoprotein (LDL) is readily
oxidized, resulting in the formation of oxidized LDL (ox-LDL). The ox-LDL promotes formation of
foam cells through scavenger receptor pathways, and LDL oxidation is thought of as an early and
essential event in atherogenesis. Therefore, circulating ox-LDL is suggested to be involved in the
initiation and progression of atherosclerosis and may be used as a biomarker for atherosclerosis
risk. This study demonstrates a significantly higher plasma concentration of ox-LDL in psoriasis
patients at disease onset (o12 months). In total 100 patients and their 100 population-matched
controls were included in the study. Ox-LDL concentrations were 12.2% (P¼ 0.006) higher in
patients than in controls. There was no significant association with Psoriasis Area and Severity
Index, C-reactive protein, psoriasis arthritis, or sex. This study supports the notion that psoriasis is
associated with an increased risk for atherosclerosis.
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Disease activity in early psoriatic arthritis: A prospective comparative study with
rheumatoid arthritis
Ulla Lindqvist, MD, PhD, University Hospital, Uppsala University, Uppsala, Sweden, Gerd-Marie
Alenius, MD, PhD, University Hospital, Umea˚, Sweden, Tomas Husmark, MD, Falu Hospital,
Falun, Sweden, Elke Theander, MD, PhD, Malmo¨ University Hospital, Malmo¨, Sweden, Gunilla
Holmstro¨m, MD, Spenshult Rheumatological Hospital, Oskarstro¨m, Sweden
The Swedish Psoriatic Arthritis register (Swe-PsA) includes 278 patients with early disease. The
aim of the register is to study early psoriatic arthritis (PsA) in the Swedish population, to find
markers for disease activity, progression, and destruction and to be able to evaluate treatments.
This study presents comparative results of early PsA and rheumatoid arthritis (RA).
Materials and Methods: Patients referred to rheumatological out clinics within 2 years of onset of
disease were included and reassessed 2 years later. Data in 101 patients were collected and
presented according to SwePsA (1). Classification of the disease, clinical and laboratory
examination, patient health assessment questionnaires, global assessment of disease activity and
pain were performed. Patients with early RA (n¼ 901, adjusted for age) recruited from the
Swedish Early Rheumatoid arthritis register were used for comparison with PsA.
Results: At inclusion 42% of all PsA were having polyarticular disease and 50% mono-
oligoarticular. The patients with polyarticular disease had the highest inflammatory activity
measured as swollen and tender joint counts, Health Assessment Questionnaire (HAQ) and
patients assessment (VAS) of pain and of global disease activity. Patients with RA had significantly
higher inflammatory activity, pain and patients assessed activity of disease, and reduced function
compared to the whole PsA patient group. PsA with polyarthritis had compatible activity with RA,
only C-reactive protein and E-SR were significantly higher both at inclusion and 2 years later.
HAQ was significantly higher in RA at inclusion but not 2 years later and PsA with polyarthritis
had significantly more tender joints at 2 years follow-up compared to RA.
Conclusions: This study has confirmed that PsA patients with polyarticular disease had the highest
inflammatory activity compatible with RA when assessing joint counts and patient assessment of
the disease. As polyarticular disease at onset is associated with destruction and proliferation of
joint damage it is of great importance to classify the patients in early disease.
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Long-term treatment of 4.5 years with infliximab: A case report of a patient with
severe psoriasis
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Michael David, MD, Rabin Medical
Center, Petah Tikva, Israel, Ilan Bank, MD, Sheba Medical Center, Ramat Gan, Israel
Long-term treatment of 4.5 years with infliximab; a case report of a patient with severe psoriasis. A
48-year-old woman with recalcitrant generalized psoriasis vulgaris (almost maximal Psoriasis
Area and Severity Index) and severe psoriatic arthritis who has been treated with infliximab for 4.5
years is described. To the best of our knowledge, this case describes the longest infliximab-treated
psoriatic patient reported in the literature so far. After the initial three infusions she was almost
completely clear, but relapsed after 9 weeks. Readministration of infliximab combined with low-
dose methotrexate again led to complete remission, only after additional six infusions. The patient
remained in remission for 4.5 years with repeated injection of infusions every 5–7 weeks and low-
dose methotrexate once weekly. Follow-up revealed no clinical side effects or laboratory tests
abnormalities apart from elevated antinuclear antibody with fluctuations of double-stranded DNA
without developing clinical lupus. We conclude that infliximab is a safe and efficacious treatment
for psoriasis and psoriatic arthritis. This case report shoes that infliximab is a safe and effective
treatment for curing psoriasis. Review of the literature about infliximab will be given.
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Efficacy and safety of 24-week therapy with continuous efalizumab in Saudi
Arabia
Samir A. T. Hantirah, MD, Abdulla A. Abanmi, MD, FRCP, Fahd Al Harthi, MD, Mohamed Al
Jamal, MD, Wadha Al Khadi, MD, Yaser Al Qubaisy, MD, Riyadh Armed Forces Hospital,
Riyadh, Saudi Arabia
Efalizumab (anti-CD11 monoclonal antibody) targets multiple T-cell-mediated processes
important in the pathogenesis of psoriasis. The efficacy and safety of efalizumab in psoriasis
have been demonstrated in many clinical trials. We present our preliminary clinical experience
with the use of Efalizumab monotherapy in 10 patients with moderate discussed in this anecdotal
report from a tertiary care hospital in Saudi Arabia. Efalizumab seems to be a safe, effective, and
well-tolerated monotherapy for moderate-to-severe chronic plaque psoriasis in our patient
population.
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Predictors for radiological damage in psoriatic arthritis: Results from a single
center
Dafna D. Gladman, MD, FRCPC, University of Toronto, Toronto Western Hospital, Toronto,
Ontario, Canada, Simon J. Bond, PhD, Institute of Public Health, Cambridge, UK, Catherine T.
Schentag, MSc, University of Toronto, Toronto Western Hospital, Vern T. Farewell, Institute of
Public Health
The aim of the current investigation was to identify predictors for radiological damage in psoriatic
arthritis.
Methods: Patients followed prospectively according to a standard protocol at The University of
Toronto between 1978 and 2004 were included. The principal outcome was the change between
visits in the number of damaged joints. Radiological damage was measured by the modified
Steinbrocker’s method, shown to be reliable and sensitive to change in our Clinic. Explanatory
variables considered included: gender, age, arthritis duration at first visit, active and swollen
joints, functional class, ESR, medication, and, to adjust for within patient correlation, the number
of damaged joints at the first of the two visits over which change was observed.
Results: At the time of this analysis there were 625 patients recorded in the database. Multivariate
analysis of predictors for both clinical and radiological damage show that age, time in clinic,
initial ESR, number of tender and swollen joints at previous visit, and number of deformed joints
at previous visit were related to both clinical and radiological damage.
Conclusions: The number of actively inflamed joints, particularly the number of swollen joints
was associated with progression of radiological damage. The higher number of previously
damaged joints, the higher the risk for progression of damage. Thus patients with PsA need to be
treated even in the presence of damage as long as there is evidence of inflammation, to prevent
progression of damage.
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How much improvement in functional status is considered important by patients
with active psoriatic arthritis: Applying the Outcome Measures in Rheumatoid
Arthritis Clinical Trials (OMERACT) Group Guidelines
Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA, USA, Rita Ganguly, Wyeth
Research, Collegeville, PA, USA, L. Wanke, Amgen, Inc., Thousand Oaks, CA, USA, Amitabh
Singh, Wyeth Research
Background: A key construct in the evaluation of functional improvement due to treatment in
rheumatic disease is the determination of ‘‘minimally important clinical difference’’, which has
been constructed in rheumatoid arthritis (RA) as a 0.22 change in Health Assessment
Questionnaire (HAQ) score, but has not been estimated in psoriatic arthritis (PsA). The
OMERACT group has proposed constructing Minimal Clinically Important Difference (MCID)
based on perspective of analysis.
Objective: To estimate MCID for characterizing improvement in functional status, based on
OMERACT group recommendations, for patients with active PsA.
Methods: Patient functional status was assessed by HAQ* at baseline and at weeks 4, 12, and 24
in a double-blind, 24-week study of 205 patients randomly assigned to etanercept 25 mg twice/
weekly (N¼101) or placebo (N¼104). Concurrently, patients were also asked to rate importance
of improvement in functioning (HAQIMP) on a seven-point scale (1¼ not at all important;
7¼ extremely important). Patient ratings of 2 or 3 on the HAQIMP scale were considered
‘‘minimally important’’. Mean change in HAQ scores for patients rating improvement in
functioning as ‘‘minimally important’’ was used as an estimate of MCID for characterizing within-
treatment group. We also estimated MCID in HAQ based on standard error of measurement (SEM)
method. As suggested by Beaton et al., the upper bound of the 95% confidence interval of SEM for
HAQ was used as an estimate of MCID. SEM-based MCID was used as an estimate to characterize
within-subject improvements in HAQ.
Results: At baseline there were no significant differences in age (etanercept 47.6 years; placebo
47.3 years), HAQ (etanercept 25 mg twice/weekly 1.1; placebo 1.1), and disease duration
(etanercept 25 mg twice/weekly 9.0 years; placebo 9.2 years) between patients in active and
control groups. The mean HAQ score improvement among patients rating improvement in
functioning as ‘‘minimally important’’ was 0.30 (95% confidence interval (CI): 0.24–0.35) as
opposed to 0.65 (95% CI: 0.57–0.72) for patients rating improvement in HAQ as ‘‘very
important’’. The difference in HAQ score improvements for the patients rating HAQ
improvements as ‘‘minimally important’’ and ‘‘very important’’ was statistically significant
(Po0.001). The mean change from baseline in HAQ scores for patients in the etanercept group
was 0.34, 0.51, and 0.54 at weeks 4, 12, and 24, respectively. Thus mean change from baseline
in the etanercept group was clinically meaningful (HAQ improvement of 0.30) at all visits. The
mean change from baseline for placebo failed to reach the clinically meaningful threshold. SEM-
based MCID in HAQ was estimated to be 0.40. A significantly large proportion of patients in the
etanercept group achieved this threshold compared with placebo at all visits (week 4: etanercept
36% vs placebo 11.5%; week 12: etanercept 47% vs placebo 17%; week 24: etanercept 50% vs
placebo 14%).
Conclusions: Improvements of 0.30 in HAQ score are considered ‘‘minimally important’’ by
patients with active PsA. A threshold of 0.30 may be used to characterize within-treatment group
changes in the HAQ Disability Index. A higher threshold of 0.40 should be used to characterize
within-subject improvements in the HAQ Disability Index.
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Results of a Phase II study of CNTO 1,275 in the treatment of psoriasis
Gerald G. Krueger, MD, University of Utah Health Science Center, Salt Lake City, UT, USA,
Richard Langley, MD, Dalhousie University, Halifax, Nova Scotia, Canada, Craig Leonardi, MD,
St Louis University Medical School, St Louis, MO, USA, Mark Lebwohl, MD, Mount Sinai School
of Medicine, New York, NY, USA
Background: We evaluated the safety and efficacy of anti-IL12p40, an antagonist to IL-12 and -23,
two key cytokines in type 1 immune responses, in the treatment of plaque psoriasis.
Methods: In this 52 week, double-blind, placebo (PBO)-controlled trial, 320 patients (pts) were
randomized to one of four doses of subcutaneously administered CNTO 1,275 (one injection of
50 mg or 100 mg; 4 weekly 50 mg injections, or 100 mg injections) or PBO. Pts in the CNTO
1,275 groups received an additional dose at week 16 if they did not have an excellent or
complete response (o75% clearing) by Physician’s Global Assessment (PGA). Pts in the PBO
group received 100 mg of CNTO 1,275 at week 20.
Results: At week 12, X75% improvement in Psoriasis Area and Severity Index (PASI) was
observed in 52, 59, 67, and 81% of pts treated with 50 mg, 100 mg, four weekly 50 mg injections,
or four weekly 100 mg injections of CNTO 1,275, respectively, vs 2% of PBO (Po0.001 for each
comparison vs PBO). At least a 90% improvement in PASI was observed in 23, 30, 44, and 52%
of pts in the respective CNTO 1,275 groups versus 2% of PBO (Po0.001 for each comparison vs
PBO). Only 87 pts were re-treated with CNTO 1,275 at week 16. Though less than half of pts
overall received re-treatment, the overall proportions of pts with X50%, X75%, and X90%
improvement in PASI or who had an excellent response as measured by PGA remained relatively
stable through week 24. Because pts received no further therapy, response rates began to decline
thereafter. Improvements in clinical measures correlated with improvements in quality of life.
CNTO 1,275 was generally well tolerated. Through week 20 (PBO-controlled portion) 79.0% of
CNTO 1,275-treated pts experiencedX1 adverse event versus 68.7% of PBO-treated pts (average
duration of follow-up was 17.9, 19.4, 19.3, 20, and 20.1 weeks for the PBO, 50, 100, 200, and
400 mg groups, respectively). Serious adverse events were uncommon in all groups.
Conclusions: This study demonstrates that subcutaneously administered anti-IL12p40 is
efficacious in psoriasis and validates the role of the p40 family of cytokines in psoriasis
pathogenesis.
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Infliximab: 1-year Phase III results
Alice B. Gottlieb, MD, PhD, Tufts-New England Medical Center, Boston, MA, USA, Steven R.
Feldman, MD, PhD, Wake Forest University School of Medicine, Winston-Salem, NC, USA,
Gerald D. Weinstein, MD, University of California Irvine Medical Center, Irvine, CA, USA, Alan
Menter, MD, Baylor University Medical Center, Dallas, TX, USA
Objective: Infliximab, a tumor necrosis factor-a (TNF-a) antagonist, is an effective psoriasis
treatment. In this placebo-controlled pivotal phase III trial, we evaluated the safety and efficacy of
several infliximab induction and maintenance regimens.
Methods: Patients with moderate-to-severe psoriasis were randomized to induction doses of
infliximab 3 or 5 mg/kg, or placebo, at weeks 0, 2, and 6. Patients in the active induction
treatment groups were randomized again at week 14 to receive either scheduled or ‘‘as-needed’’
maintenance treatment at the same dose administered during the induction phase. Patients in the
placebo group crossed over at week 16 to receive infliximab 5 mg/kg at weeks 16, 18, and 22,
then every 8 weeks through week 46.
Results: More patients treated with infliximab 3 mg/kg (70%) and 5 mg/kg (75%) achieved at least
75% improvement in Psoriasis Area and Severity Index (PASI) score from baseline at week 10
compared to patients receiving placebo (2%) (Po0.001). During the maintenance phase, a more
sustained improvement was observed with regularly scheduled compared to ‘‘as-needed’’
maintenance therapy regimens within each dose. At week 50, patients receiving 5 mg/kg as
regularly scheduled maintenance had the highest level of sustained PASI improvement. Patients’
quality of life was significantly enhanced by treatment, and this enhancement paralleled PASI
response. Adverse events were experienced during the placebo-controlled induction period by 62
and 69% of patients in the 3 and 5 mg/kg treatment groups, respectively, compared with 55% of
patients in the placebo group. Infliximab was generally well tolerated in the majority of patients.
Conclusions: These results confirm the safety and efficacy of infliximab treatment in psoriasis.
Scheduled maintenance treatment provides better long-term control of psoriasis.
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Infliximab inhibits progression of radiographic damage in patients with active
psoriatic arthritis: 54 week results from IMPACT 2
De´sire´e van der Heijde, University Hospital Maastricht, Maastricht, The Netherlands, Dafna D.
Gladman, MD, FRCPC, Toronto Western Hospital, University of Toronto, Toronto, Ontario,
Canada, Arthur Kavanaugh, MD, University of California San Diego, La Jolla CA, USA, Christian
Antoni, Friedrich-Alexander University, Erlangen, Germany, Gerald G. Krueger, MD, University
of Utah Health Sciences Center, Salt Lake City, UT, USA, Cynthia Guzzo, Bei Zhou, L.T. Dooley,
Anna Beutler, Centocor Research and Development, Inc., Malvern, PA, USA
Objectives: We report the effect of infliximab (IFX) on the progression of structural damage in
psoriatic arthritis (PsA) patients (pts) through week 54.
Methods: In this double-blind, placebo (PBO)-controlled trial, pts with active PsA were
randomized (1:1) to receive IFX 5 mg/kg at weeks 0, 2, 6, and every 8 weeks through week 46 or
PBO at weeks 0, 2, 6, 14, and 22. PBO-treated pts witho10% improvement in both swollen and
tender joints entered early escape and received IFX 5 mg/kg at weeks 16, 18, and 22 (N¼ 47). At
week 24, PBO pts who did not qualify for early escape, received IFX at weeks 24, 26, 30, 38, and
46. Pts randomized to IFX who had o20% improvement in combined tender and swollen joint
count received IFX 10 mg/kg at weeks 38 and 46. Radiographs of the hands and feet were
obtained at weeks 0, 24, and 54. Erosions and joint space narrowing were evaluated by two
independent readers blinded to treatment and film sequence using the van der Heijde-Sharp
(vdH-S) method modified for PsA. The change from baseline in the modified vdH-S scores were
compared between groups using ANOVA with pts’ baseline methotrexate usage (Y/N) as a factor
in the model based on the van der Waerden normal score.
Results: Two hundred pts were enrolled. At baseline, the median pt age was 47 years, PsA
duration was 5.5 years. Baseline mean7SD (median) total vdH-S score was 39.09782.83 (4.50)
for IFX and 30.29761.43 (6.00) for PBO. At week 24, IFX pts had less radiographic damage at
week 24 than pts receiving PBO, as measured by the mean (7SD) change from baseline in total
vdH-S score (0.7072.53 vs 0.8272.62, Po0.001). In the PBO group, 12 pts demonstrated
progression in total vdH-S score above the smallest detectable change (SDC¼ 2.69) at week 24 vs
three pts in the IFX group (P¼ 0.017). In pts continued on IFX through week 46, the mean (SD)
change from baseline at week 54 was –0.94 (3.40) versus 0.53 (2.60) in pts who crossed over from
PBO to IFX (P¼0.001). IFX randomized pts and PBO pts who crossed over to IFX at week 16 or
24 had an improvement in total score of –0.24 (2.45) and –0.29 (1.98), respectively, from weeks
24 to 54. No differences were observed in PsA-characteristic features including pencil-in-cup
deformities and gross osteolysis.
Conclusions: IFX inhibits radiographic progression in PsA pts as early as 24 weeks. Radiographic
improvement continued through 1 year. Improvement in radiographic scores was observed in
placebo pts who initiated IFX after a 16–24 weeks delay but was less than that observed in pts who
initiated IFX at the start of the study.
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Infliximab safety experience: Data from clinical trials in patients with psoriatic
disease
Kenneth B. Gordon, MD, Loyola University Medical Center, Maywood, IL, USA, Frank O. Nestle,
MD, University Hospital Zurich, Zurich, Switzerland, Cynthia Guzzo, Shu Li, Centocor Research
and Development, Inc., Malvern, PA, USA
Introduction: Infliximab (IFX), a tumor necrosis factor-a antagonist, is approved for use in patients
(pts) with psoriatic arthritis and is currently being investigated for the treatment of moderate-to-
severe psoriasis.
Objective: To assess the safety of IFX in pts with psoriatic disease using integrated clinical trial
data.
Methods: Data for the integrated safety analysis were obtained from randomized, placebo (PBO)-
controlled clinical trials in pts with moderate-to-severe psoriasis (SPIRIT, EXPRESS, EXPRESS II)
and in psoriatic arthritis (IMPACT 2). IFX doses included 3–5 mg/kg induction followed by
scheduled or ‘‘as needed’’ (PRN) maintenance therapy. Some pts in IMPACT 2 received IFX
10 mg/kg after dose escalation. The primary comparison is from week 0 to week 16 (common
PBO-controlled period). Adverse events (AEs) will also be reported from week 0 through the end
of the reporting period (through maintenance) for each study.
Results: A total of 1,657 pts with psoriatic disease were included. Through week 16 the average
duration of follow-up was comparable between IFX 3 and 5 mg/kg and PBO (15.7, 15.1, and 14.7
weeks, respectively). Through maintenance the average duration of follow-up was 41.9 weeks,
46.2 weeks, and 18.5 weeks for the IFX 3 mg/kg, 5 mg/kg, and PBO groups, respectively. Through
week 16, 67.9 and 73.0% of IFX 3- and 5-mg/kg-treated pts, respectively, experienced X 1
adverse event versus 60.0% in PBO pts; 1.7, 3.9, and 3.2% of IFX 3 mg/kg, IFX 5 mg/kg, and PBO-
treated pts experienceX 1 serious AE (SAE). Infections were reported by 32.6, 31.9, and 27.5% of
IFX 3 mg/kg, IFX 5 mg/kg, and PBO pts, respectively. Through maintenance, the incidences of AEs
per 100 patient years were higher, slightly higher, and comparable for common AEs, SAEs, and
infections, respectively, for IFX compared with PBO. The incidence of infusion reactions was
higher for IFX 3 mg/kg versus IFX 5 mg/kg or PBO. Serious infusion reactions were uncommon
(0.1%). One death from sepsis was reported (EXPRESS).
Conclusions: IFX was generally well tolerated in the majority of pts. The infrequent occurrence of
serious AEs in a small proportion of psoriasis pts suggests that careful monitoring is required.
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Treatment with infliximab is associated with ‘‘major clinical response’’ in psoriatic
arthritis patients treated with infliximab: Analysis of two double-blind placebo-
controlled trials
Arthur Kavanaugh, MD, University of California San Diego, La Jolla, CA, USA, Gerald G. Krueger,
MD, University of Utah Health Sciences Center, Salt Lake City, UT, USA, Charles Birbara,
University of Massachusetts School of Medicine, Worcester, MA, USA, Dale Halter, Houston
Institute of Clinical Research, Houston, TX, USA, Piet Geusens, Limburg University Centre,
Belgium & Rheumatology, Maastricht, The Netherlands, Kurt de Vlam, University Hospital
Leuven, Leuven, Belgium, Bei Zhou, L. Dooley, Cynthia Guzzo, M. Ann Bala, Anna Beutler,
Centocor, Inc., Malvern, PA, USA, Christian Antoni, Friedrich-Alexander University, Erlangen,
Germany
Objectives: Tumor necrosis factor-a (TNF-a) inhibitors have been shown to be effective in
psoriatic arthritis (PsA). To assess highly significant clinical responses, we analyzed two trials of
infliximab (IFX) and determined ‘‘major clinical response’’, defined as maintenance of ACR 70
response for six consecutive months in patients (pts) with active PsA.
Methods: IMPACT was a study of 104 PsA pts randomized to placebo (PBO) or IFX 5 mg/kg at
weeks 0, 2, and 6, followed by maintenance doses of IFX every 8 weeks through week 98.
Crossover of pts from PBO to IFX occurred at week 16. IMPACT 2 was a double-blind, PBO-
controlled, 54-week study of 200 pts with active PsA forX6 months with an inadequate response
to nonsteroidal anti-inflammatory drug/DMARDs and X5 swollen joints (SJs) and tender joints
(TJs), plaque psoriasis, and X1 of either: C-reactive protein levels of X1.5 mg/dl or morning
stiffness X45 minutes. Pts were randomized (1:1) to receive IFX 5 mg/kg at weeks 0, 2, 6, and
every 8 weeks through week 46 or PBO at weeks 0, 2, 6, 14, and 22. PBO-treated pts with less
than 10% improvement in both SJ and TJ entered early escape and received IFX 5 mg/kg at weeks
16, 18, and 22. At week 24, PBO pts who did not qualify for early escape, received IFX at weeks
24, 26, 30, 38, and 46. IFX pts who had o20% improvement in combined SJ and TJ count
received IFX 10 mg/kg at weeks 38 and 46. Because the PBO phase was 24 weeks or less, PBO pts
were conservatively counted as achieving ‘‘major clinical response’’ if they met ACR 70 at the
time of last evaluation before IFX start. Fisher’s exact test was used to compare between treatment
groups.
Results: In IMPACT, 34.6% of IFX randomized pts had ACR 70 improvement at week 98 and
30.8% (16/52) of pts achieved a major clinical response as compared to 0% of PBO-treated pts
(Po0.001). In IMPACT 2, at week 54, 22.2% of IFX randomized pts met ACR 70 response. ‘‘Major
clinical response’’ was observed in 12.1% of IFX pts (12/99) at week 54 compared with 2.0% of
PBO-treated pts (P¼ 0.006).
Conclusions: In controlled clinical trials through 2 years, a significant proportion of IFX-treated pts
were able to attain a very high degree of sustained clinical improvement in arthritis, as assessed
by using rheumatoid arthritis definition for ‘‘major clinical response’’. More research is needed to
define major clinical response specific for PsA, which will include sustained high degree
improvements in arthritic and dermatologic components of the disease.
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Psoriasis: The key role of mycosis – a novel finding that gives rise to new
therapeutics
Isabel Irma Cesaroni, Laboratory Labbce, Buenos Aires, Argentina, Fausta Ines Negro, Pharmacy
Grattoni, Buenos Aires, Argentina, Miguel Cesar Guerrini, Laboratory Experts Judicial Power,
Buenos Aires, Argentina
Introduction: The hyperproliferation dermic of the psoriatic patient provides the ideal atmosphere
for the development of fungi and bacterium, added to its immunological deficiency, which allows
it. Its meticulous study offers the essential guidelines for a effective treatment.
Materials Muestra: Scraped and hyssop of psoriatic injuries. Means of culture: for bacterium,
those of frequent use and for fungi, means of formulate and preparation own. Fungigram In Agar
Shadomy modified and antifungi tablets.
Methods: Scraped of skin with instruments surgical on sterile plate, it cultivates, typifies, and
proves with antifungus and antibacterium agents, later analyzes treatment on basis of the obtained
results combining the action of the antifungus and antibiotic, with the of one keratylitic agent who
facilitates the removal of the plate and the renovation of the skin.
Results: Surprisingly, he was observed in more than 300 patients, the sweeping of the psoriatic
plate, recovering the skin, its texture and luxuriance.
Conclusion: Is the psoriasis a mycosis with genetic predisposition? Obtaining an effective
treatment for the eradication of the mycosis, but a support with minerals and vitamins, that
optimizes the state immunological of the patient, we will be able to eradicate it. P.D.: The work
consists of statistics of the fungus species found in the injuries and of their answer to antifungus,
microphotographies same and photography of its cultures and of the injuries pre- and post-cure.
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Polymorphisms in folate, pyrimidine, and purine metabolism have an impact on
clinical response to treatment with methotrexate in psoriasis
Emanuela Campalani, St John’s Institute of Dermatology, King’s College, London, UK, M. Arenas,
A.M. Marinaki, Purine Research Laboratory, Guy’s and St Thomas’ NHS Foundation Trust,
London, UK, Jonathon N.W.N. Barker, MD, FRCP, FRCPath, C.H. Smith, St John’s Institute of
Dermatology
Recently, polymorphisms in enzymes involved in folate, pyrimidine, and purine metabolism were
shown to influence clinical response to methotrexate in patients with rheumatoid arthritis.
Methotrexate is the gold standard therapy for moderate-to-severe psoriasis, but its therapeutic
efficacy varies from patient to patient and up to 40% of patients experience side effects. We
hypothesized that in psoriasis patients-specific common polymorphisms in the reduced folate
carrier (RFC), thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), 5-
aminoimidazole-4-carboxiamide ribonucleotide transformylase (ATIC), and adenosine deami-
nase (ADA) genes are associated with methotrexate efficacy and/or toxicity. DNA from 203
retrospectively recruited psoriasis patients treated with methotrexate was collected and
genotyped by restriction endonuclease digestion or length polymorphism assays. The RFC 80A
allele was associated with overall methotrexate-induced toxicity (P¼0.018) and methotrexate
discontinuation due to any adverse event (P¼0.048 in all patients, P¼ 0.00021 in patients not on
folic acid); TS 50-untranslated region (UTR 3R was associated poor clinical outcome (P¼ 0.029) in
all patients, overall toxicity (P¼0.0025), and methotrexate discontinuation (P¼ 0.033) in patients
not on folic acid; TS 30-UTR 6 bp deletion was associated with overall toxicity (P¼ 0.029) in all
patients, and hepatotoxicity (P¼ 0.012) in patients not on folic acid; MTHFR 1298C was
associated with a lower risk of hepatotoxicity (P¼ 0.042) in patients not on folic acid; ATIC 347G
was associated with methotrexate discontinuation (P¼0.038). We have demonstrated potential
evidence that specific polymorphisms of enzyme involved in folate, pyrimidine, and purine
metabolism have a significant effect on clinical response to methotrexate, and could be used as
potential markers for predicting methotrexate efficacy and toxicity in patients with psoriasis.
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Clinical efficacy, safety, and patient-reported outcomes of EDUCATE, a multi-
center, community-based, open-label study of the effect of etanercept on skin and
joint disease in patients with psoriatic arthritis.
Alice B. Gottlieb, MD, PhD, Tufts-New England Medical Center, Boston, MA, USA, Ellen H.
Frankel, Clinical Partners LLC, Cranston, RI, USA, Bruce E. Strober, MD, PhD, New York
University School of Medicine, New York, NY, USA, David Fivenson, Dermatology, PLLC, Ann
Arbor, MI, USA, Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA, USA, Seth R.
Stevens, MD, Amgen Inc., Thousand Oaks, CA, USA
Purpose: To assess the efficacy, safety, and both the arthritic and cutaneous parameters as well as
patient-reported outcomes (PROs) of etanercept (ETN) in patients with psoriatic arthritis (PsA) in
community-based clinics, as well as academic settings, from baseline through week 24 of a long-
term open-label study.
Methods: All patients (N¼1122) had psoriasis and PsA, characterized by stable moderate-to-
severe plaque psoriasis involving at least 10% body surface area, a minimum of two swollen
joints and two tender/painful joints of at least 3 months’ duration, and/or sacroiliitis or spondylitis.
Patients received 50 mg weekly of etanercept by subcutaneous injection (two 25-mg injections
every week within 1 hour of each other). Patients were assessed at a baseline visit and at weeks 2,
6, 12, and 24. Efficacy was measured by physician global assessment of psoriasis, patient global
assessment of psoriasis, and patient global assessment of joint disease, all measured on a five-
point scale with 0¼ clear or no symptoms; patient assessment of morning stiffness, in minutes,
was also evaluated. PROs included the Health Assessment Questionnaire (HAQ; 0–3 with
0¼ good and 3¼ severe) for assessment of joint disease and Dermatology Life Quality Index
(DLQI; 0–30 with 0¼ good and 30¼ severe) for assessment of skin disease. Improvements X5
points in the DLQI and X0.3 in the HAQ Disability Index (HAQ DI) were defined as a minimal
clinically important difference (MCID). Intention-to-treat analysis with last observation carried
forward was used for imputation of missing data, except for Physician Global Assessment of
Psoriasis which was a responders’ analysis.
Results: Patients reported a baseline mean severity of joint disease of 2.8. Physician global
assessment of psoriasis at week 24 indicated a clear or almost clear status and improvement from
baseline in 57% of patients. These results were in agreement with those of three previous phase
three PsA and psoriasis studies in academic rheumatology and dermatology settings. After 24
weeks of ETN, patient global assessment of psoriasis had mean improvement of 54%. Patients
reported a mean improvement of 1.5 (47%) in global assessment of joint disease and a mean 62%
improvement in duration of morning stiffness. Mean DLQI scores improved from 13.9 at baseline
to 4.3 at week 24, meeting the MCID criterion. HAQ DI showed a mean improvement from
baseline of 0.41; 52% of patients reported an MCID in the HAQ; and 47% achieved HAQ DI¼ 0.
Thirty-five (3.1%) patients experienced at least one serious adverse event (0.6% treatment-
related); eight (0.7%) patients experienced serious infections, of which two infections in a patient
were treatment-related). No tuberculosis, opportunistic infections, or granulomas were reported.
Conclusions: During the initial 24 weeks of this phase 4 study of patients with psoriatic arthritis,
conducted in community dermatology clinics, etanercept was safe and effective. These patients
reported meaningful improvements in both clinical parameters (skin and joint disease) as well as
patient reported outcomes (HAQ, DLQI) after 24 weeks of etanercept therapy. No TB or
opportunistic infections were noted.
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